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Insulin stimulates the uptake of glucose in responsive tissues through the 
insulin-regulated glucose transporter (GLUT4). In the resting cell, GLUT4 is 
localised in an intracellular GLUT4 storage vesicle (GSV). In response to 
insulin stimulation, GLUT4 is rapidly mobilised from the GSV to the plasma 
membrane.
The work described in this thesis investigates the phosphorylation state of 
GLUT4. The FQQI motif at the N-terminus of GLUT4 has a potential 
downstream phosphorylation site at serine 10. The sequence surrounding 
serine 10 (GS10EDGE) has a high sequence identity with a domain in GAD65a, 
which is phosphorylated by an unknown kinase. A phosphorylation site at 
serine 488 in GLUT4 has previously been identified.
To aid this study, work was undertaken to purify a phospho-specific antibody 
raised to a phosphorylated serine 10 peptide as well as raising an antibody to 
the C-terminus of GLUT4.
Experiments in which both adipocytes and cardiomyocytes were labelled with 
radioactive inorganic phosphate, and in which GLUT4 was subsequently 
cleaved with Endoproteinase Lys-C, have led to the identification of a 
phosphorylation site in the N-terminus of GLUT4 as well as confirming the 
presence of the C-terminal phosphorylation site. From comparison with a 
phosphorylation site prediction program, it is concluded that the putative 
phosphorylation site at serine 10 is likely to be a bone fide phosphorylation site 
at the N-terminus of GLUT4.
Site-directed mutagenesis was carried out to mutate serine 10 and serine 488 
in GLUT4 to either alanine or aspartic acid residues which were designed to 
mimic the non-phosphorylated and phosphorylated state, respectively. The 
effect of the mutations on the rate of trafficking of GLUT4 to the plasma 
membrane was investigated. The only mutation to have an effect was the 
aspartic acid 10 mutation which resulted in a decreased level of GLUT4 at the 
plasma membrane in insulin-stimulated cells.
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Glucose is the major source of fuel in eukaryotic cells; it is an important source 
of fuel for many tissues and an essential source for others. Glucose is 
catabolised via glycolysis, the citric acid cycle and oxidative phosphorylation to 
provide ATP, the cellular energy source. When the levels of blood glucose are 
high, glycogen, a polymer of glucose, is produced by glycogenesis. Glycogen 
is then stored until times of glucose shortage. Glucose homeostasis is 
therefore an important phenomenon, which maintains a constant source of 
glucose for the varying metabolic demands of the animal. Glucose circulates 
freely in the blood and is constantly being removed or replaced due to the 
metabolic demands of the surrounding tissues. Blood glucose levels remain 
relatively constant at 5 mM but post-prandial glucose levels can rise up to 7 
mM (Reaven et al., 1988). The constant level of glucose in the blood is 
achieved by the control of various aspects of glucose metabolism. Insulin and 
glucagon are two hormones that have antagonistic roles in glucose 
homeostasis. In response to elevated blood glucose levels, insulin is secreted 
by the p-cells from the islets of Langerhans found in the pancreas. Insulin 
stimulates glucose uptake and storage in insulin responsive tissues (muscle 
and adipose tissues) as well as inhibiting gluconeogenesis, particularly in the 
liver. Conversely, in situations where blood glucose is low, i.e. during periods 
of starvation, glucagon is released from the pancreas and promotes the 
breakdown of glycogen and thus the release of glucose into the blood by a 
process known as glycogenolysis.
Diabetes mellitus is a disease which is associated with a failure in glucose 
homeostasis. There are two forms of diabetes mellitus. Type 1 or insulin- 
dependent diabetes mellitus is due to a deficiency in insulin, which develops 
after the auto-immune destruction of the insulin-secreting cells in the pancreas. 
The only effective treatment is insulin injections. The other type of diabetes
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mellitus is called Type 2 or non-insulin-dependent diabetes mellitus. Type 2 
diabetes occurs as a result of insulin resistance, in which there is not a 
deficiency of insulin per se, but rather a failure of insulin to exert its effects. 
Having a strict diet is the most common way to control Type 2 diabetes, but 
drugs are available, e.g. metformin, which increase the sensitivity of the tissues 
to insulin. Type 2 diabetes was traditionally a disease that affected older 
people. However, insulin resistance is a prominent feature of obesity and, with 
the increasing problem of obesity in children following the prevalence of the TV 
and video gaming culture, Type 2 diabetes is becoming an increasing health 
problem in juveniles. Type 2 diabetes is one of the major risks to human 
health. It is currently estimated that there are 150 million people suffering from 
diabetes and this number is predicted to increase to 300 million in 2025 
(Zimmet et al., 2001). This has fuelled research into all aspects of glucose 
biology and the mechanism of Type 2 diabetes.
1.2 The Glucose Transporter Family
Following the post-prandial release of insulin, the blood glucose concentration 
returns to about 5 mM through the uptake of glucose into various tissues. 
Glucose is a hydrophilic molecule and thus cannot penetrate the plasma 
membrane by simple diffusion. Therefore, proteins must exist to transport 
glucose into the cell. There are two different types of transporter proteins that 
transport glucose and other sugars across the cell membrane, the Na+-coupled 
carrier system (SGLT) and the facilitative glucose transporters (GLUT). Both 
types of transporters belong to families of the solute carrier gene series (SLC), 
SLC5 and SLC2 respectively.
Each member of the GLUT family of proteins forms a transporter across the 
cell membrane through which glucose can enter the cell. In 1985, the first 
glucose transporter to be cloned and sequenced was in erythrocyte cells
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(Mueckler et al., 1985). This transporter is now known as GLUT1. Over the last 
20 years, thirteen more transporters have been identified which are at least 
29% identical with GLUT1 (Scheepers etal., 2004). The members of the GLUT 
family have varying tissue distributions, which suggest that each plays a 
distinct role in the regulation of whole body glucose homeostasis.
The GLUT family of proteins are predicted to have twelve transmembrane 
spanning helices with both the amino- and carboxyl-termini having a cytosolic 
localisation as well as a highly hydrophilic domain between helices 6 and 7 
(Figure 1.1). Sequence comparisons of all the members of the GLUT family 
(Joost and Thorens, 2001) have further corroborated this structural model, 
which was first suggested by evidence from hydropathy plots (Mueckler et al., 
1985). This model was further confirmed after the 3D structure of the 
Escherichia coli (E. coli) glycerol-3-phosphate transporter (GIpT), a structurally- 
related protein to the glucose transporters, was solved (Lemieux et al., 2003).
The 14 members of the extended GLUT family can be divided into three 
subclasses, classes I, II and III. Class I are the glucose transporters GLUT1 to 
4 and 14, which differ in their subcellular localisation, affinity for glucose and 
their hormonal regulation. Class II are fructose-specific transporters (GLUT5) 
and related proteins (GLUT7, 9 and 11). Finally, class III transporters (GLUTs 
6, 8, 10, 12 and HMIT1) are structurally atypical members of the GLUT family. 
They are composed of a shorter extracellular loop between helices 1 and 2, 
which results in a lack of glycosylation site in that region. However, a 
glycosylation site is present in the extracellular loop between helix 9 and 10 
(Table 1.1) (Joost and Thorens, 2001, Scheepers et al., 2004). The term 
glucose transporter must also be used with care because the newer members 
of the GLUT family have different substrate specificities and may transport 





Figure 1.1 Predicted structure of the class I family of GLUT proteins. The GLUT family of proteins are predicted to have twelve 
transmembrane spanning helices with both the amino- and carboxyl-termini having a cytosolic localisation as well as a highly 
hydrophilic domain between helices 6 and 7. Adapted from (Joost and Thorens, 2001).
17
Human Gene j 
Name + Locus
Protein Alias Predominant 
Substrates






GLUT1 j Glucose, Galactose,
S Mannose, Glucosamine
Erythrocytes, brain, blood brain barrier, 




GLUT2 Glucose, Galactose, 
Fructose, Mannose,
| Glucosamine






GLUT3 Glucose, Galactose, 
| Mannose, Xylose
Brain (neurons), testis, low levels in 














Small intestine, kidney, testies] NM_003039
SLC2A6 ; GLUT6 ! GLL)f9 Glucose Brain, spleen, leukocytes NM_017585
9q34 ! I ! I !
SLC2A7 i GLUT7 ! Glucose, Fructose Intestine (ileum), testis, prostate i NM_207420
1p36.2 j  | | !
SLC2A8 GLUT8 GLUTX1 j Glucose, Fructose, J Testis, brain, adrenal gland, liver, spleen, NM 014580
! 9 Galactose brown adipose tissue, lung
i SLC2A9 
4p15.3-16








Glucose, Galactose ! Liver, pancreas, heart, lung, brain, skeletal




























Table 1.1 Classification and tissue expression of the different GLUT isoforms. (Joost and Thorens, 2001, Hediger et al., 2004).
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1.2.1 The Insulin-Regulatable Glucose Transporter -  GLUT4
Insulin increases the rate of glucose uptake into adipocytes by at least 20-fold. 
For many years, it was believed that insulin altered the intrinsic activity of the 
glucose transporters located in adipocyte cell membranes. However, in 1980 it 
was first demonstrated, by the use of cytochalasin B-binding, that in the basal 
state the glucose transporters were sequestered in intracellular membranes. 
Following stimulation with insulin, the glucose transporters then translocated to 
the plasma membrane where they could transport glucose into the cell 
(Cushman and Wardzala, 1980, Suzuki and Kono, 1980). In 1988, this 
transporter was identified as the insulin-regulatable glucose transport (IRGT), 
which is now more commonly known as GLUT4. The following year, five 
independent laboratories were successful in cloning GLUT4 from a variety of 
different tissues and cell lines (Birnbaum, 1989, Charron et al., 1989, 
Fukumoto et al., 1989, Kaestner et al., 1989, James et al., 1989b). The human 
and rat GLUT4 proteins consist of 509 amino acids (Birnbaum, 1989, Charron 
et al., 1989, James et al., 1989b), whereas, the mouse GLUT4 protein has 510 
amino acids (Kaestner et al., 1989). GLUT4 has 65% sequence homology to 
GLUT1. The major differences in identity are in the amino and carboxyl termini 
and the large cytoplasmic loop between helices 6 and 7. The sequence 
homology of this area is only 40%, compared to that of the putative membrane 
spanning regions which are reported to have 73% homology (Birnbaum, 1989).
GLUT1 is a ubiquitously expressed transporter and is also present in insulin 
responsive tissues, but only at low levels (Flier et al., 1987). GLUT1 and 
GLUT4 must therefore both contribute to glucose uptake in adipocyte and 
muscle tissue. GLUT1 is present predominantly in the plasma membrane of 
both basal and insulin-stimulated cells and, following insulin stimulation, there 
is only a relatively small increase in the level of GLUT 1 at the cell surface (~ 5- 
fold) (Holman et al., 1990). However, GLUT4 contributes to about 90% of the
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glucose transporters in the plasma membrane of insulin-stimulated adipocytes 
and the level of GLUT4 at the cell surface increases 15- to 20-fold above basal 
levels (Holman et al., 1990). Thus it was concluded that the GLUT4 protein is 
the key glucose transporter involved in insulin-stimulated glucose uptake. The 
molecular mechanism by which insulin causes this redistribution of GLUT4 still 
has to be fully elucidated, and, while huge progress has occurred throughout 
the last 20 years, GLUT4 currently remains under intense investigation.
1.3 Insulin Signalling Pathways Involved in Glucose Uptake
An extensive signalling cascade is involved in insulin-stimulated glucose 
transport, the full extent of which has not, as yet, been identified. The 
translocation of GLUT4 to the plasma membrane following stimulation with 
insulin is complex and may require regulation in the various steps. Our 
understanding of the insulin signalling involved in glucose transport will be out­
lined below, the knowledge of which will help us to fully understand the 
mechanism of insulin-stimulated glucose transport (Figure 1.2). The signalling 
cascade described will focus on the signalling molecules involved in GLUT4 
translocation to the plasma membrane. It is by no means a full description of all 
of the interacting molecules involved in signalling downstream from the insulin 
receptor. Insulin-stimulated glucose transport is mediated through a 
phosphatidylinositol 3-kinase-dependent pathway. A phosphatidylinositol 3- 
kinase-independent pathway has also been reported but has remained 
controversial in the GLUT4 field.
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1.3.1 Phosphatidylinositol 3-Kinase-Dependent Pathway
1.3.1.1 The Insulin Receptor
The insulin receptor is a member of the receptor tyrosine kinase family. It is 
synthesised as a single polypeptide ‘proreceptor’ molecule and is cleaved in 
the trans-Golgi network (TGN) by furin, a serine protease, to give the mature 
receptor (Bravo et a!., 1994). The mature insulin receptor is a heterotetrameric 
structure comprising of two a- and two P-subunits (a2p2). The two a-subunits 
are extracellular and are linked by disulfide bonds. The two p-subunits consist 
of transmembrane spanning and cytosolic domains. Each p-subunit can be 
phosphorylated following insulin binding to its receptor (Kasuga et al., 1982a, 
Kasuga et al., 1982b). The p-subunits have exogenous and endogenous 
tyrosine kinase activity and are each linked to one of the a-subunits through a 
disulfide bond. Insulin binds to the a-subunits of the insulin receptor, which 
causes a conformational change in the receptor. This triggers the 
transphosphorylation of one p-subunit by the other on specific tyrosine 
residues, which increases the catalytic activity of the kinase domain. There are 
also two other regions in the p-subunit, the juxtamembrane region and the C- 
terminal domain, which undergo autophosphorylation in response to insulin 
binding (Lee and Pilch, 1994, Watson et al., 2004b). Phosphorylation of the 
insulin receptor is important in substrate recognition for downstream proteins in 
the insulin-signalling cascade.
1.3.1.2 Insulin Receptor Substrates
The insulin receptor differs from other members of the receptor kinase family in 
that it does not interact directly with downstream effector molecules. Instead it 
binds and phosphorylates various scaffold proteins, which in turn bind to 
various effector molecules (Lee and Pilch, 1994). The major substrate of the 
insulin receptor, and the most widely studied, is the family of insulin receptor
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substrate (IRS) proteins (Shepherd et al., 1998). Six members of the IRS 
family have been identified. IRS-1 and IRS-2 (Sun et al., 1991, Sun et al., 
1995) are ubiquitously expressed (muscle, liver, fat, and pancreatic islets). 
IRS-3 was cloned from rat adipocytes (Lavan et al., 1997b). However, IRS-3 
was not expressed in human adipocytes (Bjornholm et al., 2002) and is 
therefore not involved in insulin signalling in humans. IRS-4 was first cloned in 
1997 (Lavan et al., 1997a) and is expressed in pituitary and thyroid glands but 
is undetectable in insulin-sensitive tissues (Uchida et al., 2000). IRS-4 would 
therefore not have a role in insulin-stimulated GLUT4 uptake. IRS-5 is 
expressed in kidney and liver and IRS-6 is expressed in muscle (Cai et al., 
2003). Both proteins are substrates for the insulin receptor but further work is 
needed to determine if the classification as a member of the ‘insulin receptor 
substrate’ family is justified (Cai et al., 2003). Three members of the IRS 
protein family may therefore be involved in glucose transport as they are 
expressed in the target, insulin-responsive tissue. However, IRS-3 is not 
expressed in humans so IRS-1 and IRS-2 are the most likely candidates to be 
involved in insulin-stimulated glucose transport. The effect each of these 
proteins has on insulin-stimulated glucose transport in muscle was investigated 
using small interfering RNA (siRNA). It was concluded that IRS-1 and IRS-2 
have different roles in muscle cells. IRS-1 regulates GLUT4 translocation, 
glucose uptake, actin remodelling, and protein kinase B (PKB)a and PKBp 
phosphorylation. IRS-2 regulates PKBp activation but does not have a major 
effect on these other functions (Huang et al., 2005). IRS-1 is, therefore, the 
major IRS protein to affect insulin-stimulated glucose transport.
The insulin receptor substrates are not classified according to their amino acid 
sequence but according to their similar structural features. There is an amino- 
terminal targeting domain that comprises a Pleckstrin-homology (PH) domain 
and / or a phosphotyrosine binding (PTB) domain. These domains mediate 
protein-lipid or protein-protein interactions. There is also a region in the C- 
terminus of the protein containing tyrosine residues, which, when
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phosphorylated, act as a binding site for proteins which contain Src homology 
2 (SH2) domains. There are also proline rich regions to bind Src homology 3 
(SH3) / VWV domain containing proteins, and serine / threonine rich regions, 
which are believed to regulate the overall function of the protein through 
protein-protein interactions (Shepherd et al., 1998, White, 1998).
The insulin receptor contains a NPEY motif in the juxtamembrane region and 
the PTB domain of the IRS binds through this (He et al., 1995, Wolf et al., 
1995). The PH domain in the N-terminus of the IRS protein is also needed for 
insulin receptor association, through binding to phosphoinositides, and 
consequential phosphorylation by the insulin receptor (Voliovitch et al., 1995, 
Yenush et al., 1996). The majority of the phosphorylation sites in IRS proteins 
consist of YMXM or YXXM motifs (Shoelson et al., 1992). After binding to the 
insulin receptor, multiple tyrosine residues are phosphorylated within the IRS-1 
protein and promote the recruitment of a number of signalling molecules (Sun 
etal., 1992).
1.3.1.2.1 Inhibition of Insulin Receptor Signalling
Protein tyrosine phosphatases (PTPases) attenuate the effect of insulin by 
rapidly dephosphorylating the insulin receptor. Many PTPases have been 
implicated in this but protein tyrosine phosphatase 1B (PTP-1B) is the most 
highly studied. PTP-1B knockout mice have been shown to have increased 
tyrosine phosphorylation of the insulin receptor and IRS proteins (Elchebly et 
al., 1999).
Serine phosphorylation of the insulin receptor and IRS proteins is also a 
mechanism whereby the insulin signal can be controlled. There is a negative 
feedback system in which serine phosphorylation ultimately leads to a
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decrease in insulin-stimulated tyrosine phosphorylation and is involved in 
insulin resistance pathways (Saltiel and Kahn, 2001).
1.3.1.3 Phosphatidvlinositol 3-kinase
In 1993, it was first reported that phosphatidylinositol 3-kinase (PI3K) was 
involved in glucose transport because of the fact that low nano-molar 
concentrations of the PI3K inhibitor, wortmannin, inhibit insulin-stimulated 
glucose transport (Kanai et al., 1993a). Furthermore, wortmannin inhibits the 
translocation of GLUT4 following insulin stimulation but has no effect on basal 
translocation of the transporter (Clarke et al., 1994). The site of PI3K action in 
insulin-stimulated glucose transport has been narrowed down and has been 
shown to be involved in the exocytosis of GLUT4 from the intracellular storage 
compartment to the plasma membrane (Yang et al., 1996).
There are three classes of PI3K -  classes I, II and III. Each class is defined by 
its primary structure, regulation and in vitro lipid substrate specificity. Class I is 
further subdivided into two categories ( U  and I b ) ,  differentiated by the adaptor 
subunit to which they bind. Class lA PI3Ks bind to adaptor proteins containing 
SH2 domains. PI3Ks belonging to class Ib are stimulated by G-protein py 
subunits and do not interact with proteins containing SH2 domains 
(Vanhaesebroeck etal., 1997).
Phosphatidylinositol 3-kinases are enzymes that catalyse the phosphorylation 
of phosphatidylinositol [PI], phosphatidylinositol-4-phosphate [PI(4)P] or 
phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] at the D-3 position of the 
inositol ring (Carpenter et al., 1990) to produce phosphatidylinositol-3- 
phosphate [PI(3)P], phosphatidylinositol-3,4-bisphosphate [PI(3,4)P2] and 
phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3] respectively. This broad 
substrate range has since been limited to PI3K from Class I but their preferred
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substrate appears to be PI(4,5)P2. PI3K from Class II only phosphorylates PI 
and PI(4)P and PI3K from class III only uses PI as a substrate 
(Vanhaesebroeck et al., 1997).
Class lA is the major class of PI3Ks involved in insulin signalling (Shepherd, 
2005). Each Class lA PI3K is a dimer consisting of two subunits, a 110 kDa 
catalytic subunit (p110) and an 85 kDa adapter subunit (p85). The p85 subunit 
contains two SH2 domains and a SH3 domain. Three p110 isoforms have 
been identified (p110a, p110b and p110d) and seven adapter proteins have 
been identified. These arise as splice variants from three different genes: p85a 
and p85p express full-length proteins and the p55y gene expresses a 
truncated protein. PI3K is activated when the phosphorylated YMXM motifs in 
the IRS protein occupy both SH2 domains in the p85 subunit (Backer et al., 
1992). Not only is PI3K activated, but binding to IRS targets the p110 catalytic 
subunit to its substrate in the plasma membrane -  PI(4,5)P2. The production of 
a localised concentration of PI(3,4,5)P3 leads to the recruitment of downstream 
signalling molecules containing a pleckstrin homology (PH) domain.
1.3.1.4 Inhibition of PI3K Signalling
The action of PI3K is controlled through the action of lipid PI(3,4,5)P3 
phosphatases. One enzyme is called Type II SH2-domain-containing inositol 
5-phosphatase’ (SHIP2) which removes the 5’ phosphate from PI(3,4,5)P3 to 
form PI(3,4)P2 and can be regulated by tyrosine kinases through its SH2 
domain. SHIP2 activity is found downstream of the insulin receptor (Guilherme 
et al., 1996). SHIP2 regulates insulin-stimulated glucose transport as it has 
been shown that SHIP2 knockout mice have increased insulin sensitivity and 
increased recruitment of GLUT4 to the plasma membrane (Clement et al., 
2001).
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The second enzyme involved is the ‘phosphatase and tensin homologue’ -  
PTEN. PTEN is a specific 3’ phosphatase that results in the conversion of 
PI(3,4,5)P3 to PI(4,5)P2. Overexpression of PTEN prevents the formation of 
PI(3,4,5)P3 and results in the inhibition of GLUT4 translocation to the plasma 
membrane following insulin stimulation (Nakashima etal., 2000).
1.3.1.5 Downstream Signalling from PI3K
1.3.1.5.1 3’-Phosphoinositide-Dependent Kinase-1
The pleckstrin homology (PH) domain is a specialised domain of about 100 
amino acids which bind phospholipids. PI3K therefore generates lipids, through 
which signalling molecules bind, thus recruiting the proteins to the plasma 
membrane. 3’-phosphoinositide-dependent kinase-1 (PDK1) is a 63 kDa serine 
/ threonine kinase ubiquitously expressed in human tissues. PDK1 consists of 
two domains, an N-terminal kinase domain and a C-terminal PH domain which 
binds PI(3,4,5)P3 and PI(3,4)P2 in vitro, with high affinity (Vanhaesebroeck 
and Alessi, 2000). PDK1 was first identified in 1997 as the kinase that 
phosphorylates protein kinase B (PKB) at threonine 308 (Alessi et al., 1997). 
PKB had been shown to increase GLUT4 translocation (Kohn et a!., 1996) and 
is discussed further in section 1.3.1.5.2. PDK1 is a signalling molecule involved 
in insulin-stimulated GLUT4 translocation and the PH domain is essential in 
this process (Grillo et al., 1999). Recently, a study using hearts from PDK1 
knockout mice has provided genetic evidence that PDK1 plays a crucial role in 
promoting insulin-stimulated glucose uptake in cardiac muscle (Mora et al., 
2005). PDK1 therefore provides the link between PI3K and PKB in the insulin- 
stimulated glucose transport pathway. The subcellular distribution of PDK1 has 
not been definitively identified. In the basal cell, PDK1 is found in the cytosol 
and at the plasma membrane which is thought to be linked via the PH domain. 
There is also conflicting evidence as to whether PDK1 translocates to the 
plasma membrane following growth factor activation (Vanhaesebroeck and
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Alessi, 2000). Activation of PDK1 ultimately leads to the phosphorylation and 
activation of further serine / threonine kinases namely PKB (isoforms a and (3) 
(Section 1.3.1.5.2) and the atypical PKC isoforms £ and A (Section 1.3.1.5.4).
1.3.1.5.2 Protein Kinase B
Protein kinase B (PKB), so called due to its homology with protein kinase A 
and protein kinase C, is also known as Akt. PKB is a serine / threonine kinase 
and has a molecular weight of 57 kDa. Three main isoforms of PKB have been 
identified in mammalian cells: PKBa / Akt1, PKB(3 / Akt2 and PKBy / Akt3. PKB 
comprises an N-terminal PH domain, a catalytic domain and a C-terminal 
regulatory domain. PKB is phosphorylated at two sites -  one residue is 
threonine 308 in the catalytic domain and the other is serine 473 in the 
regulatory domain. The inactive, unphosphorylated, form of PKB resides in the 
cytosol. The generation of PI(3,4,5)P3 by PI3K recruits PKB to the plasma 
membrane. The binding of PKB to the plasma membrane through its PH 
domain results in a conformational change in the kinase. This leads to the 
phosphorylation of Thr308 and Ser473. PDK1 phosphorylates Thr308 in the 
catalytic domain (Brazil and Hemmings, 2001). The Ser473 kinase, known as 
‘PDK2’ for many years, has been identified earlier this year as the mammalian 
target of rapamycin (mTOR) kinase complexed to the regulatory protein 
RICTOR (Sarbassov et al., 2005). Since this initial study, the mTOR-RICTOR 
complex has also been shown to phosphorylate Ser473 in insulin-responsive 
tissues (Hresko and Mueckler, 2005). Therefore, mTOR-RICTOR is likely to be 
the Ser473 kinase involved in insulin-stimulated GLUT4 translocation to the 
plasma membrane. Following phosphorylation at both sites, the activated PKB 
then phosphorylates substrates at the plasma membrane, in the cytosol or in 
the nucleus containing a RXRXXS/T motif.
PKB is important in GLUT4 translocation. A constitutively active form of PKB 
increases the rate of glucose transport and the level of GLUT4 at the plasma
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membrane (Kohn et al., 1996), whereas a dominant-negative form of PKB 
prevents the insulin-dependent translocation of GLUT4 to the plasma 
membrane (Wang et al., 1999). PKBp is the most important PKB isoform 
involved in insulin-stimulated glucose uptake. Knockdown studies using small- 
interfering RNA (siRNA) have shown that reduction in the levels of PKBa alone 
slightly impairs insulin-stimulated glucose transport. However, a 70% reduction 
in the levels of PKBp inhibits approximately half of the insulin responsiveness 
(Jiang et al., 2003). Work using PKBa and PKBp knockout mice also 
corroborates the significance for PKBp in insulin-stimulated glucose uptake 
(Bae et al., 2003). The role of PKBa cannot be excluded, however, as 
combined depletions of PKBa and PKBp further attenuate the action of insulin 
on GLUT4 translocation (Jiang et al., 2003). By fusing constitutively active and 
kinase-inactive mutants of PKB to the N-terminus of GLUT4 in intracellular 
vesicles, it was found that PKB activation at, or close to, the GLUT4 vesicle 
was necessary, but not sufficient, to induce GLUT4 vesicle translocation to the 
plasma membrane (Ducluzeau et al., 2002). PKB must therefore phosphorylate 
substrates localised close to GLUT4 vesicles.
1.3.1.5.3 PKB Substrates
PKB phosphorylates proteins containing RXRXXS/T motifs. Two such proteins 
have been identified as being involved in insulin-stimulated glucose transport 
although many more PKB substrates have been identified. These two proteins 
are AS 160 and ‘ghosphoinositide kinase for five position containing a fwe 
finger’ (PIKfyve).
AS160 was first identified as a substrate for PKB in 2002 (Kane et al., 2002). 
The name derives from the fact that it is an Akt Substrate of 160 kDa. AS160 
consists of two PTB domains, a Rab-GAP domain (GAP stands for GTPase- 
activating protein) and five PKB phosphorylation sites (Sano et al., 2003). Rab 
proteins are small G-proteins involved in vesicle trafficking. In their GTP-bound
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form, the Rab protein is involved in vesicle movement and fusion. The GAP for 
a Rab stimulates the intrinsic GTPase activity of the Rab to generate the 
inactive GDP-bound form of the Rab. The insulin-stimulated phosphorylation of 
AS160 and a functional GAP domain is required for GLUT4 translocation to the 
plasma membrane (Sano et al., 2003), thus providing evidence that AS160 is 
important in insulin-stimulated glucose transport. AS160 is specific for Rabs 
2A, 8A, 10 and 14 which are present on the GLUT4 vesicle (Larance et al., 
2005, Miinea et al., 2005). AS160 is associated with GLUT4 vesicles in the 
basal state but not with insulin-stimulated GLUT4 vesicles (Larance et al., 
2005). A mechanism involving AS160 and GLUT4 translocation to the plasma 
membrane has been postulated, in which the insulin-stimulated translocation of 
GLUT4 requires a Rab in its active GTP form. In basal cells, the Rab involved 
in translocation is maintained in its inactive GDP form by the GAP domain of 
AS160. This GAP activity of AS160 is inhibited after AS160 is phosphorylated 
by insulin-activated PKB. This increases the level of the active GTP form of a 
Rab and thus GLUT4 vesicle translocation is triggered (Sano et al., 2003). This 
theory has further been confirmed recently by the use of short-hairpin RNA 
(shRNA) to knockdown the AS160 protein. Results confirmed that the AS160 
GAP activity was required for the basal retention of GLUT4 (Eguez et al., 
2005).
PIKfyve is the second protein identified as being downstream of PKB and 
involved in insulin-stimulated GLUT4 translocation. PIKfyve catalyses the 
synthesis of PI(5)P and PI(3,5)P2. PIKfyve consists of a PI(3)P-binding FYVE 
domain at the N-terminus, a DEP (dishevelled, Egl-10 and pleckstrin 
homology) domain of unknown function, a chaperonin-like region and a PI 5- 
kinase catalytic domain at the C-terminus. PIKfyve was first reported to have a 
role in insulin-stimulated glucose transport by the use of dominant-negative 
PIKfyve (Ikonomov et al., 2002). PIKfyve is phosphorylated by PKB at serine 
318 and this phosphorylation stimulated the PI(3)P 5-kinase activity of the 
enzyme. PIKfyve does co-localise with a highly motile subpopulation of GLUT4
29
vesicles. Furthermore, expression of a PIKfyve construct mutated at the PKB 
phosphorylation site enhances insulin-stimulated GLUT4 translocation 
(Berwick et al., 2004). This gives evidence for the role of PIKfyve in GLUT4 
trafficking. However, further experiments are needed to determine if PIKfyve is 
an important signalling molecule in this process.
1.3.1.5.4 Protein Kinase C
Protein kinase C (PKC) is a serine / threonine kinase. The PKC family of 
enzymes is subdivided into three categories (conventional, novel and atypical) 
depending on their activation requirements. The conventional (cPKC) isoforms 
(a, pi, Pm and y) require phosphatidylserine (PS), calcium and diacylglycerol 
(DAG) for activation. The novel (nPKC) isoforms (5, e, q, 0 and p) require PS 
and DAG, and the atypical aPKC isoforms (£, i and A) require PS but not 
calcium or DAG.
The general structure of a PKC molecule consists of a catalytic and a 
regulatory domain, composed of a number of conserved regions, interspersed 
with regions of lower homology, the variable domains. The aPKC isoforms, i 
and A, but not the conventional or novel isoforms, are required for insulin- 
stimulated glucose transport (Bandyopadhyay et al., 1997). aPKC is composed 
of a regulatory N-terminus and a catalytic C-terminus. The N-terminus 
regulatory subunit includes a pseudosubstrate which binds to, and inhibits, its 
own kinase domain by preventing both autophosphorylation and 
phosphorylation by other signalling molecules. Binding of acidic phospholipids, 
PI(3,4,5)P3 and PS (although PKC lacks a PH domain), to the regulatory 
subunit of aPKC increases the catalytic activity of the protein in response to 
insulin, by three separate but interrelated pathways: (1) abolishing the 
pseudosubstrate-dependent autoinhibition, resulting in a conformational 
change in PKC and subsequent activation, (2) increasing the level of 
phosphorylation at threonine-410 by PDK-1, and (3) increasing the level of
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autophosphorylation at threonine-560 (Standaert et al., 2001). Thus there are 
both phosphorylation and PDK-1 dependent and independent pathways to 
activate a PKC.
Several studies have reported a role for aPKC in insulin-stimulated glucose 
transport and GLUT4 translocation. These are highlighted in a review by 
Farese (Farese, 2002). Insulin-stimulated glucose transport is inhibited by both 
general PKC inhibitors in ail insulin-responsive tissues and by a cell permeable 
myristoylated PKC-£ pseudosubstrate (Bandyopadhyay et al., 1997).
Expression of constitutively active PKC-A mimicked the effect of insulin- 
stimulated glucose transport and the expression of a kinase-dead form of PKC- 
A completely blocked glucose uptake in insulin-stimulated but not in basal 
muscle cells. In agreement with the effect on insulin-stimulated glucose 
transport, constitutively active PKC-A mimicked, and kinase-dead PKC-A 
completely inhibited, insulin-stimulated GLUT4 translocation to the plasma 
membrane (Bandyopadhyay et al., 2000).
Mouse embryonic stem cells have had both alleles that encode the major 
aPKC (PKC-A) knocked out. The effect of insulin on glucose transport was 
severely compromised but can be fully rescued by the adenoviral-mediated 
expression of PKC-A (Bandyopadhyay et al., 2004). At present, it is not known 
how PKC mediates its effects to increase the level of GLUT4 at the plasma 
membrane. It is interesting to note that PKC is not involved in insulin- 
stimulated glucose transport in cardiomyocytes. Instead PKC activation 
induces insulin resistance by modifying the insulin sensitivity of the 
cardiomyocyte (Russ and Eckel, 1995).
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1.3.2 Phosphatidylinositol 3-Kinase-Independent Pathway
PI3K is accepted as a critical component in the transmission of the insulin 
signal to mobilise GLUT4 to the plasma membrane. However it seems that 
PI3K alone is not sufficient to promote insulin-stimulated GLUT4 translocation 
and glucose uptake. Cell permeable derivatives of PI(3,4,5)P3 were unable to 
stimulate glucose transport in adipocytes. However, they did restore insulin- 
stimulated glucose transport in cells where PI3K was inhibited by wortmannin 
(Jiang et al., 1998). Other evidence supporting this concept includes the fact 
that growth factors such as PDGF, IL4, or (31-integrin clustering, stimulate IRS- 
1 associated PI3K activity to a similar extent to that seen with insulin. However, 
only minor effects were observed with regard to changes in glucose uptake 
(Isakoff et al., 1995, Guilherme and Czech, 1998). It has therefore been 
postulated that a second insulin signalling pathway, distinct but perhaps acting 
in conjunction with the PI3K-dependent pathway, is necessary for insulin- 
stimulated GLUT4 translocation and glucose uptake in adipocytes. Several 
studies have identified this additional insulin-signalling pathway as the 
‘CAP/Cbl pathway’. However, the CAP/Cbl pathway stimulating GLUT4 
translocation is only present in adipocytes, it is not functional in muscle 
(JeBailey et al., 2004). The CAP/Cbl pathway has remained controversial in 
the GLUT4 field and recent evidence, presented below, has further questioned 
the relevance of this pathway.
1.3.2.1 The CAP/Cbl pathway
A subset of functional insulin receptors is present in specialised caveolae- 
enriched lipid raft microdomains in the plasma membrane (Gustavsson et al., 
1999). The proto-oncogenes c-Cbl and Cbl-b are phosphorylated after 
activation of the insulin receptor and are recruited by adapter proteins to the 
caveolin-enriched lipid raft compartments (Baumann et al., 2000). APS and
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CAP are two adapter proteins involved in this recruitment. The CAP (c-Cbl- 
associated protein) adapter protein contains three SH3 domains in its C- 
terminus and a region of homology to the gut peptide sorbin in its N-terminus 
referred to as a SoHo domain. The proline-rich domains in Cbl bind to the SH3 
domains in CAP and the CAP/Cbl complex forms. APS is a second adapter 
protein implicated in the CAP/Cbl pathway. APS contains a SH2 domain, 
through which it interacts with the insulin receptor. Following phosphorylation 
by insulin, APS binds to the SH2 domain of Cbl. This recruits the CAP/Cbl 
complex to the insulin receptor and Cbl is phosphorylated by the insulin 
receptor at three tyrosine residues (Liu et al., 2002). The CAP/Cbl complex 
dissociates from the insulin receptor after Cbl is phosphorylated. The SoHo 
domain in the CAP protein binds to the lipid raft protein flotillin and so localises 
Cbl to the lipid raft domain in the cell membrane (Baumann et al., 2000, Kimura 
et al., 2001). Deletion of the SoHo domain disrupts this targeting and inhibits 
insulin-stimulated glucose uptake and GLUT4 translocation to the plasma 
membrane (Kimura et al., 2001). The SH2 domain of another adapter protein, 
Crkll, binds to a phosphorylated tyrosine in Cbl. Crkll contains a SH3 domain, 
through which it is associated to a guanylnucleotide exchange factor (GEF) 
called C3G. C3G activates the Rho family protein TC10 by catalysing the 
exchange of GTP to GDP (Chiang et al., 2001). Two isoforms of TC10 (TC10a 
and TC10p) are both activated by insulin and are both present in lipid raft 
domains in adipocyte cell membranes (Chiang et al., 2002). TC10 is important 
in insulin-stimulated glucose transport as a dominant-interfering TC10 mutant 
inhibits insulin-stimulated glucose uptake (Chiang et al., 2001). TC10 interacts 
with various effector molecules that may play a role in insulin-stimulated 
glucose transport. The CIP4/2 (Cdc42-interacting protein 4/2) protein has an 
intracellular localisation and, following insulin stimulation, it translocates to the 
plasma membrane. Insulin-stimulated GLUT4 translocation is inhibited 
following transfection of a mutant form of CIP4/2, suggesting a role for CIP4/2 
in glucose uptake (Chang et al., 2002). TC10 also interacts with a component 
from the exocyst complex, Exo70 (Inoue et al., 2003). Exo70 translocates to
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the plasma membrane after insulin-induced activation of TC10. The exocyst 
complex may have a role in GLUT4 vesicle fusion with the plasma membrane 
because mutant Exo70 does not affect the rate of trafficking of the GLUT4 
vesicle but inhibits glucose uptake (Inoue et al., 2003). Further work is needed 
to elucidate a mechanism whereby these signalling molecules stimulate the 
translocation of GLUT4 to the plasma membrane.
Two independent studies involving the use of small interfering RNA (siRNA) 
have given conflicting results as to the importance of the CAP/Cbl pathway in 
insulin-stimulated glucose uptake. The first study involved the siRNA depletion 
of APS or Cbl which resulted in the inhibition of insulin-stimulated glucose 
transport (Ahn et al., 2004), implicating a role for the CAP/Cbl pathway in this 
mechanism. The second study used siRNA to deplete Cbl, CAP or Crkll. This 
depletion failed to diminish insulin-stimulated glucose transport or GLUT4 
translocation (Mitra et al., 2004, Zhou et al., 2004). This study argues against 
the role of the CAP/Cbl pathway in insulin-stimulated glucose transport. It has 
not been resolved which of these studies is correct. However, following the 
knockdown of the proteins, the first study did not determine whether the levels 
of the GLUT4 protein were reduced due to the toxicity of the siRNAs used.
1.3.2.1.1 Intersection of the PI3K-Dependent and -Independent Pathways
Atypical PKC is phosphorylated by PDK1 in the PI3K-dependent pathway 
(Section 1.3.1.5.4). However, following the activation of TC10, aPKC has also 
been reported to be phosphorylated and recruited to lipid raft microdomains 
when it is in complex with Par3 and Par6 proteins (Kanzaki et al., 2004). Thus, 
aPKC is also involved in the CAP/Cbl insulin-signalling pathway. Other 





















Figure 1.2 Insulin signalling cascades which culminate in the translocation of
GLUT4 to the plasma membrane. Two insulin-dependent pathways are involved in 
GLUT4 translocation, a PI3K-dependent (A) and a PI3K-independent (B) pathway. 
See text for details. Adapted from (Saltiel and Kahn, 2001) and (Chang etal., 2005).
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1.4 Insulin-Independent Signalling Pathways Involved in
Glucose Uptake
Contracting muscle increases glucose transport via stimulating the 
translocation of GLUT4 to the plasma membrane. The contraction-stimulated 
pathway occurs through an insulin-independent mechanism but the mediators 
of this signal are still unknown. AMP-activated protein kinase (AMPK) has been 
implicated as being involved in contraction-stimulated glucose transport. 
However, studies using transgenic mice expressing a dominant inhibitory form 
of AMPK suggest that other AMPK-independent pathways are also involved in 
contraction-mediated glucose uptake (Mu et al., 2001).
It is difficult to assess the effect of contraction-stimulated GLUT4 translocation 
in basal cardiomyocytes because the heart is continually contracting. It has 
been proposed that in mice lacking the insulin receptor, glucose uptake in non­
contracting cells is reduced. Therefore, in non-contracting cells the majority of 
GLUT4 is intracellular (Belke et al., 2002). The mechanism for GLUT4 
translocation in response to contraction in cardiomyocytes has been 
investigated in a few studies. The effect of insulin and contraction on glucose 
transport activation is not additive. This is more likely to be because the two 
pathways converge in cardiomyocytes rather than there being two separate 
pools of GLUT4 in the heart (Kolter et al., 1992, Till et al., 1997). Additional 
work has concluded that glucose transport in response to contraction, involves 
the activation of PI3K (i.e. a wortmannin-sensitive pathway) without the 
activation of the insulin receptor or IRS signalling molecules and also does not 
lead to the downstream activation of PKB (Till et al., 2000). Like insulin 
stimulation, contraction stimulates the exocytosis of GLUT4 without any 
marked change in the rate of endocytosis (Yang and Holman, 2005). However, 
further work is needed before the mechanism of contraction-stimulated glucose 
transport in cardiomyocytes can be fully understood.
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Skeletal muscle is composed of a heterogeneous population of fiber types. The 
contraction-stimulated signalling pathways that lead to GLUT4 translocation to 
the plasma membrane are variable between the different skeletal muscle fiber 
types. In slow twitch oxidative muscle fibers (e.g. soleus muscle), contraction 
stimulates glucose transport via a pathway that does not include the key 
signalling molecules involved in the insulin-stimulated pathway. The 
contraction-stimulated pathway does not involve PKB. PI3K is also not involved 
as contraction-stimulated glucose transport is not inhibited by wortmannin (a 
PI3K inhibitor). The effect of both insulin and contraction on glucose transport 
activity and the cell surface levels of GLUT4 were almost completely additive 
(Lund et al., 1995, Lund et al., 1998). In fast twitch glycolytic fibers (e.g. 
extensor digitorum longus muscle) the contraction-stimulated pathway does 
include the key signalling molecules involved in the insulin-stimulated glucose 
transport pathway. Contraction of fast twitch glycolytic fibers leads to the 
activation of PKB via a PI3K-sensitive pathway which is inhibited by 
wortmannin (Sakamoto et al., 2002, Sakamoto et al., 2003). Therefore, the 
signalling pathway initiated following contraction in cardiomyocytes (although 
very dependent on oxidative metabolism), may resemble the contraction- 
stimulated signalling pathway in fast twitch muscle more closely than in slow 
twitch skeletal muscle (Yang and Holman, 2005).
Hypoxia and ischemia are two important pathological conditions which also 
induce glucose uptake in muscle cells. Under hypoxic and ischemic conditions 
GLUT4 translocates to the sarcolemma and increases the glucose transport 
into the cell (Young et al., 1997, Montessuit et al., 1998, Fuller et al., 2001). 
This signalling pathway terminating in GLUT4 translocation is independent 
from the insulin-stimulated pathway but may have additive effects on GLUT4 
translocation to the plasma membrane (Sun et al., 1994). AMPK activity 
increases during ischemia. Therefore, Russell and colleagues investigated 
whether AMPK stimulates GLUT4 translocation through the use of 5- 
aminoimidazole-4-carboxyamide-1-p-D-ribofuranoside (AICAR), an activator of
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AMPK. AICAR increases AMPK activation and GLUT4 translocation and use of 
a competitive inhibitor of AMPK decreases the level of glucose uptake. It has 
therefore been concluded that AMPK is important in GLUT4 translocation in 
hypoxic conditions (Russell, III et al., 1999). The full mechanism by which 
AMPK activates GLUT4 translocation has not been fully elucidated but it is 
thought that an increase in the AMP/ATP ratio stimulates AMPK activity. The 
signalling pathways resulting in the translocation of GLUT4 to the plasma 
membrane in response to contraction and hypoxia must differ even though 
AMPK is implicated in both pathways. This is because the two pathways 
converge on the GLUT4 trafficking pathway at different steps. Contraction, like 
insulin stimulation, increases the rate of GLUT4 exocytosis with little effect on 
the rate of endocytosis. However, in contrast to insulin- and contraction- 
stimulated glucose transport, hypoxia and ischemia do not stimulate GLUT4 
exocytosis. Instead, it leads to a reduction in GLUT4 endocytosis (Yang and 
Holman, 2005).
1.5 GLUT4 Trafficking
The following section will highlight the complexity of GLUT4 vesicle trafficking. 
However, as will be seen, a lot more investigation is needed before the full 
extent of GLUT4 trafficking will be fully understood. Figure 1.3 illustrates what 
has been identified thus far.
1.5.1 The Intracellular GLUT4 Compartment
GLUT4 constitutively cycles between intracellular compartments and the 
plasma membrane in both basal and insulin-stimulated adipocytes (Yang and 
Holman, 1993). Insulin increases the number of GLUT4 transporters on the 
plasma membrane without increasing the total number of transporters in the
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cell. It does this by increasing the rate of exocytosis of GLUT4 to the plasma 
membrane and has little or no effect on the rate of endocytosis (Yang and 
Holman, 1993, Satoh et al., 1993). GLUT4 must therefore be sequestered 
inside the cell under basal conditions. Through the use of electron microscopy, 
GLUT4 has been found to have an intracellular localisation in basal conditions. 
GLUT4 is predominantly in the trans-Golgi network (TGN) and tubulo-vesicular 
structures throughout the cytoplasm (Slot et al., 1991, Malide et al., 2000). In 
unstimulated cells, a subset of GLUT4 transporters co-localise with endosomal 
markers (TGN-38, Mannose-6-phosphate, transferrin receptor) in the peri­
nuclear region, probably late endosomes and the TGN. GLUT4 is also present 
in specialised compartments, which are associated with VAMP2. Following 
insulin stimulation, GLUT4 still co-localises with the endosomal markers but not 
with VAMP2. Therefore, the specialised GLUT4 vesicles associated with 
VAMP2 must be the predominant pool of GLUT4 that translocates to the 
plasma membrane in response to insulin (Malide et al., 1997). Chemical 
ablation of endosomes using a transferrin/HRP construct has revealed that 
60% of GLUT4 in basal adipocytes is not present in the endosomal system and 
that insulin-stimulated glucose transport is not affected by the ablation (Martin 
et al., 1996, Martin et al., 1998).
Insulin stimulates the fusion of GLUT4 vesicles with the plasma membrane. 
These vesicles are primarily VAMP2 positive vesicles but a small population of 
mannose-6-phosphate positive GLUT4 vesicles also fuses with the plasma 
membrane. The authors conclude that insulin causes the fusion of pre-existing 
VAMP2 positive GLUT4 vesicles and also increases the sorting of GLUT4 from 
the endosomal-TGN system (Ramm et al., 2000). Other studies have shown 
that GLUT4 in the endosomal system as well as GLUT4 in the specialised 
compartments is translocated to the plasma membrane (through the 
specialised compartment) following insulin stimulation (Millar et al., 2000, 
Zeigerer et al., 2002).
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Figure 1.3 The current understanding of GLUT4 vesicle trafficking. See text for details.
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The slow rate of basal GLUT4 exocytosis indicates that under basal conditions 
GLUT4 is specifically sequestered in intracellular compartments. These 
intracellular GLUT4 vesicles are highly specialised, insulin-sensitive 
compartments, distinct from the recycling endosomes and will be referred to as 
a ‘GLUT4 storage vesicle’ (GSV).
1.5.1.1 Proteins Identified in the GLUT4 Storage Vesicle
An insulin-responsive aminopeptidase (IRAP) has been identified as a major 
protein that co-localises with GLUT4 on GSVs. In response to insulin, IRAP 
traffics in a manner very similar to GLUT4. IRAP is not just present on GSVs 
but is present in all GLUT4-containing compartments (Keller et al., 1995, Ross 
et al., 1996). Interaction of the N-terminus of IRAP with a protein termed p115 
in the peri-nuclear region of the cell has led to the theory that IRAP may have a 
role in the tethering of GLUT4 in an intracellular location (Hosaka et al., 2005).
The v-SNARE vesicle-associated membrane protein 2 (VAMP2) is found on 
GSVs (where v-SNARE stands for a vesicular soluble N-ethylmaleimide- 
sensitive factor attachment protein receptor) but it is not found on other 
GLUT4-containing compartments. VAMP3 (cellubrevin) co-localises with 
GLUT4 in the endosomal compartments (Martin etal., 1996). VAMP2 has been 
found to play a role in insulin-stimulated translocation of GLUT4 from GSVs 
(Olson et al., 1997, Martin et al., 1998).
A recent study has identified three Rab proteins that are present on GLUT4 
vesicles. These proteins are Rab10, Rab11 and Rab14. In the basal state the 
downstream target of PKB, the Rab GTP-ase activating protein AS160 
(Section 1.3.1.5.3), is associated with the GLUT4 vesicles. The Rab proteins 




Adaptor proteins (AP) are a growing family of proteins that select cargo for 
inclusion into coated vesicles in the late secretory and endocytic pathways. 
The family is composed of four adaptor proteins (AP1-4) together with a family 
of monomeric adaptors called GGAs. Each member of the family of adaptor 
proteins has a distinct cellular distribution and they select specific cargo into 
distinct types of vesicles.
AP1, AP2, AP3 and AP4 have a heterotetrameric structure consisting of two 
large subunits, a medium sized p subunit and a small a subunit (AP1: y, (31, 
p1 and ct1, AP2: a, (32, p2 and o2, AP3: 5, (33, p3 and o3 and AP4: z, (34, p4 
and o4). AP1 and AP2 are found in clathrin-coated vesicles. AP1 is localised 
on the TGN and AP2 is localised on the plasma membrane. They attach the 
clathrin to the membrane, select the vesicle cargo and recruit accessory 
proteins that regulate vesicle formation. AP3 and AP4, like AP1, are localised 
on intracellular membranes. AP3 is predominantly found on endosomes and 
AP4 is found on the TGN. However, AP3 and AP4 differ from AP1 and AP2 
because they are not found on clathrin coated-vesicles (Robinson, 2004).
The family of Golgi-localised, y-ear-containing, ARF-binding (GGA) proteins 
have also been identified as adaptor proteins. GGA proteins are monomeric 
and take their name because the C-terminal domain contains an ‘ear’ domain 
similar to the y subunit in AP1. The GGA proteins are found on the membrane 
of both the TGN and endosomes, similar to AP1. The extent of the co­
localisation between AP1 and GGAs has not been fully determined. There is 
co-localisation but it is still under debate as to their relationship, whether they 
act in parallel or opposing trafficking pathways. The GGA proteins function with 
clathrin but they are not detected on clathrin-coated vesicles (Robinson, 2004).
The mechanism by which GLUT4 is sequestered from the endosomal system 
into the GSV may involve the interaction of GLUT4 with a range of adaptor
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complexes. The first evidence to suggest this comes from observations using 
immunoelectron microscopy, which identified GLUT4 localised to intracellular 
vesicles containing the Golgi-derived y-adaptin subunit of AP1 (Marsh et al.,
1998). In addition, GLUT4 vesicles have been shown to associate with 
significant levels of AP1 adaptor subunits y, p1 and 51, which are localised in 
the TGN (Gillingham et al., 1999). Further evidence for the interaction of 
GLUT4 with the AP1 complex, is the observation that the (31 subunit of AP1 
binds a peptide based on the C-terminal sequence of GLUT4 which contains 
the di-leucine motif (|_489|_490) (Rapoport et al., 1998). AP1 could be involved in 
the budding of vesicles containing GLUT4 to and from the TGN to the GSV. 
This could be particularly important in the basal retention of GLUT4 in its 
intracellular compartment in the proposed cycling models (Section 1.5.2). AP3 
has also been found to associate with isolated GLUT4 vesicles and could also 
be involved in the intracellular sorting of GLUT4 into GSVs (Gillingham et al.,
1999).
Clathrin-mediated endocytosis from the plasma membrane involves the AP2 
complex. AP2 facilitates the recruitment of proteins into clathrin coated pits for 
efficient endocytosis. AP2 interacts with proteins that contain a YXXO motif (Y 
is tyrosine or potentially phenylalanine, X is any amino acid and O is any 
hydrophobic amino acid). The FQQI motif in the N-terminus of GLUT4 is a 
possible interaction motif for AP2. Indeed, mutation of the FQQI domain has 
identified it as an important internalisation motif (Section 1.6.1). The GGAs are 
also important in GLUT4 intracellular sorting and will be explained in section 
1.5.1.3.
1.5.1.3 Generation of GLUT4 Storage Vesicles
There are two possibilities for the mechanism whereby newly synthesised 
GLUT4 enters the GSV. The first is that the GLUT4 first traffics to the plasma 
membrane, where during sorting following endocytosis, GLUT4 is sorted into
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the GSV. The second way is that GLUT4 is sorted directly from the TGN into 
the GSV. This issue has been resolved by the use of a dominant-interfering 
dynamin mutant, which inhibits endocytosis. The inhibition of endocytosis did 
not affect insulin-stimulated GLUT4 translocation (Watson etal., 2004a). Newly 
synthesised GLUT4, therefore, directly traffics from the TGN to the GSV (the 
second scenario above). GGA proteins are involved in the sorting of the 
mannose-6-phosphate receptor at the TGN (Puertollano et al., 2001). GLUT4 
co-localises with a subset of mannose-6-phosphate receptors in the 
endosomal system and so the potential effect of the GGA adapter proteins on 
the sorting of GLUT4 into the GSV has been investigated. By using a 
dominant-interfering GGA mutant it was concluded that following GLUT4 
biosynthesis, GLUT4 traffics and sorts into the GSV in a GGA-dependent 
process. This is either directly or indirectly through an endosomal intermediate. 
However, exit from the GSV is GGA independent (Watson et al., 2004a). No 
direct interaction of GLUT4 and GGA proteins has been found so the authors 
concluded that the selection of GLUT4 by the GGA proteins must occur 
through interaction with another vesicular protein. In addition to newly 
synthesised GLUT4, the recycling pool of GLUT4, i.e. GLUT4 that had been 
translocated to the plasma membrane and had undergone endocytosis, 
localises to the GGA-containing compartments in the peri-nuclear region of the 
cell (in the TGN and in some endosomes) (Li and Kandror, 2005). From the 
use of immuno-adsorption and GST-pulldown assays, it was shown that GGA 
proteins interact with GLUT4 vesicles. As the newly synthesised and recycling 
pools of GLUT4 both undergo GGA-dependent entry into the GSV, the two 
pathways could converge in either the TGN or endosomal compartments (Li 
and Kandror, 2005). Further investigation is needed to determine the precise 
mechanism whereby GGA proteins control the entry of GLUT4 into GSVs. The 
role AP1 has in this process, either in a parallel or an opposing pathway, also 
needs to be investigated. Sortilin is a protein found in the TGN and on 
endosomes and has a GGA-binding motif in its cytoplasmic tail (Nielsen et al., 
2001). Sortilin is associated with GLUT4, probably in endosomal vesicles (Lin
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et al., 1997, Morris et al., 1998). Further studies have shown that sortilin is 
necessary and sufficient for the formation of GSVs (Shi and Kandror, 2005). 
The authors predict that the induction of sortilin is the major event that leads to 
the formation of GSVs.
1.5.2 Models of GLUT4 Cycling
The mechanism of the storage and the cycling of GLUT4 to the plasma 
membrane in unstimulated cells and in response to insulin is still under debate. 
There are several mechanisms that can explain the basal retention of GLUT4. 
The retention of GLUT4 could occur in endosomes, perhaps involving an 
intracellular tethering factor. Alternatively, the retention of GLUT4 could occur 
in the GSVs. A combination of both of these mechanisms could also exist 
(Coster et al., 2004). Over the years of research into GLUT4, different models 
have been proposed. The current theories are described below in more detail. 
Two different laboratories have put forward independent models of GLUT4 
cycling in bone fide insulin target cells (3T3-L1 adipocytes). The two models 
differ in the basal trafficking of GLUT4 to the plasma membrane, the presence 
of a latent (non-translocating) pool of GLUT4 and the involvement of the TGN 
in the GSV. It is likely that the precise mechanism of the storage and cycling of 
GLUT4 is in fact a combination of the two models. McGraw and colleagues 
proposed one model and James and colleagues proposed the second. The 
models are illustrated diagrammatically in Figure 1.4 A and B respectively.
McGraw and colleagues have proposed that, in the basal state, GLUT4 is 
retained in the cell by a continual intracellular retrieval / retention mechanism 
but all GLUT4 can translocate to the plasma membrane in unstimulated cells 
(Karylowski et al., 2004). GLUT4 rapidly recycles between the GSV and the 
endosomal compartments that contain the transferrin receptor. It was found 
that GLUT4-containing vesicles are five times as likely to fuse with endosomes
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as they are to fuse with the plasma membrane and hence the intracellular 
retention of GLUT4. GLUT4 only localises with furin in transferrin receptor- 
containing endosomes. Furin is present in late endosomes and the TGN 
(Thomas, 2002) which implies that the TGN is not a major intracellular 
reservoir of GLUT4. Insulin can stimulate the translocation of GLUT4 to the 
plasma membrane from either the GSV or the endosomal pool (which traffics 
through the GSV) (Zeigerer et al., 2002). Rab11 is a GTPase which is required 
for the trafficking of the transferrin receptor both between the endosomes and 
the TGN and between the endosomes and the plasma membrane (Ren et al., 
1998, Wilcke et al., 2000). Rab11 is necessary for sorting GLUT4 from 
endosomes and into the GSV. The fact that failure to do this results in a 
decrease in the rate of translocation observed with insulin, gives further 
evidence that endosomal GLUT4 translocation is important in insulin- 
stimulated GLUT4 translocation (Zeigerer etal., 2002) (Figure 1.4 A).
James and colleagues have provided a contrasting mechanism in which there 
are two interconnected trafficking loops. The first involves trafficking between 
the plasma membrane and endosomes and the second involves trafficking 
between endosomes and GSVs. It is proposed that the endosomal recycling 
pool of GLUT4 and the GSV do not co-operate and only GLUT4 in the 
endosomal pool transits to the plasma membrane in the basal state (Govers et 
al., 2004). The James laboratory found that there are two insulin-regulatable 
pathways involved in insulin-stimulated GLUT4 translocation: (1) insulin 
increases the number of GLUT4 molecules in the recycling pathway in a dose- 
dependent manner, (2) insulin increases the rate of exocytosis from 
endosomes to the plasma membrane. Insulin induces the translocation of 
GLUT4 from the GSV to the endosomes before translocation to the plasma 
membrane (Coster et al., 2004). Maximum doses of insulin do not result in all 
of the GLUT4 from the GSV being translocated to the plasma membrane. This 
‘latent pool’ of GLUT4 could be ‘older’ GLUT4 i.e. synthesised earlier in the 
lifetime of the cell and ‘newer’ GLUT4 could preferentially translocate to the
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plasma membrane in response to insulin (Govers et al., 2004). The TGN has 
also been suggested to play a role in the site of storage for the insulin- 
responsive GLUT4 molecules i.e. the GSV. The role of the TGN as a GSV has 
largely been ignored in other models. It has been predicted that the TGN is 
part of the GSV because, following endocytosis, GLUT4 is translocated 
through endosomes to a subdomain of the TGN. This subdomain is enriched in 
the TGN target-soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (t-SNAREs) syntaxin 6 and 16. However, the TGN marker TGN38 is 
not present in this subdomain (Shewan et al., 2003). Syntaxin 6 and 16 have 
both been implicated in the trafficking of cargo between the endosomes and 
TGN. However, further work is needed to determine if the TGN is part of the 
GSV (Figure 1.4 B).
1.5.3 GLUT4 Exocytosis
Insulin increases the rate of GLUT4 exocytosis (Yang and Holman, 1993, 
Satoh et al., 1993). As previously discussed, the insulin-signalling pathway is 
diverse and the full extent of how the insulin signal is transmitted to GLUT4 is 
not fully understood (Section 1.3). Insulin may exert its effects at a number of 
steps in the exocytotic pathway: (1) intracellular vesicle budding, (2) trafficking 
of GLUT4 to the plasma membrane, (3) vesicle docking at the plasma 
membrane, or, (4) vesicle fusion with the plasma membrane. The downstream 
target of insulin receptor stimulation, AS160 (Section 1.3.1.5.3), has shown a 
role for insulin in a step before the docking and fusion to the plasma membrane 
(Zeigerer et al., 2004). Another downstream target of the insulin receptor, 
PIKfyve (Section 1.3.1.5.3), is believed to be involved in increasing the rate at 
which GLUT4 is sorted from the internalising endosomes through the TGN and 
into the GSV pool of GLUT4 (Welsh et al., 2005).
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Endosomes Latent Pool 
of GLUT4
Figure 1 4  Current models of GLUT4 storage and cycling. The models differ in
whether there is a latent pool of GLUT4 or if all transporters translocate to the plasma 
membrane, in the contribution of the TGN as an intracellular storage site for GLUT4, 
and in the route in which GLUT4 translocates to the plasma membrane. Blue arrows = 
basal translocation, green arrows = translocation in response to insulin and red arrows 
= translocation in basal and insulin stimulated conditions.
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The mechanism by which GLUT4 translocates to the plasma membrane was 
discussed in section 1.5.2 and occurs either directly from the endosomal pool 
following trafficking from the GSV to the endosomal pool or from both the 
endosomal- and GSV-containing GLUT4 pools simultaneously. Studies in our 
laboratory have also concluded a role for insulin in stimulating GLUT4 vesicle 
fusion to the plasma membrane (section 1.5.4) (Koumanov eta l., 2005).
1.5.4 GLUT4 Fusion with the Plasma Membrane
Once GLUT4 has translocated to the plasma membrane, GLUT4 undergoes a 
docking and fusion step before it is fully inserted into the membrane and 
glucose can enter the cell. Fusion of GLUT4 vesicles with the plasma 
membrane requires specific proteins, which are present on both the GLUT4 
vesicle and on the target plasma membrane. The cellular machinery involved 
in membrane fusion is conserved in all eukaryotes and includes the proteins N- 
ethylmaleimide sensitive factor (NSF), soluble NSF attachment proteins 
(SNAPs), SNAP receptors (SNAREs). There are two classes of SNARE 
protein, v-SNAREs are present on vesicles and t-SNAREs are present on 
‘target’ plasma membranes.
In adipocytes, the vesicle-associated membrane protein 2 (VAMP2 or 
synaptobrevin 2) is the v-SNARE in the GSV and VAMP3 (cellubrevin) is the v- 
SNARE on GLUT4-containing endosomes (Cain et al., 1992, Timmers et al., 
1996). There is another protein called pantophysin present on GLUT4 vesicles 
(Brooks et al., 2000). It is believed that pantophysin binds to VAMP2 and thus 
limits the availability of this SNARE. The t-SNARE proteins involved in GLUT4 
vesicle fusion in adipocyte plasma membranes are syntaxin4 (Timmers et al., 
1996) and SNAP23 (Rea et al., 1998). Together syntaxin4, SNAP23 and 
VAMP2 can form an SDS-resistant complex in vitro supporting the fact that this 
complex forms in GSV fusion to the plasma membrane (Rea et al., 1998). This
49
brings the GSV in close proximity to the plasma membrane. The core of the 
SNARE complex consists of a bundle of four helices, three from the t-SNARE 
and one from the v-SNARE (Poirier et al., 1998). Syntaxin4 and VAMP2 each 
contribute one coil, and SNAP23 contributes two coils to the complex.
Syntaxin4-interacting proteins have been identified, which bind to syntaxin4 in 
the basal state and so are negative regulators of insulin-induced vesicle fusion. 
Munc18c prevents vesicle fusion with the plasma membrane by inhibiting the 
binding of syntaxin4 to VAMP2 (Tellam et al., 1997). Insulin relieves this 
inhibition by inducing the dissociation of Munc18c from syntaxin4 and by 
sequestering Munc18c to an alternative plasma membrane binding site 
(Thurmond et al., 1998). The discovery of AS 160 as a downstream target of 
the insulin receptor has led to the theory that phosphorylation of AS160 in 
response to insulin and the consequential disabling of its GAP activity leads to 
the activation of a Rab protein. The GTP-Rab could then directly or indirectly 
bind to munc18c, thus weakening the munc18c-syntaxin4 interaction. 
Syntaxin4 could then change its conformation, allowing GSVs to dock and fuse 
with the plasma membrane (James, 2005). In unstimulated cells, 
overexpression of Munc18c also enhances the level of GLUT4 in the plasma 
membrane. This may reflect a positive role for Munc18c in promoting SNARE 
assembly (Widberg et al., 2003).
Synip, another syntaxin4-interacting protein, has been identified, which binds in 
the basal state but not in insulin-stimulated cells (Min et al., 1999). Synip has 
been proposed to be a downstream target of PKBp at serine 99. A Ser—>Phe 
mutant prevents insulin-stimulated syntaxin4 dissociation, suggesting that 
phosphorylation at serine 99 is essential for the insulin-stimulated dissociation 
of synip from syntaxin4 (Yamada et al., 2005). However, shortly after this 
report was published, another group showed that overexpression of a Ser—>Ala 
mutant at residue 99 in synip, which lacks a phosphorylation site, has no effect 
on insulin-stimulated GLUT4 translocation. Therefore, this study concluded that 
phosphorylation of synip at serine 99 is not required for GLUT4 translocation
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(Sano et al., 2005). The major difference between the two studies was the 
amino acid the serine was mutated to. Alanine resembles the 
unphosphorylated form of serine and so this mutation is unlikely to have any 
major changes on protein structure. However, phenylalanine is a bulky 
hydrophobic molecule which might lead to a change in conformation of the 
protein. The study by Sano and colleagues is likely to be the more accurate 
due to their alanine mutation of serine 99. Thus phosphorylation of synip is 
unlikely to play a role in GLUT4 vesicle fusion (Sano et al., 2005). Synip 
contains a PDZ domain in the N-terminus of the protein. Insulin could, 
therefore, regulate an interaction between the PDZ domain of synip and 
another regulatory protein (Min etal., 1999).
Tomosyn is the final syntaxin4 interacting protein that has been identified and 
is present at the plasma membrane and in adipocyte cytosol. Tomosyn binds 
with high affinity to syntaxin4 and SNAP23 via a VAMP-2 like domain and 
overexpression of tomosyn inhibits the insulin-dependent translocation of 
GLUT4 to the plasma membrane (Widberg et al., 2003). The exact function of 
insulin signalling intermediates in the tethering / docking step still needs further 
investigation to identify the actual site of insulin action. The fusion process is 
highly regulated. Insulin induces an 8-fold increase in the rate of fusion and 
insulin activation of the plasma membrane is the essential regulatory step. 
Fusion of the vesicle with the plasma membrane is SNARE-dependent and 
PKB recruitment to the insulin-activated plasma membrane is needed for 
fusion (Koumanov et al., 2005). Use of the cell-free fusion assay developed in 
the study will be crucial for further investigation into the fusion of GLUT4 
vesicles to the plasma membrane.
1.5.5 GLUT4 Endocytosis
Once GLUT4 has fused with the plasma membrane, it is rapidly internalised in 
both basal and insulin-stimulated cells (Yang and Holman, 1993, Satoh et al.,
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1993). Insulin does result in a slight decrease in the rate of endocytosis, even 
though its main action is in the exocytotic arm of the trafficking pathway. The 
use of electron microscopy has identified a clustering of GLUT4 at the plasma 
membrane in clathrin-coated pits in both basal and insulin-stimulated cells (Slot 
et al., 1991, Robinson et al., 1992). This is further corroborated by the fact that 
decreasing the intracellular potassium concentration, which disassembles 
clathrin lattices and prevents their reassembly, results in an accumulation of 
GLUT4 at the cell surface, following the inhibition of endocytosis (Nishimura et 
al., 1993). Clathrin-mediated endocytosis is the mode of internalisation for 
constitutively recycling proteins, e.g. GLUT1 and the transferrin receptor, thus 
GLUT4 is internalised by the same mechanism as constitutively recycling 
proteins. However, the means by which the clathrin coated pits bud from the 
plasma membrane is not fully understood. Dynamin is a 100 kDa GTPase and 
is an important protein involved in the formation of clathrin-coated vesicles (van 
der Bliek et al., 1993). Hydrolysis of GTP by oligomeric rings of dynamin 
around the neck of the budding vesicle is required for vesicle scission (Takei 
and Haucke, 2001). Studies involving transfection of mutant dynamin have 
highlighted its importance in GLUT4 endocytosis, as a GTPase-negative 
dynamin mutant prevents GLUT4 endocytosis (Al Hasani et al., 1998, Kao et 
al., 1998). However, the molecular mechanism of GLUT4 endocytosis is not 
known.
1.5.6 Role of the Cytoskeleton in GLUT4 Trafficking
The cytoskeleton plays a role in many aspects of membrane trafficking, which 
includes the intracellular retention and trafficking of the GLUT4 protein. The 
first evidence that the cytoskeleton was involved in GLUT4 processes was 
through the use of immuno-electron microscopy. It was found that GLUT4 
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Figure 1.5 Diagram illustrating the current understanding of GLUT4 fusion. See text for details.
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Following disruption of the intermediate filaments and microtubules in 3T3-L1 
adipocytes, the localisation of GLUT4 changed from being peri-nuclear to the 
cell surface regions of the cell. The role of the microtubule-based motor, 
dynein, in GLUT4 trafficking was assessed. Inhibition of dynein inhibited 
insulin-stimulated GLUT4 translocation to the plasma membrane and so dynein 
was considered important for this process (Guilherme et al., 2000). 
Furthermore, inhibition of microtubule and actin filament function decreased 
insulin-stimulated glucose transport by 70% and 50%, respectively. When both 
microtubule and actin filaments were impaired insulin-stimulated glucose 
transport was completely inhibited. This shows that both actin and 
microtubules are essential for insulin-stimulated GLUT4 translocation to the 
plasma membrane (Patki et al., 2001). A few key studies will be illustrated 
below to show the importance and complexity of the involvement of the 
cytoskeleton in GLUT4 translocation.
Actin polymerisation plays an important role in insulin-dependent GLUT4 
translocation. The use of latrunculin to inhibit G actin polymerisation results in 
a decrease in GLUT4 exocytosis but has no effect on the level of endocytosis 
(Omata et al., 2000). Furthermore, the unconventional myosin 1C (Myolc), the 
motor protein that drives movements along actin filaments, is present in 
GLUT4-containing vesicles purified from 3T3-L1 adipocytes. The use of a 
dominant-negative Myolc has highlighted the requirement for Myolc for the 
insulin-stimulated GLUT4 translocation from the intracellular compartment to 
the plasma membrane. Myolc is not sensitive to wortmannin so Myolc must 
function in a PI(3)K-independent insulin signalling pathway that controls the 
movement of intracellular GLUT4-containing vesicles to the plasma membrane. 
To fully confirm a role for Myolc in insulin-stimulated GLUT4 translocation, 
siRNA was transfected into cells to prevent the endogenous expression of 
Myolc. This inhibited insulin-stimulated glucose uptake (Bose et al., 2002).
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Microtubules also have an effect on insulin-stimulated GLUT4 trafficking. 
Dynein interacts with the small GTP-binding protein Rab5. Insulin inhibits 
Rab5-GTP loading and decreases binding of dynein to microtubules in a PI3- 
kinase-dependent manner. The authors concluded that insulin inhibits the 
inward movement of GLUT4 from the plasma membrane back to its 
intracellular compartment, thereby regulating endocytosis (Huang et al., 2001). 
However, contrary to the work done by Huang et al, two independent 
laboratories have reported that microtubules do not have an effect on insulin- 
stimulated GLUT4 translocation but rather microtubules have an effect on the 
intracellular trafficking from endosomes to the GSV (Molero et al., 2001, 
Shigematsu et al., 2002). Microtubules, therefore, seem to play a role in the 
intracellular sorting of GLUT4 but the role in insulin-stimulated GLUT4 
translocation is still not known.
A lot of work has been done to identify that the cytoskeleton is important in 
GLUT4 trafficking. However, the precise mechanism whereby the cytoskeleton 
controls GLUT4 function is not fully understood.
1.6 GLUT4 Sorting Motifs
GLUT4 has a highly controlled trafficking mechanism in both basal and insulin- 
stimulated cells and GLUT4 is found in many different cellular compartments 
throughout the trafficking pathway (Section 1.5). To maintain this unique 
feature of GLUT4 compared to the constitutively recycling homologue GLUT1, 
GLUT4 must contain specific targeting motifs. It has been the goal of many 
laboratories to define these domains. Figure 1.6 illustrates the location of these 
potential targeting domains in the GLUT4 protein. GLUT4 and GLUT1 share 
least homology in the stretches of amino acids at the amino- and carboxyl- 
termini, as well as the large cytoplasmic loop between helices 6 and 7. The
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motifs involved in the targeting and sorting of GLUT4 are likely to be located in 
these regions.
1.6.1 The Amino-Terminal Targeting Motifs
The amino-terminus was first reported to be important in the intracellular 
retention of GLUT4 by Piper et al. Chimeras of GLUT1 and GLUT4 were 
generated and transiently expressed in CHO cells. When the full length GLUT1 
or GLUT4 proteins were transfected into the CHO cells, GLUT1 had a 
predominantly cell surface localisation and GLUT4 had an intracellular 
localisation in the basal state. Substitution of the amino-terminal region of 
GLUT4, with that of GLUT1, abolished its intracellular localisation. Conversely, 
if the amino-terminal region of GLUT 1 was substituted for that of GLUT4 the 
resulting protein was located in an intracellular compartment. A substitution of 
the carboxyl-terminus of GLUT4 and GLUT1 did not affect the subcellular 
localisation of the proteins (Piper et al., 1992). The authors therefore 
concluded that the amino-terminus of GLUT4 is both necessary and sufficient 
for intracellular sequestration.
Further studies were carried out using deletion and alanine substitution 
mutants in the N-terminus of GLUT4 to identify the subcellular localisation of 
the mutants and narrow down the critical residues for the sequestration. The 
mutants in which the first eight amino acids were deleted in GLUT4 or where 
phenylalanine 5 was mutated to alanine resulted in an increase in the cell 
surface expression of the protein. This indicates that these residues are 
important for the intracellular sequestration (Piper et al., 1993b). In addition, 
the Phe5 to Ala mutant proteins were also excluded from their co-localisation 





FQQI and LL - GLUT4 Internalisation motifs
FQQI - Intracellular sorting between endosomes and the GSV
LL - Intracellular sorting between the endosomes and theTGN
EQE - Endosomal trafficking of GLUT4
TELEYLGP - GLUT4 sorting from the recycling endosomes to the GSV
- GLUT4 storage in the GSV
Figure 1.6 Sorting Motifs within the cytoplasmic domains of GLUT4. These motifs 
may be involved in the unique trafficking properties of GLUT4 through direct 
interaction with adaptor-binding proteins. The strength of this interaction may be 
facilitated by other surrounding motifs e.g. the phosphorylated residues (green P).
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The FQQI domain fulfils the requirements for a functional clathrin-coated pit 
internalisation motif: an aromatic residue separated by two amino acids from a 
bulky hydrophobic residue. However, tyrosine-containing internalisation motifs, 
which have been identified in the cytoplasmic tails of the transferrin receptor, 
are more common than phenylalanine-based motifs (Collawn et al., 1990). A 
year after the study by Piper and colleagues, the potential of the FQQI motif in 
facilitating the intracellular sequestration of GLUT4 was questioned, following 
kinetic studies using chimeras of GLUT4 and the transferrin receptor. The N- 
terminus of the transferrin receptor was substituted for that of GLUT4. The 
GLUT4:transferrin receptor chimera recycled back to the plasma membrane at 
the same rate as that observed for the wild type transferrin receptor. This 
suggests that the N-terminus of GLUT4 did not facilitate its intracellular 
sequestration (Garippa et al., 1994). However, the FQQI motif was still 
implicated in internalisation as there was a 50% reduction in the internalisation 
rate of the chimeric protein. This finding was corroborated by a study by Araki 
et al, in which ATB-BMPA-tagged GLUT4 mutated at F5Q6 had a 40% 
reduction in the rate of internalisation compared to wild type GLUT4 (Araki et 
al., 1996). Mutation of F5 to a tyrosine residue in the GLUT4:transferrin 
receptor chimera, to form the classical consensus sequence, increased the 
rate of internalisation of the protein (Garippa et al., 1994). These experiments 
suggest that the FQQI motif in the N-terminus of GLUT4 is important for 
internalisation, although its presence results in a reduced rate of endocytosis 
compared with the classical consensus sequence observed in other recycling 
proteins.
Further experiments involving mutagenesis of the FQQI motif have led to the 
conclusion that, in addition to its role in internalisation, the N-terminus of 
GLUT4 is also required for sorting between intracellular compartments. The 
F5QQI motif at the N-terminus of GLUT4 was mutated to S5QQI and 
transfected into 3T3-L1 adipocytes. The mutated GLUT4 was mis-targeted to 
the late endosomes / lysosomes, showing that F5 was essential for correct 
trafficking to the GSV (Palacios et al., 2001). In addition, GLUT4 was mutated
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from F5QQI to A5QQI and transfected into 3T3-L1 adipocytes. Endosomal 
ablation illustrates that the mutated GLUT4 was only present in the endosomal- 
ablated compartment and not in the non-ablated GSV compartment. The 
mutated N-terminus of GLUT4 therefore results in the mis-trafficking of GLUT4, 
as the GLUT4 is not present in the GSV but only in the endosomes (Melvin et 
al., 1999). These sorting motifs responsible for GLUT4 trafficking have all been 
studied in fully matured, continually cycling GLUT4. In one recent study, the 
trafficking motifs involved in the initial trafficking from the TGN to the GSV, 
following biosynthesis, was investigated (Khan et al., 2004). GLUT4:GLUT1 
chimeras were made and transfected into 3T3-L1 adipocytes. Substituting the 
carboxyl-terminal domain of GLUT4 with that of GLUT1 had no significant 
effect on the trafficking to the GSV. However, substitution of either the GLUT4 
amino-terminal domain or the large cytoplasmic loop between transmembrane 
domains 6 and 7 resulted in the mis-targeting of GLUT4 to the plasma 
membrane. In agreement, only the substitution of the amino terminus plus the 
cytoplasmic loop of GLUT4 in the GLUT1 backbone resulted in the accurate 
trafficking of GLUT4 to the GSV. Following alanine-scanning mutagenesis, the 
essential residues for the efficient trafficking of GLUT4 from the TGN to the 
GSV were identified as F5 and I8 (and to a lesser extent D12G13) at the N- 
terminus and residues 227 -  271 in the large cytoplasmic loop. In conclusion, 
the N-terminus of GLUT4 is necessary for the efficient targeting of newly 
synthesised GLUT4 into the GSV (Khan et al., 2004).
The FQQI motif in the N-terminus of GLUT4 is therefore important for the 
internalisation of GLUT4 from the plasma membrane as well as for the 
intracellular sorting process that separates GLUT4 away from the endosomal 
system into the peri-nuclear GSV compartment, for both recycling and newly 
synthesised GLUT4.
59
1.6.2 The Carboxyl-Terminal Targeting Motifs
At the same time as the N-terminus of GLUT4 was being reported as an 
important trafficking domain, the C-terminus of GLUT4 was also reported as 
the domain that was important for intracellular sequestration (Verhey et al., 
1993, Marshall et al., 1993, Czech et al., 1993). The investigators created 
chimeras of GLUT4 and GLUT1, substituting the C-terminal regions of the 
protein. The chimeras were expressed in COS-7 cells (Czech et al., 1993), 
Xenopus oocytes (Marshall et al., 1993) or NIH 3T3 and PC 12 cells (Verhey et 
al., 1993). Each study showed that substitution of the GLUT4 C-terminal 
domain for that of GLUT1 resulted in the GLUT4 chimera displaying GLUT1 
trafficking characteristics (localised at the cell surface). Conversely the 
substitution of the C-terminal domain of GLUT1 with that of GLUT4 led to the 
GLUT1 chimera being sequestered into an intracellular compartment. Verhey 
and colleagues did find a partial role for the first 183 amino acids of GLUT4 in 
the intracellular sequestration of the protein but concluded that the C-terminal 
region of GLUT4 was of primary significance. The region in the C-terminus of 
GLUT4 that was responsible for the intracellular sequestration has been 
narrowed down to the dileucine motif |_489l_490. Chimeras were made in which 
the C-terminus of GLUT4 was substituted onto the GLUT1 protein and the 
dileucine motif was mutated to an alanine-serine motif (Verhey and Birnbaum,
1994). Alternatively, the C-terminus of GLUT4 was substituted onto the 
transferrin receptor and the dileucine motif was mutated to a dialanine motif 
(Garippa et al., 1996). Both mutants resulted in a decrease in the amount of 
GLUT4 in the GSV and a shift towards a cell surface localisation. The results 
from the chimera studies were supported by a study in which ATB-BMPA- 
tagged GLUT4 had the dileucine motif mutated to a dialanine motif. 
Transfection of this mutant protein resulted in a poor intracellular retention of 
GLUT4. The rate of endocytosis was not altered by the mutation but there was 
an increase in the rate of exocytosis (Araki et al., 1996).
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Like the FQQI motif, the dileucine motif appears to have an additional role in 
the sorting of intracellular GLUT4. The dileucine motif at the C-terminus of 
GLUT4 is also involved in sorting between the TGN and GSVs. The dileucine 
motif was mutated to a dialanine motif and expressed in 3T3-L1 adipocytes at 
endogenous levels i.e. the protein was not overexpressed. The subcellular 
location of the mutant was determined following ablation of the endosomal 
compartment. The mutant escaped ablation and so was not in the endosomal 
compartment. This mutant, therefore, does not prevent GLUT4 from reaching 
the non-ablated compartment and this implies a role for the dileucine motif in 
sorting from a separate intracellular compartment (Melvin et al., 1999). Its role 
in the intracellular sorting of GLUT4 is further corroborated through the use of 
the mutated dialanine motif. It has been shown that the dileucine motif is 
involved in targeting from the TGN to the GSV (Martinez-Arca et al., 2000). 
However, another study using chimeras of GLUT4 and GLUT1 have concluded 
that the dileucine motif, although important, is not sufficient for targeting 
GLUT4 to GSVs. Therefore, other residues within the C-terminal region must 
also have a role in the intracellular sorting of GLUT4 (Haney et al., 1995).
Further studies have identified the other motifs in the C-terminus of GLUT4 that 
are important for efficient GLUT4 sorting (Cope et al., 2000, Shewan et al., 
2000, Martinez-Arca et al., 2000). A chimera of GLUT4:GLUT3 was generated 
in which the last 12 amino acids of GLUT4 (residues 498 -  509) was 
substituted for the last 12 amino acids of GLUT3. The chimeric protein was 
then expressed in 3T3-L1 adipocytes. In unstimulated adipocytes, the chimeric 
protein had a cell surface expression instead of the typical intracellular 
compartment. This illustrates that it is not only the dileucine motif that is 
important in the intracellular sequestration but there is also a motif at the very 
C-terminus of GLUT4. The last 12 amino acids were mutated to alanine 
residues in groups of 4 residues (498-501 (TELE), 502-505 (YLGP) or 506-509 
(DEND)). The mutants were again transfected into 3T3-L1 adipocytes and the 
subcellular localisation of the proteins was identified by subcellular
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fractionation and endosome ablation. Residues T^ELEYLGP505 were 
identified as being important in regulating the sorting of GLUT4 from recycling 
endosomes into the GSV post-endosomal compartment (Shewan et al., 2000). 
Further work identified that, following internalisation, GLUT4 trafficked from the 
endosomes into a compartment of the TGN. Although the compartment did not 
contain the classical TGN marker TGN38, it co-localised with syntaxins 6 and 
16 (which have been implicated in the trafficking of cargo between the 
endosomes and TGN). Mutation of the acidic targeting motif (E499LEY) in the 
C-terminus of GLUT4 resulted in the retention of GLUT4 in an endosomal 
compartment. The authors therefore conclude that the acidic E499LEY motif 
regulates the accumulation of GLUT4 in the syntaxins 6- and 16-positive TGN 
compartment (Shewan et al., 2003).
An independent study also carried out a mutation at the very end of the GLUT4 
protein. Amino acids P505DEND509 were deleted from the C-terminus of 
GLUT4. This mutation prevented the storage of GLUT4 in the GSV and instead 
the protein had an endosomal location. In addition, tyrosine 502 was also 
shown to be important in GLUT4 retention in the GSV but this function was 
dependent on the presence of residues 505 -  509 (Martinez-Arca et al., 2000). 
Two further residues have also been shown to be important in the subcellular 
trafficking of GLUT4. The amino acids adjacent to the dileucine motif (E491QE) 
were sequentially mutated to alanine. Mutation of glutamic acid residues 491 
and 493 resulted in an increase in the levels of the mutated proteins at the cell 
surface, reduced insulin-stimulated translocation and increased susceptibility to 
endosomal ablation. The EQE may have a role in modulating the adjacent 
dileucine motif, or it may have an independent trafficking role (Cope et al., 
2000).
The regions downstream of the dileucine motif, therefore, play a critical role in 
GLUT4 trafficking. These motifs may all work together, in combination, or 
independently with the dileucine motif, to regulate distinct steps in the 
subcellular trafficking pathway of GLUT4.
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1.6.3 Phosphorylation Motifs -  Modulation of Intracellular 
Trafficking
A phosphorylation site has been identified in the C-terminus of GLUT4 at 
serine 488 (Lawrence, Jr. et al., 1990a). The phosphorylated serine is the 
residue preceding the dileucine motif (s488L489L490). An in vitro kinase assay 
identified the kinase responsible as being protein kinase A (PKA). 
Phosphorylation at serine 488 could therefore modulate the effect of the 
dileucine motif (Section 1.6.2) or it could have an independent function. The 
effect of phosphorylation at serine 488 has been investigated by several 
groups. The level of GLUT4 phosphorylation was calculated following the 
treatment of adipocytes with various agents. Investigations were also 
undertaken to determine whether the subcellular distribution of GLUT4 was 
affected by phosphorylation at serine 488.
It was reported that insulin does not have an effect on the relative level of 
phosphorylation in either intracellular or plasma membrane-localised GLUT4 
(James et al., 1989a). The authors therefore conclude that phosphorylation of 
GLUT4 is unlikely to promote the translocation of GLUT4 from an intracellular 
location to the plasma membrane.
Isoproterenol (a p-adrenergic agonist) inhibits insulin-stimulated glucose 
transport by 40% but increases the level of phosphorylation by twofold (James 
et al., 1989a). However, isoproterenol does not lead to a decrease in the 
number of transporters at the plasma membrane but rather it affects the 
intrinsic activity of GLUT4 (Smith et al., 1984, Kuroda et al., 1987). It could 
therefore be concluded that the effect of the phosphorylation at serine 488 
could be to alter the intrinsic activity of GLUT4 (James et al., 1989a). However, 
other studies have not observed a link between the phosphorylation and the 
intrinsic activity of the transporter (Joost et al., 1987, Nishimura et al., 1991). 
Okadaic acid also leads to an increase in GLUT4 phosphorylation and, 
although okadaic acid stimulates basal glucose transport, it inhibits the level of 
insulin-stimulated glucose transport. The authors concluded that
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phosphorylation of GLUT4 could promote internalisation of the transporter 
rather than stimulating translocation. This was due to the fact that insulin did 
not increase the level of GLUT4 phosphorylation and the fact that okadaic acid 
had an inhibitory effect on insulin-stimulated glucose transport (Lawrence, Jr. 
et al., 1990b).
One group, while investigating the role of the dileucine motif on the subcellular 
trafficking of GLUT4, also mutated serine 488 (Garippa et al., 1996). The 
mutation was carried out in a chimeric protein in which the C-terminus of the 
transferrin receptor had been substituted for the C-terminus of GLUT4. Serine 
488 was mutated to either alanine or aspartic acid, to mimic an 
unphosphorylated form of serine or to mimic the negative charge of a 
phosphorylated serine respectively. The mutations resulted in a threefold 
reduction in the rate of internalisation of the chimeric protein. The mutations did 
not affect the GLUT4 recycling rate. These results suggest that serine 488, 
together with the dileucine motif, has a role as an internalisation motif. 
However, this study must be viewed with caution because the mutated 
chimeric proteins behaved the same when serine 488 was mutated to either an 
alanine or an aspartic acid residue (Garippa et al., 1996). The effect of 
phosphorylation at serine 488 was also investigated in another study (Marsh et 
al., 1998). Serine 488 was mutated to alanine and the effect of the 
phosphorylation on the intracellular trafficking of GLUT4 was examined. 
Phosphorylation of GLUT4 did not affect its subcellular localisation in either 
basal or insulin-stimulated adipocytes and so the authors concluded that 
phosphorylation does not play a major role in GLUT4 exocytosis. However, a 
difference was observed in the extent of the co-localisation between GLUT4 
and the y-adaptin subunit of the Golgi adaptor complex (AP1) (Section 1.5.1.2). 
The extent of co-localisation between GLUT4 and AP1 was significantly 
increased when serine 488 was mutated to alanine. Thus it was suggested that 
phosphorylation might modulate the intracellular sorting of GLUT4 at the TGN 
(Marsh et al., 1998). The exact function of the phosphorylation of serine 488
64
still rem a ins  not fu lly  understood . S ection  4.1 w ill g ive  a de ta iled  accoun t o f the 
e ffec t the  p hosph o ry la tion  o f se rine  488  has on G LU T 4  tra ffick ing .
T he  N -te rm inus  o f G LU T 4  sha res  s ig n ifica n t se quen ce  iden tity  w ith  the  N- 
te rm ina l ta rge ting  dom a in  o f the  a subun it o f g lu ta m ic  acid deca rboxy la se  65 
(G A D 65), in w h ich  e igh t out o f e leven  am ino  ac ids  are iden tica l to the  N 
te rm in u s  o f G LU T 4  (F igu re  1.7). T he re  are tw o  iso fo rm s o f G A D 65 - a  and p 
and, in 1997, it w as show n  tha t the  a  iso fo rm  but no t p w as  phospho ry la ted  on 
se rine  res idues  4, 6, 10 and 13 by an un iden tified  m em brane -asso c ia ted  
k inase, w h ich  w as th o u g h t to regu la te  the  sp e c ific  func tion  o f G A D 65 in the 
syn a p tic  ve s ic le  m em brane  (N am chuk  et al., 1997). T he re  is a po ten tia l case in  
k inase  II (C K II) ac id ic  c lus te r p hosph o ry la tion  s ite  w ith in  the  area o f hom o logy 
be tw een  G LU T 4 and G A D 65a . The  po ten tia l phosph o ry la tion  s ite  on G LU T 4 is 
S 10ED G E. P hospho ry la tion  at se rine  10 cou ld  m odu la te  the  in te rac tion  o f 
p ro te ins  w ith  the upstream  FQQI m o tif o r it cou ld have  an indepe nden t role by 
itse lf.
G L U T 4  P -S -G -F -Q -Q -l-G -S 10-E -D -G -E -P -P -Q -Q -R -V -T -G
N -te rm in u s  |
G A D 6 5  G -S -G -F -W -S -F -G -S 13-E -D -G -S -G -D -S -E -N -P -G -T
a  S u b u n it
Figure 1.7 Sequence identity between GAD65a and the N-terminus of GLUT4.
The sequences of GLUT4 and GAD65a were obtained from Entrez Protein (NCBI).
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1.6.3.1 Casein Kinase Enzymes
Casein kinase (CK) enzymes are protein kinases and are defined by their 
ability to phosphorylate serine / threonine residues that are proximal to acidic 
amino acids instead of basic or prolyl residues. The name casein kinase 
comes from the ability to phosphorylate casein in vitro. There are three sub­
families of casein kinase enzymes; casein kinase I (CKI), casein kinase II 
(CKII) and Golgi casein kinase (GCK). Each of the CK enzymes has a different 
phosphorylation consensus sequence. The consensus sequence for the CK 
enzymes are: CKI [pS/pT]-X2-3-[S/T], CKII X-[S/T]-X-X-[D/E] and GCK is X-S-X- 
(E/pS) (pS stands for phospho-serine) (Pinna and Ruzzene, 1996). The 
predicted GLUT4 N-terminal phosphorylation site is S10EDGE and so CKI is 
not a candidate for being the GLUT4 N-terminal kinase. Both CKII and GCK 
have phosphorylation consensus sequences similar for the GLUT4 N-terminal 
sequence but the sequence is not identical. The aspartic acid residue cannot 
be substituted for glutamic acid in the GCK consensus sequence (S-X-E- to S- 
X-D) (Lasa-Benito et al., 1996). GCK is therefore unable to phosphorylate the 
N-terminus of GLUT4 but an unidentified kinase, related to GCK, may 
phosphorylate Ser10 in GLUT4. The consensus sequence for CKII has an 
acidic residue at n=3 but the N-terminus of GLUT4 contains a glycine residue 
at n=3. However, there are proteins that are phosphorylated by CKII that do not 
contain the CKII consensus sequence, e.g. the p53 tumour suppressor. The 
inverse is also true, the minimum consensus sequence does not guarantee 
CKII phosphorylation (Litchfield, 2003). Serine 10 in GLUT4 could therefore be 
phosphorylated by CKII through a novel CKII consensus sequence or by a 
kinase that is as yet unidentified but which is likely to be related to the casein 
kinase family of proteins.
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1.7 Experimental Aims of the Work Described in this Thesis
The work described in this thesis has three main themes -  the identification of 
any additional phosphorylation sites in GLUT4 (other than the previously 
identified serine 488) with a special focus on serine 10, the determination of 
the effect different stimuli have on the level of phosphorylation at each site and 
the effect the phosphorylation has on the trafficking of GLUT4 to the plasma 
membrane. Initially, work was undertaken to purify a highly phosphorylation- 
specific antibody raised to the phosphorylated form of serine 10 to aid the 
study.
Investigations were undertaken to determine the sites of GLUT4 
phosphorylation in adipocytes and cardiomyocytes. The regions which 
contained the phosphorylation sites were identified following cleavage by 
Endoproteinase Lys C. Then comparison with the predicted GLUT4 
phosphorylation sites, obtained from a web-based phosphorylation prediction 
program was made. Work was undertaken to determine what stimuli affected 
the level of phosphorylation and also the stoichiometry of phosphorylation.
Studies were also undertaken to investigate if the phosphorylation sites in 
GLUT4 had any role in translocation to the plasma membrane. To address this 
aim, site-directed mutagenesis was used to mutate the phosphorylation sites to 
either an alanine or an aspartic acid to mimic an unphosphorylated or 
phosphorylated residue respectively. The mutants were transfected into 
adipocytes and the level of GLUT4 at the plasma membrane was determined 
through the presence of an epitope tag in the first exofacial loop of GLUT4.
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2 Materials and Methods
2.1 M a te r ia ls
2 .1 .1  L a b o ra to ry  C h e m ic a ls
All general laboratory chemicals were of analytical grade and purchased from 
either Sigma-Aldrich Chemical Company [S] or Fisher Scientific UK Ltd. [F], 
unless otherwise stated. Table 2.1 gives the address and website for each of 
the suppliers along with the abbreviation that will be used to denote each 
company.
Company Address W ebsite Abbreviation
Alexis Nottingham, UK www.alexis- [AC]
Corporation biochemicals.com
ATCC Middlesex, UK www.attc.org [ATCC]
Amersham Little Chalfont, www.amershambioscien [A]
International UK ces.com
Applied Warrington, www.appliedbiosystem s. [AB]
Biosystems Cheshire, UK com/index.cfm
Atto Tokyo, Japan www.atto.co.jp/ [AT]
Corporation englishtop.html
BD Oxford, UK www.bdbiosciences.com [BD]
Biosciences
BDH Poole, Dorset, www.bdh.com [BDH]
Laboratory UK
Supplies
Beckman High Wycombe, www. beckmancoulter. [BC]



















































Sheffield, UK www.raytek.co.uk [FU]
Gelman
Sciences






Intergen Co. Newark NJ, USA www.intergenco.com [IT]
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Invitrogen Paisley, UK www.invitrogen.com [1]






Merck Nottingham, UK www.m erckbiosciences.
co.uk
[M]
Millipore Watford, UK www.m illipore.com [ML]






The Netherlands http://probes, invitrogen. c 
om/
[MP]
MP Cambridge, UK www.mpbio.com [MPB]
Biomedicals
















































Southern Birmingham, www.southernbiotech.co [SB]
Biotech Alabama, USA m
Stratagene La Jolia, Ca, 
USA
www.stratagene.com [ST]






Upstate Dundee, UK www.upstate.com [U]
















Table 2.1 The address and website of each of the suppliers along with the 
abbreviation used to denote each company.
2 .1 .2  B u ffe rs
Dulbecco’s Modified Eagles Medium -  Newborn Calf Serum (DMEM-NCS):
Dulbecco’s Modified Eagles Medium [C], 100 Ill/ml Penicillin, 100 [ig/rr\\ 
Streptomycin [S], 2 mM Glutamine [S] and 10% Newborn Calf Serum [I],
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Dulbecco’s Modified Eagles Medium -  Fetal Calf Serum (DMEM-FCS):
Dulbecco’s Modified Eagle Medium [C], 100 lU/ml Penicillin, 100 |jg/ml 
Streptomycin [S], 2 mM Glutamine [S] and 10% Fetal Calf Serum myoclone 
superplus [I].
Adipocyte Krebs-Ringer-HEPES (aKRH): 140 mM NaCI, 4.7 mM KCI, 2.5 
mM CaCI2, 1.25 mM MgS04) 2.5 mM NaH2P04, 10 mM HEPES, (pH 7.4).
Low phosphate adipocyte Krebs-Ringer-HEPES (low Pi aKRH): 140 mM
NaCI, 4.7 mM KCI, 2.5 mM CaCI2, 1.25 mM MgS04, 0.2 mM NaH2P04, 10 mM 
HEPES, (pH 7.4).
Cardiomyocyte Krebs-Ringer-HEPES (cKRH): 128 mM NaCI, 6 mM KCI, 1.4 
mM MgS04, 0.2 mM NaH2P04, 1 mM Na2HP04, 10 mM HEPES, (pH 7.4) 
made up with double distilled water (ddH20) gassed with 0 2 for at least 20 min.
Low phosphate cardiomyocyte Krebs-Ringer-HEPES (low P, cKRH): 128
mM NaCI, 6 mM KCI, 1.4 mM MgS04, 0.2 mM NaH2P04, 10 mM HEPES, (pH 
7.4) made up with ddH20  gassed with 0 2 for at least 20 min.
Buffer A: cKRH buffer, 5.5 mM glucose, 2 mM ultrapure pyruvic acid [S].
Buffer B: Buffer A, 0.7% (w/v) BSA, 1.1 mg/ml collagenase [W], 2.65 mg/ml 
hyaluronidase Type 1-S [S], 15 mM 2,3-butanedione monoxime (BDM) [S].
Buffer C: Buffer A, 0.2 mg/ml DNAse I [R], 15 mM 2,3-butanedione monoxime 
(BDM), 200 pM CaCI2, and 2% (w/v) BSA.
Buffer D: Buffer A, 1 mM CaCI2 (physiological calcium concentration), and 2% 
(w/v) BSA.
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Buffer E: Buffer A, 1 mM CaCI2 and 0.5% (w/v) Fatty acid free Albumin, 
Fraction V, [R].
Low phosphate Buffer E (Low P, Buffer E): Buffer E made from low Pj 
cKRH.
Phosphate Buffered Saline (PBS): 154 mM NaCI, 12.5 mM Na2HP0 4 . 1 2  
H20, (pH 7.2).
PBS-Tween 20 (PBS-T): PBS, 0.1% (v/v) Tween-20.
Tris Buffered Saline - Tween 20 (TBS-T): 10 mM Tris, (pH 7.4), 154 mM 
NaCI, 0.1% (v/v) Tween-20.
Tris-EDTA-Sucrose (TES): 10 mM Tris, (pH 7.2), 5 mM EDTA, 255 mM 
Sucrose.
TES Sucrose Cushion: 20 mM Tris, (pH 7.2), 1 mM EDTA, 1.12 M Sucrose.
Adipocyte Digestion Buffer: 3.5% (w/v) BSA in aKRH buffer supplemented 
with 5 mM glucose and 700 ng/ml Collagenase type 1 from Clostridium 
histolyticum [W].
Adipocyte Lysis Buffer: 2% (w/v) Nonaethylene glycol monododecyl ether 
(Thesit) (C30H62O10) [S], PBS.
Cardiomyocyte Lysis Buffer: 1% (v/v) Triton X-100 (TX-100), 1% (w/v) 
Deoxycholic Acid, 0.2% (w/v) Sodium dodecyl sulphate (SDS), PBS.
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Sample Buffer: Protein samples were solubilised in 2% (w/v) SDS, 62.5 mM 
Tris HCI (pH 6.8), 0.01% (w/v) bromophenol blue, 10% (v/v) glycerol. The 
reducing agent was 20 mM Dithiothreitol (DTT) unless otherwise stated.
Tris-Tricine Sample Buffer: 50 mM Tris HCI (pH 6.8), 0.5% (w/v) SDS, 0.01% 
(w/v) brilliant blue G, 12% (v/v) Glycerol. The reducing agent was 2% (v/v) p- 
mercapto-ethanol.
Resolving Gel Buffer: 1.5 M Tris HCI, 0.4% (w/v) SDS, (pH 8.8).
Stacking Gel Buffer: 0.5 M Tris HCI, 0.4% (w/v) SDS, (pH 6.1).
Electrophoresis Running Buffer: 25 mM Tris HCI, (pH 6.3), 0.1% (w/v) SDS, 
0.2 M Glycine.
Gel Buffer: 3 M Tris, 0.3% (w/v) SDS, (pH 8.45).
Anode Buffer: 200 mM Tris, (pH 8.9).
Cathode Buffer: 100 mM Tris, 100 mM Tricine, 0.1% (w/v) SDS, (pH 8.5).
Transfer Buffer: 39 mM Glycine, 48 mM Tris, 0.0375% SDS (w/v), 20% 
methanol (v/v), (pH 8.8).
Ponceau S Stain: 0.1% (w/v) Ponceau S, 3% (w/v) trichloroacetic acid.
Stripping Buffer: 100 mM p-Mercaptoethanol, 2% SDS, 62.5 mM Tris HCI 
(pH 6.7).
Coupling Buffer: 50mM Tris, 5mM EDTA-Na, (pH 8.5).
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ELISA Plate Coating Buffer: 15 mM Na2C03) 35 mM NaHC03, 0.01% (v/v) 
Na Azide, (pH 9.6).
ELISA Plate Blocking Buffer: PBS, 0.1% (v/v) Tween-20, 1% (w/v) Casein, 
add casein and dissolve with mixing overnight at 4°C.
ELISA Sodium Acetate/Citrate Buffer: 1.66 M Sodium Acetate, 33 mM Citric 
acid, (pH6.0).
BCA Reagent B: 4% (w/v) CuS0 4 .5 H20 .
Conjugation Buffer: 0.1 M Na2HP04, 0.15 M NaCI, 1 mM EDTA, (pH 7.2).
Tris-acetate EDTA buffer (TAE): 40 mM Tris-acetate, 1 mM EDTA, (pH 8).
Luria Broth (LB): 1% (w/v) Bacto™ Tryptone [BD], 0.5% (w/v) Bacto™ Yeast 
Extract [BD], 0.5% NaCI, (pH 7.5) (autoclaved).
Agar Plates: 1% (w/v) Bacto™ Tryptone [BD], 0.5% (w/v) Bacto™ Yeast 
Extract [BD], 0.5% NaCI, 1.5% (w/v) Agar, (pH 7.5) (autoclaved).
Dulbecco’s Modified Eagles Medium 1 (DMEM (1)): Dulbecco’s modified 
Eagles medium [C], 0.2 pM Adenosine, 2 mM Glutamine.
Dulbecco’s Modified Eagles Medium 2 (DMEM (2)): DMEM (1), 100 pg/ml 
Gentamicin.
Dulbecco’s Modified Eagles Medium 3 (DMEM (3)): DMEM (2), 3.5% (w/v) 
BSA.
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C onfoca l P e rm eab ilisa tion  B u ffe r: 1% (w /v) BSA, 3%  (v/v) goa t serum , 0 .1%  
(w /v) sapon in , PBS.
C onfoca l Wash B u ffe r: 1% (w /v) BSA, 0 .1%  (w /v) sapon in , PBS.
2 .1 .3  A n t ib o d ie s
T he  so u rce  and d ilu tion  o f the  p rim ary  and se co n d a ry  an tibod ies  used fo r 
W este rn  b lo t ana lys is  (S ection  2 .2 .8 .3 ), the  an tibod y  b ind ing  assay  (S ection  
2 .2 .13 ) and con foca l m icroscopy (S ection  2 .2 .14 ) are  show n in the tab les  
be low , T ab les  2.2, 2.3, 2 .4  and 2 .5  respective ly .
Antibody Polyclonal/ Source Dilution fo
Monoclonal Western
Purified/Serum Blotting
Rabbit anti-GLUT4 Polyclonal In House production 1:1000
phosphorylated N- Purified
terminus
Rabbit anti-GLUT4 C- Polyclonal In House production 1:20,000
terminus Serum and Purified (Holman eta /., 1990)
Mouse anti-GLUT4 C- Monoclonal (clone 1F8) [BG] 1:1000
terminus Purified
Sheep anti-GLUT4 Polyclonal In House production 1:1000
Phosphorylated N- Serum and purified
terminus
Sheep anti-GLUT4 C- Polyclonal In House production 1:1000
terminus Purified
Mouse anti- Monoclonal [CV] 1:1000
Haemagglutinin (HA) Purified
Table 2.2 Source and dilution of primary antibodies used in Western blot 
analysis. Antibodies were diluted in TBS-T, 1% (w/v) BSA, 0.02% (w/v) sodium azide.
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Antibody Source Dilution for Western 
Blotting
Goat anti-rabbit IgG HRP conjugate [S] 1:4000
Goat anti-mouse IgG HRP 
conjugate
[S] 1:1000
Goat anti-sheep IgG HRP conjugate [S] 1:4000
Table 2.3 Source and dilution of secondary antibodies used in Western blot 















Table 2.4 Source and dilution of antibodies used in the antibody binding assay.




Source Dilution for 
confocal 
microscopy






Rabbit anti-GLUT4 Polyclonal In House 1:50
pSer10 
from final bleed serum
Purified production 
(chapter 3)
Mouse anti-GLUT4 Monoclonal [BG] 1:740
C-terminus (clone 1F8) 
Purified
1 pg/ml
Rabbit anti-GLUT4 Polyclonal In House 2 pg/ml
C-terminus Purified production
Sheep anti-GLUT4 Polyclonal In House 4 pg/ml
pSer10 Purified production 
(chapter 3)
Sheep anti-GLUT4 C- Polyclonal In House 4 pg/ml
terminus Purified production 
(chapter 3)
Alexa Fluor® 488 goat - [MP] 2 pg/ml
anti-rabbit IgG
Alexa Fluor® 568 goat - [MP] 2 pg/ml
anti-mouse IgG
Alexa Fluor® 633 goat - [MP] 4 pg/ml
anti-sheep IgG
Alexa Fluor® 488 goat - [MP] 4 pg/ml
anti-sheep IgG
Table 2.5 Source and dilution of antibodies used in confocal microscopy.
Antibodies were diluted in confocal permeabilisation buffer (1% (w/v) BSA, 3% (v/v) 
goat serum and 0.1% (w/v) saponin in PBS).
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2.1.4 Insulin
Monocomponent porcine insulin was kindly supplied by Dr. G. Daniellson 
(Novo Nordisk). 1 mg insulin was dissolved in 1 ml of 30 mM HCI and was 
subsequently diluted to 3 ml in PBS. 1 ml of this stock solution was then diluted 
to 50 mi in PBS with the resulting 1 pM solution aliquoted and stored at -20°C. 
Once thawed, aliquots were not re-frozen.
2.1.5 Bovine Serum Albumin (BSA)
BSA (Bovine Cohn Fraction V) [IT] was dissolved in double distilled water 
overnight at 4 °C. The BSA solution was filtered through Millipore type A 
(mixed cellulose esters) membrane filters (0.8 pm pore size) [ML] and the pH 
was adjusted to pH 7.6 with 10 M NaOH. The final BSA concentration was 
adjusted to 10% (w/v) with double distilled water. Aliquots were stored at - 
20°C.
2.1.6 Heparin
Heparin Grade 1A [S] isolated from porcine intestinal mucosa was 
reconstituted in 0.9% (w/v) NaCI (2000 Units/ml) and filter sterilised through a 
0.2 pm filter [ML]. Aliquots were stored at 4 °C.
2.1.7 Protease and Phosphatase Inhibitors
Where it is not stated, the protease and phosphatase inhibitors, and the 




Anti pain Ser and Cys Proteases 1 pg/ml (1.65 pM)
Aprotinin Ser Proteases 1 pg/ml
Pepstatin A Ser and Cys Proteases 1 pg/ml (1.46 pM)
Leupeptin Acid Proteases 1 pg/ml (2.1 pM)
AEBSF Ser protease 100 pM
Sodium Fluoride Ser / Thr phosphatase 10 mM
Sodium Molybdate Acid phosphatases 1 mM




Cypermethrin PP2B 50 nM
Dephostatin Protein Tyrosine 
Phosphatases
5 pM
Okadaic acid PP2A, PP1, PP2B 100 nM
NIPP-1 PP1 10 pM
Table 2.6 Protease and phosphatase inhibitors and the working concentration.
2 .2  M e th o d s
2 .2 .1  C e ll C u ltu re  o f  3 T 3 -L 1  F ib ro b la s ts
Cell culture and media preparations were carried out in sterile conditions. 
Mouse 3T3-L1 fibroblast cells were obtained from the American Type Culture 
Collection [ATCC] and stored in liquid nitrogen in cell freezing medium [S].
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Fetal bovine serum (myoclone super plus) [I] and newborn calf serum [I] were 
heat treated before use. The serum was allowed to thaw slowly at 4 °C 
overnight and heat treated at 56 °C for 30 min. The serum was divided into 50 
ml aliquots and stored at -20 °C until needed. 3T3-L1 cell culture was 
essentially carried out as described in Sadowski et al (Sadowski et al., 1992). 
All buffers were warmed to 37 °C before use.
2.2.1.1 Seeding of 3T3-L1 Fibroblasts
3T3-L1 fibroblasts were removed from liquid nitrogen and rapidly thawed at 37 
°C. The cells were transferred to a sterile universal tube containing 20 ml 
DMEM-NCS and centrifuged at 180 x g (1,000 rpm) for 3 min in an Eppendorf 
5804 R centrifuge [E]. The medium was aspirated and the cells were 
resuspended in 2 ml DMEM-NCS. The cells were seeded into a 175 cm2 flask 
containing 40 ml DMEM-NCS and incubated at 37 °C, in an atmosphere of 
10% (v/v) C02. The media was changed on the following day to remove the 
dead cells. The media was then replaced every 2 days until the cells reached 
sub-confluency.
2.2.1.2 Harvesting of 3T3-L1 Fibroblasts
The cells were grown until they reached sub-confluency, usually about 7 days 
after seeding. The flask of sub-confluent cells was washed twice with 10 ml 
phosphate buffered saline (PBS) (Dulbecco A) [O]. 4 ml Trypsin [S] was added 
and the flask was incubated at 37 °C for 3 min. 20 ml DMEM-NCS was added 
to the flask and the suspension of cells were transferred into a sterile universal 
tube. The cells were centrifuged at 180 x g (1,000 rpm) for 3 min in an 
Eppendorf 5804 R centrifuge [E] to pellet the cells. The cells were 
resuspended in 20 ml of media and plated onto sterile coverslips in 35 mm 
petri dishes for immunocytochemistry. Cells were also plated into a 175 cm2
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flask and grown to sub-confluency to maintain the culture. The media was 
replaced every two days. The cells were passaged a total of twelve times 
before they were discarded.
2.2.1.3 Differentiation of 3T3-L1 Fibroblasts
The cells that had been plated onto petri dishes were grown until they had 
been confluent for 3 days (about 10 days after seeding) and then they were 
differentiated into adipocytes. The media was replaced with DMEM-FBS 
containing 0.25 pM dexamethasone [S], 0.5 mM isobutylmethylxanthine [S] 
and 0.2 pM insulin. After 2 days the media was replaced with DMEM-FCS 
containing 0.2pM insulin and then with DMEM-FCS every two days after that. 
The cells were fully differentiated after 9 days.
2.2.1.4 Treatment of 3T3-L1 adipocytes with Brefeldin A
Cells at different days of differentiation were washed with PBS and incubated 
in serum free media (DMEM only) for 2 h at 37 °C. The cells were then 
incubated with 10 pg/ml Brefeldin A [S] for 30 min at 37 °C.
2.2.2 Preparation of Insulin sensitive cells
2.2.2.1 Rat Adipocytes
2.2.2.1.1 Isolation of Rat Adipocytes
Adipose cells were isolated from the epididymal fat pads of male Wistar rats 
(180 -  220 g) fed ad libitum. The rats were stunned and their necks dislocated.
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The whole epididymal fat pads were quickly removed and incubated briefly in 
1% (w/v) BSA in adipocyte Krebs-Ringers-HEPES buffer (aKRH) at 37 °C. 200 
nM adenosine was added to the aKRH buffer and the digestion buffer to 
prevent lipolysis. 4 fat pads were added per universal tube containing 5 ml 
digestion buffer. The fat pads were finely minced and incubated in a 37 °C 
shaking water bath for about 30 min until all the lumps had digested. The 
resulting cell suspension was filtered, through a nylon mesh with a 250 pm 
pore size [LK], into a 23 ml polystyrene flat-bottomed tube [SR]. The cells were 
washed with 1% (w/v) BSA / aKRH. The cells were allowed to float and the 
infranatant buffer was removed using a needle (2 mm dia. x 100 mm) attached 
to a 20 ml plastic syringe. 15 -  20 ml 1% (w/v) BSA / aKRH was added back to 
the cells and the wash step was repeated a further 3 times. The cell suspension 
was then adjusted to a 40% cytocrit. The cell density was estimated by taking a 
sample of cell suspension into a capillary tube and then sealing the end with 
plasticine. The tube was centrifuged briefly at 1,000 x g and the packed cell 
volume was calculated as the fraction of the length of packed cells to the total 
length of the cells and buffer in the tube.
2.2.2.1.2 Insulin Stimulation of Isolated Rat Adipocytes
The isolated adipocytes with a 40% cytocrit were stimulated with 20 nM insulin for 
20 min at 37 °C.
2.2.2.1.3 Subcellular fractionation of Rat Adipocytes
The isolated adipocyte cells were washed with TES buffer containing protease 
and phosphatase inhibitors at 18 °C and the cells were left to float. The 
infranatant buffer was removed and 1 ml of TES was added to the cells. The 
cells were homogenised using 10 strokes of a 55 ml Potter-Elvehjem 
homogeniser [T] with a clearance of 0.15 mm at a rotation speed of
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approximately 1,600 rpm. The homogenates were centrifuged at 1,000 x g at 4 
°C for 1 min in a refrigerated Ole Dich centrifuge [CL]. This resulted in a pellet 
of red blood cells, an infranatant layer containing homogenised cells and a top 
layer of fat. The infranatant layer was removed using a needle (21 g x 1.5”) and 
syringe. The following spins were carried out at 4 °C in a Beckman TL-100 
benchtop ultracentrifuge with a TLA-100.3 fixed angle rotor (or a TLS-55 swing- 
out rotor, where stated otherwise). The following centrifugation scheme is 
illustrated in Figure 2.1. The infranatant layer was centrifuged at 17,500 x g 
(18,000 rpm) for 20 min to obtain a crude plasma membrane (PM) pellet 
containing both mitochondria and nuclei and a microsomal cytosolic fraction in 
the supernatant. The supernatant was centrifuged at 49,000 x g (30,000 rpm) 
for 9 min to pellet the high density microsomes (HDM), leaving the low density 
microsomes and cytosol in the supernatant. The pellet was resuspended in 2 
ml TES and pelleted again at 49,000 x g (30,000 rpm) for 9 min. The high 
density microsomes were then resuspended in 50 pi TES. The low density 
microsomes (LDM) were pelleted by centrifugation at 541,000 x g (100,000 
rpm) for 17 min with the remaining supernatant being the cytosol fraction. The 
low density microsome pellet was washed with 2 ml TES and again pelleted at 
541,000 x g for 17 min. Finally the low density microsomes were resuspended 
in 100 pi TES. The pellet containing plasma membrane was resuspended in 1 
ml TES by homogenisation with 5 strokes of a 2 ml homogeniser. The 
homogeniser was washed out with a further 1 ml TES which was added to the 
membranes and centrifuged at 17,500 x g (18,000 rpm) for 20 min. The pellet 
was resuspended in 300 pi TES and loaded onto a 600 pi TES sucrose 
cushion and centrifuged at 105,000 x g (35,000 rpm) for 20 min in the TLS-55 
swing out rotor. The mitochondria and nuclei were found in the pellet. The 
plasma membrane was recovered from the cushion interface, resuspended in 
2 ml TES and centrifuged at 74,000 x g (37,000 rpm) for 9 min. The plasma 
membrane pellet was washed with another 2 ml TES and re-pelleted at 74,000 
x g for 9 min. The plasma membranes were then resuspended in 100 pi TES. 
All of the fractions were assayed for protein content and stored at -70 °C.
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Figure 2.1 The subcellular fractionation centrifugation method.
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2.2.2.1.4 Deglycosylation of Rat Adipocyte LDM Membranes
20 pg LDM membranes from basal adipocytes were denatured in glycoprotein 
denaturing buffer [NEB] for 10 min at 100 °C. G7 Buffer [NEB] and 1% (v/v) 
NP-40 [NEB] were added to the reaction. After the addition of 3 pi (1500 U) 
Peptide: N-Glycosidase F (PNGase F) [NEB] the reaction was incubated for 1 
h at 37 °C. The reaction was terminated by the addition of sample buffer.
2.2.2.1.5 [32Pj] Labelling and treatments of Rat Adipocytes
Isolated adipocytes were washed twice with 3% (w/v) BSA / low Pj aKRH. The 
cells were made back to a 40% cytocrit and incubated with radioactive 32P 
orthophosphate [32PJ [A] at 0.3 mCi [32Pj] / ml cells for 2 h, shaking gently at 37 
°C. The buffer was removed and fresh buffer added back to a 40% cytocrit. 
The cells were then incubated with different treatments (Table 2.7). The cells 
were washed twice with low Pj aKRH containing no BSA, Ca2+ or Mg2+ but 
containing the treatments used. The cells were briefly centrifuged in the 
Allegra™ X-22 centrifuge [BC] at 1,000 rpm (193 x g) to pack the cells at the 
top of the tube. The infranatant was discarded and the cells were lysed in 
adipocyte lysis buffer containing protease and phosphatase inhibitors for 30 
min at 4 °C. The insoluble material was pelleted at 16,000 x g at 4 °C in a 




20 nM Insulin 20 m in  a fte r [32Pj]  incubation
1 pM  O k a d a ic A c id  [AC] 20  m in a fte r [32P j]  incubation
50 pM  5 ,6-D ich loro-1-(3-D - 2 h du ring  [32P j]  incubation
rib o fu ra n o sy lb e n z im id a zo le  (D R B )
[CB]
25 pM  4 ,5 ,6 ,7 - 2 h du ring  [32P,] incubation
T e tra b ro m o b e n zo tria zo le  (TBB)
[C B ]
1 pM  Isop ro te reno l [S] + 0.5 U /m l 10 m in at end o f insu lin  s tim u la tion
A d e n o s in e  d eam inase  [S]
Table 2.7 The treatment and length of incubation carried out on [32Pj] labelled 
adipocytes.
2.2.2.2 Rat Cardiomyocytes
2.2.2.2.1 Isolation of Rat Cardiomyocytes
C a lc iu m -re s is ta n t, rod -shaped  ca rd io m yo cy te s  from  a du lt m a le  W is ta r rats 
(260 -280  g fed ad libitum ) w e re  p repared  using a m ethod o rig ina lly  described  
(F isch e r et al., 1991) w ith  som e  m od ifica tions . Briefly, an im a ls  w ere  
ana e s th e tise d  w ith  350 pi S aga ta l™  (P en to b a rb ito n e  S od ium  b.p., 60 m g/m l, 
[R M ]) be fo re  adm in is tra tion  o f 500 un its  o f heparin  so lu tion  v ia  the  ta il ve in. 
A fte r 5 m in the neck w as d is loca ted  and the heart rap id ly  rem oved  into se m i­
frozen  B u ffe r A  (0 -  4 °C ). The  heart w as im m e d ia te ly  m oun ted  on to  a cannu la  
and pe rfused  by the  m ethod o f Langendorff, w ith  B u ffe r A, a t 37 °C, fo r 5 m in
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in order to remove blood and metabolites from the coronary vessels and atrial 
and ventricular chambers. The perfusion was then switched to Buffer B 
equilibrated with oxygen and was recirculated by means of a peristaltic pump. 
After approximately 30 min, 100 pM CaCI2 was added to the recirculating 
buffer. The CaCI2 concentration was raised to 200 pM after a further 2 - 3  min. 
The heart was perfused for a total of 40 min prior to its removal from the 
cannula. The heart tissue was dissociated in a buffer containing 10 ml Buffer B 
and 10 ml Buffer C pre-warmed to 37 °C and under an oxygen atmosphere. 
The calcium concentration was increased in 200 juM steps until the final 
concentration was 800 ^M.
The digested suspension was filtered through 250 jim2 nylon gauze [LK] and 
the cardiomyocytes were allowed to settle for 3 -  4 min to form a loose pellet. 
The supernatant was removed and the cells resuspended in 30 ml Buffer D. 
The cells were allowed to settle again for 3 -  4 min at room temperature and 
the supernatant was removed. The pellet was resuspended in 25 ml Buffer E 
and the cell suspension was incubated for 20 min at 37°C under an oxygen 
atmosphere to allow the cells to recover from the isolation procedure. Viability 
was assessed by counting the number of rod-shaped (viable) versus round­
shaped (dead) cells under the light microscope.
2.2.2.2.2 Insulin Stimulation of Isolated Cardiomyocytes
The isolated cardiomyocyte cells were stimulated with 30 nM insulin for 30 min at
37 °C.
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2.2.2.2.3 [32Pj] Labelling and Treatments of Cardiomyocytes
Isolated cardiomyocytes were left to recover in a low Pj Buffer E for 20 min at 
37°C. Cells were incubated with 0.3 mCi [32PJ / ml cells for 2.5 h shaking gently 
at 37°C under an oxygen atmosphere. During this incubation, the cells were 
treated where necessary with 5 pM oligomycin for 90 min and / or 30 nM 
insulin for 30 min. Following the [32Pj] labelling, the cells were washed twice 
with low Pj cKRH containing no BSA, Ca2+ or Mg2+ but containing insulin or 
oligomycin depending on the treatments. After the second wash, the cells were 
centrifuged in the Allegra™ X-22 centrifuge [BC] at 700 rpm (94 x g) for 1 min. 
The supernatant was removed and the cells were lysed in cardiomyocyte lysis 
buffer containing protease and phosphatase inhibitors for 50 min at 4 °C, with 
rotation. The insoluble material was pelleted at 16,000 x g at 4 °C in a 
Beckman GS-15R centrifuge [BC]. GLUT4 was then immunoprecipitated from 
the cell lysate.
2.2.3 Perchloric Acid Precipitation
Adipocytes: 300 pi 40% (w/v) adipocytes were taken and added to 33 pi 25% 
(v/v) perchloric acid (PCA).
Cardiomyocytes: An aliquot of cardiomyocytes (1/5 of a heart) were taken and 
pulse spun to pellet the cells. The buffer was removed and 250 pi 2.5 % (v/v) 
PCA was added to the cells.
The cells (adipocytes or cardiomyocytes) and PCA were mixed vigorously and 
incubated on ice for 10 min. Following centrifugation at 10,000 x g for 10 min at 
4 °C, the supernatant was neutralised with an equal volume of 4.2 M KOH, 1 M 
HEPES, and water (1:2:7) (pH 7.6) and incubated on ice for 10 min. The
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precipitate was removed by brief centrifugation and the supernatant was frozen 
until needed.
2.2.4 ATP Determination Assay
The amount of ATP in the neutralised supernatant (Section 2.2.3) was 
determined using a bioluminescent ATP determination kit [MP] in which the 
level of ATP is determined using recombinant firefly luciferase and its substrate 
D-luciferin, according to the protocol provided by the manufacturer.
2.2.5 Protein Kinase A (PKA) Assay
Adipocytes: The PKA assay carried out was essentially that of Nishimura et al. 
The PKA assay reaction mixture contained 100 pM Kemptide [CB] or 100 pM 
Histone [S], 20 mM 3-(N-Morpholino)propanesulfonic acid (Mops) (pH 7.0), 16 
mM magnesium acetate, 4 mM DTT and 20 pi neutralised supernatant (Section
2.2.3). The reaction was initiated by the addition of 2500 U PKA [NEB]. The 60 
pi reactions were incubated for 1 h at 30 °C (Nishimura et al., 1991). At the end 
of the incubation, the reactions were stopped. The tubes containing histone 
were placed on ice and the tubes containing kemptide were stopped with 20 pi 
stop solution consisting of 100 mM ATP (pH 7.0), 100 mM EDTA, 250 mM DTT 
and 5% (w/v) SDS.
The 32P-labelled kemptide was purified using a tandem chromatographic 
column method from Egan et al. 1 ml of a washing solution consisting of 5 mM 
ATP (pH 6.8) was added to the stopped reaction and the reaction was added 
into a column containing CM-Sephadex cation exchange resin (C50). The 32P- 
kemptide binds to the column and the ATP passes through in the eluate and is 
discarded. The CM-Sephadex column was washed with a further 1 ml of 
washing solution. The CM-Sephadex column was mounted on top of a column
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containing Dowex 1X-8 anion exchange resin. The 32P-kemptide was eluted 
from the CM-Sephadex column by the addition of 8 ml 30% (v/v) acetic acid. 
The 32P-kemptide passed through the Dowex 1X-8 column, in which any 
residual [32P-ATP] was trapped. The eluate was collected and counted in 1 ml 
fractions in the scintillation counter (Egan etal., 1988).
The reactions containing histone were spotted onto P81 phosphocellulose 
squares [U] and allowed to dry. The squares were then washed four times in 
75 mM phosphoric acid for 5 min each, foilowed by a few seconds in acetone. 
The squares were allowed to dry and then were added to scintillation fluid 
before being counted in the scintillation counter.
Cardiomyocytes: [y-32P] ATP [A] or 18 pi of the neutralised supernatant from 
the PCA precipitation was added to 40 pM Kemptide [CB] and PKA buffer 
[NEB]. The reaction was initiated by the addition of 2500 U PKA [NEB]. The 60 
pi reactions were incubated for 1 h at 30 °C. At the end of the reaction the 
tubes were placed on ice. The reactions were then spotted in duplicate onto 
P81 phosphocellulose squares [U] and allowed to dry. The squares were then 
washed four times in 75 mM phosphoric acid for 5 min each, followed by a few 
seconds in acetone. The squares were allowed to dry and then were added to 
scintillation fluid before being counted in the scintillation counter.
2.2.6 Immunoprecipitation
2.2.6.1 Immunoprecipitation using Protein A
Immunoprecipitation was carried out using antibody linked to Protein A 
(immobilised on sepharose CL-4B) [S]. 5 mg Protein A Sepharose was swollen 
on ice in 1 ml PBS for 10 min and then washed with 1 ml PBS. All wash steps 
were followed by centrifugation at 6,000 rpm in a MSE microcentaur microfuge 
to pellet the beads. The beads were incubated overnight, at 4 °C, in 1 ml PBS
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containing a 16-fold molar excess of antibody over the amount of GLUT4 to be 
immunoprecipitated. The unbound antibody was then removed by washing the 
pellet 4 times with PBS.
Whole cell fractions or low density microsomes (LDM), obtained after 
subcellular fractionation, were lysed in either adipocyte or cardiomyocyte lysis 
buffer containing protease and phosphatase inhibitors, for 20 min at 4 °C. The 
unsolubilised material was pelleted by centrifugation in a refrigerated Ole Dich 
centrifuge [CL] at 20,000 x g for 20 min.
The solubilised protein fractions were then incubated with the antibody-linked 
beads for 2 h at 4 °C with rotation. The supernatant was recovered after 
centrifugation at 6,000 rpm for 1 min and retained until the end of the 
experiment at -20 °C. The pellet was washed 3 times with lysis buffer, 3 times 
with a 10-fold dilution of lysis buffer and 3 times with PBS. The bound protein 
was then eluted from the pellets using sample buffer containing 100 mM 
Dithiothreitol (DTT) unless otherwise stated, for 20 min at room temperature, 
with occasional vortexing. The wash buffers and elution buffer contained the 
phosphatase inhibitors, sodium fluoride, sodium orthovanadate and sodium 
molybdate when phosphorylated samples were being analysed. Samples were 
then analysed by SDS-PAGE and Western blotting.
2.2.6.2 Seize® Primary Immunoprecipitation Kit
Immunoprecipitation using the Seize® Primary Immunoprecipitation Kit [P] was 
carried out according to the protocol provided by the manufacturer.
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2.2.7 Protein Digestion Techniques
2.2.7A Endoproteinase Lvs C Digestion
GLUT4, eluted from the immunoprecipitation, was incubated with 2 pg 
Endoproteinase Lys C (Endo LysC) [R] for 19 h at 37 °C.
2.2.7.2 Cyanogen Bromide Digestion
Following immunoprecipitation, GLUT4 was either excised from the gel (as for 
the adipocytes) or from polyvinylidene fluoride (PVDF) membrane following 
transfer of a SDS-PAGE gel (as for the 3T3-L1 adipocytes).
The gel containing the GLUT4 protein was macerated and the protein was 
precipitated using 67% (v/v) acetone including 4 pg BSA as a carrier protein, 
for 30 min at -20 °C. The pellet was resuspended in 3 mg/ml cyanogen 
bromide (CNBr) in 70% (v/v) formic acid and incubated for 15 h at room 
temperature.
The PVDF membrane was washed with methanol and ddH20  and then 
incubated with 3 mg/ml CNBr in 70% (v/v) formic acid for 36 h at room 
temperature. Following the addition of a further 3 mg/ml CNBr (to give a final 
concentration of 6 mg/ml) for a further 15 h, the samples were vortexed and 
centrifuged and the supernatant was collected. The membrane was then 
washed with 70% (v/v) formic acid, followed by 0.1% (v/v) trifluoroacetic acid. 
The acid was evaporated on a speed vac and traces of acid were removed by 
washing the membrane with ddH20  and evaporating again.
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Tris-tricine sample buffer was added to each of the samples containing the 
cleaved GLUT4. The samples were resolved by tris-tricine SDS-PAGE.
2.2.8 Protein Biochemistry Techniques
2.2.8.1 Sodium Dodecvl Sulphate - Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)
2.2.8.1.1 Tris-Glycine SDS-PAGE
Electrophoresis was carried out using the Laemmli discontinuous buffer system 
(Laemmli, 1970). Slab gels were prepared using either the mini-Protean II 
apparatus [BR] or the Atto Dual Mini Vertical PAGE cell system [AT]. All gels 
were made with a 1.5 mm thickness. Gels were prepared using acrylamide/bis- 
acrylamide (30% (w/v) acrylamide) [ND] and gel buffers. Polymerisation of the 
gels was initiated by the addition of 10% (w/v) ammonium persulphate (APS) 
[BR] and N,N,N,N’-tetramethylethylenediamine (TEMED) [BR]. The 
composition of the resolving and stacking gels is given in Table 2.8. Samples 
were solubilised by the addition of sample buffer and incubated for 20 -  30 min 
at room temperature with occasional vortexing. Samples were loaded onto the 
gels with high molecular weight (HMW) markers [S] and were run in 
electrophoresis buffer. The gels were run at 200 V for about 1 h until the dye 
front had run out of the gel. High molecular weight markers consist of myosin 
(205 kDa), p-galactosidase (116 kDa), phosphorylase b (97.4 kDa), bovine 
albumin (66 kDa), ovalbumin (45 kDa) and carbonic anhydrase (29 kDa).
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Stock Solutions Resolving Gel Stacking
8% 10% Gel
R eso lv ing  gel bu ffe r (m l) 25 25 -
S tack ing  gel bu ffe r (m l) - - 5
A c ry la m id e  s tock  (m l) 20 25 3.4
D oub le -d is tille d  w a te r (m l) 30 25 7.5
A m m o n iu m  pe rsu lpha te  (m l) 0.5 0.5 0.1
T E M E D  (pi) 40 40 20
Table 2.8 Quantities of stock solutions required to make up the resolving gel 
(either 8 or 10 percent acrylamide) and the stacking gel for tris-glycine SDS- 
PAGE.
2.2.8.1.2 Tris-Tricine SDS-PAGE
E le c tro p h o re s is  w as  carried  ou t us ing the  m ethod described  in S chagge r and 
von Ja g lo w  (S chagge r and von Jagow , 1987). Th is  m ethod g ives  be tte r 
reso lu tion  fo r sm a ll pep tides  than  the  tris -g lyc ine  S D S -P A G E  m ethod. S lab 
ge ls  w e re  p repared  using the  A tto  Dual M ini V e rtica l PAG E cell system  [AT], 
A ll ge ls  w e re  m ade  to  a th ickness  o f 1.5 m m . G els w ere  p repared  using 40  % 
(w /v) A c ry la m id e  29:1 [S] and gel buffer. P o lym erisa tion  o f the  ge ls  w as 
in itia ted  by the  add ition  o f 10%  (w /v) A P S  [BR ] and T E M E D  [S]. The 
com p o s itio n  o f the  reso lv ing , sp a ce r and s tack ing  ge ls  are  g iven  in T ab le  2.9. 
The  reso lv ing  gel w as  poured  to  4 cm  and the  sp a ce r ge l to 1 cm. S am p les  
w e re  so lub ilised  by the  add ition  o f T ris -T ric ine  sam p le  bu ffe r and heating  fo r 2 
m in  a t 65  °C. S am p les  w ere  loaded on to  the  ge ls  w ith  u ltra -low  range 
m o le cu la r w e ig h t (LM W ) m arke rs  [S] and run w ith  anode  and ca thode  bu ffe rs  
in the  co rrespond ing  cham bers  o f the  ge l tank. The  ge ls  w e re  run a t 100 V  fo r
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abou t 3 h until the  dye  fron t had run ou t o f the  gel. U ltra -low  range m o lecu la r 
w e ig h t m a rke rs  cons is t o f triose  phospha te  isom erase  (26 .6  kDa), m yog lob in  
(17 kDa), a - la c ta lb u m in  (14.2  kD a), ap ro tin in  (6 .5  kD a), insu lin  chain B (3 .496 









Gel bu ffe r (m l) 13.3 13.3 10
A c ry la m id e  29:1 16 10 5
(m l)
50%  (v/v) 7 - -
G lyce ro l (m l)
D oub le -d is tille d 3.7 16.7 25
w a te r (m l)
A m m on ium 200 200 320
p e rsu lpha te  (m l)
T E M E D  (pi) 40 40 60
Table 2.9. Quantities of stock solutions required to make up the resolving, 
spacer and stacking gels for tris-tricine SDS-PAGE.
2.2.8.2 Electrophoretic Transfer of Proteins to Nitrocellulose Membranes
F o llow ing  S D S -P A G E , p ro te ins  on the  ge l w e re  tra n s fe rre d  on to  n itroce llu lose  
m em brane  using the  M u ltipho r II N ovaB lo t e le c tro p h o re tic  tra n s fe r appara tus  
[A]. The  gel w as incuba ted  b rie fly  in tra n s fe r bu ffe r to  rem ove the 
e le c tro p h o re s is  runn ing  buffe r. The  e lec trode  pape r and n itroce llu lose  w ere
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also briefly immersed in transfer buffer. Nine pieces of NovaBlot electrode 
paper [A] cut to the size of the gel were placed on the anode, followed by a 
piece of nitrocellulose membrane with a 45 pM pore size [GE]. The resolving 
gel was then placed on top followed by another nine pieces of electrode paper 
and then the cathode. It was ensured that there were no bubbles trapped 
between any of the layers. The transfer was run at (area of the gel cm2) x 0.8 
mA for 1 h 50 min. Following transfer, the nitrocellulose membrane was 
washed briefly in ddH20, and stained with Ponceau S stain for a few minutes. 
Excess stain was washed off with ddH20  and the protein bands were 
visualised. The nitrocellulose was left to air dry and the molecular weight 
markers were marked on the nitrocellulose.
2.2.8.3 Western Blotting
The nitrocellulose was washed in Tris-buffered Saline containing Tween-20 
(TBS-T) to remove the Ponceau S stain. The nitrocellulose was then blocked in 
5% (w/v) Marvel (dried skimmed milk powder) in TBS-T for 60 min (unless 
otherwise stated) to block non-specific protein sites. The membrane was 
washed 4 x 1 5  min in TBS-T followed by incubation with the primary antibody 
(Table 2.2) for 90 min. The nitrocellulose was washed 6 x 5  min with TBS-T 
followed by incubation with the secondary antibody (Table 2.3) for 45 min. 
Finally the nitrocellulose was washed again 6 x 5  min in TBS-T and developed 
using ECL or ECL Advance [A] following the manufacturers guidelines. 
Essentially solutions were mixed in a 1:1 ratio and the membrane incubated for 
1 min for ECL and 5 min for ECL advance. The image was detected by use of 
a Hamamatsu camera attached to the EPI Chemi II darkroom [UVP].
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2.2.8.4 Stripping a Western Blot
The nitrocellulose was added to the stripping buffer and incubated at 50 °C for 
30 min with gentle agitation. The membrane was washed 2 x 1 0  min in TBS-T. 
Western blot analysis was then carried out as section 2.2.8.3.
2.2.8.5 BCA Protein Assay
The bicinchoninic acid (BCA) protein assay [P] was used to determine protein 
concentrations. A standard curve of BSA (1 mg/ml BSA in 0.1 M NaOH) was 
prepared. 10 pi of 0 -  10 pg BSA was added to a microtitre plate [BS] in 
duplicate. 10 pi of sample was also added to the plate, either undiluted or with 
a final concentration of 0.1 M NaOH. The BCA working solution was prepared 
by adding Reagent A [P] and Reagent B together in a ratio of 50:1. 200 pi of 
this was then added to each of the wells containing standard and sample. The 
plate was incubated at 37 °C for 30 min, allowed to cool and then read on a 
Spectra Rainbow Thermo microplate spectrophotometer [TE] at 565 nm.
2.2.8.6 Data Analysis
GraphPad PRISM version 4.0 was used for all graphical analysis. Labworks 
version 4 [UVP] was used for analysis of the Western blots. The intensity of the 




P ep tides w e re  syn thes ised  by D r G raham  B loom berg  at the  U n ive rs ity  o f 
B ris to l (F igu re  2.2). P eptides w e re  syn th e s ise d  w ith  a cys te ine  at e ith e r the 
a m ino - o r the  ca rb o xy l-te rm in u s  o f the  pep tide . Th is  w as to  fac ilita te  
con juga tion  o f the  pep tide  to o th e r p ro te ins  or fo r its im m ob ilisa tion  on to  a so lid  
su p p o rt to  aid an tibod y  pu rifica tion . The  pep tide s  w e re  ove r 95%  pu re  and 
w e re  lyoph ilised  and s to red  at -20  °C  until requ ired.
Antigen used in rabbit ^ - i-g -s (P) -e -d -g -e -p-p-q -q -c -cooh
Unphosphorylated form 
of the rabbit antigen m2- i - G - s  -e-d-g-e-p-p-q-q-c-coob
PAN-specific peptide hH2-c-g-e -p-p-q -q -cooh
Antigen used in sheep „2-C-Q-Q-I-G-S (P) -E-D-G-E-cooh
Unphosphorylated form 
of the sheep antigen
NH2-c -q -q -i-g -s -e -d -g -e -cooh
FQQI phospho-peptide nh2-C-F-Q-Q-I-G-S (P) -e -d -cooh
C-terminal peptide ^-C-S-T-E-L-E-Y-L-G-P-D-E-N-D-c^
Figure 2.2 Sequence of the peptides used in the antibody purification study.
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2.2.9.2 Quantification of the Free Sulphvdrvl Content in Peptides
The cysteine residue in the peptide needs to be in a reduced state for 
conjugation to carrier proteins. It is possible to determine the level of reduced 
cysteines by quantifying the free sulphydryl content within the peptide. 5,5’- 
Dithiobis (2-nitrobenzoic acid) or Ellman’s reagent [Pj will react with sulfhydryl 
groups to produce a chromaphore. Thus the amount of reduced peptide can be 
calculated by comparison to a standard curve of L-cysteine.
A 1 mg/ml stock of Ellman’s reagent was made in PBS. 1 mg/ml stock 
solutions were also prepared of L-cysteine and peptide, both in PBS. 200 pi 
PBS was added to each well of a 96 well microtitre plates [N]. 10 pi of the 
peptide solution was added to two buffer containing wells. Serial dilutions of L- 
cysteine were prepared and 10 pi were added to buffer containing wells to give 
a standard curve of 0 -  10 pg L-cysteine. 20 pi of the 1 mg/ml Ellman’s reagent 
was added to the each well containing the peptide or L-cysteine. The plate was 
incubated for 15 min at room temperature and the absorbance read at 412 nm 
in a Spectra Rainbow Thermo spectrophotometer [TE]. A negative control of 
buffer only was used as a background level. The level of reduced peptide was 
determined by comparing the O.D. of the peptides to that of the standard curve 
of cysteine.
2.2.9.3 Preparation of Peptide Conjugated to KLH
To effectively raise antibodies against small non-immunogenic molecules i.e. 
peptides, it is necessary to couple them to a carrier protein via a cross linker. 
The phosphorylated N-terminal peptide (antigen used in sheep) and the C- 
terminal peptide were coupled to the carrier protein, Imject® Mariculture 
Keyhole Limpet Hemocyanin (KLH) [P], using the crosslinker m- 
Maleimidobenzoyl-A/-Hydroxysuccinimide ester (MBS) [P]. KLH was in a 
lyophilised form and was reconstituted with 2 ml ddH20  to make a 10 mg/ml
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solution containing PBS with proprietary stabiliser. MBS was dissolved in 
dimethyl sulfoxide (DMSO) to give a final concentration of 10 mg/ml. 1 mg 
MBS was added to 5 mg KLH (per antibody being produced) and mixed for 1 h 
at room temperature to allow amide bond formation.
The MBS-activated KLH was separated from free MBS via gel filtration on an 8 
ml Sephadex G-25 column. The column was washed with 5 column volumes of 
conjugation buffer. The MBS-KLH sample was applied to the equilibrated 
column. 0.5 ml fractions were collected and the elution of the MBS-KLH was 
followed at 280 nm. Two peaks elute, with the first being the MBS activated 
KLH and the second unreacted MBS. The fractions containing MBS-KLH were 
pooled. 5 mg peptide was dissolved in 1.25 ml conjugation buffer and added to 
the pooled MBS-KLH fractions. This was incubated for 2 h at room 
temperature. The peptide-MBS-KLH conjugate was dialysed against 5 L PBS, 
overnight, at 4 °C to purify the conjugate and remove EDTA. The concentration 
of the conjugate was determined by BCA protein assay. 1 mg samples of the 
peptide-MBS-KLH conjugate were aliquoted and stored at -20 °C.
2.2.9.4 Injection Protocol
The immunisations were carried out by Diagnostics Scotland [D]. For each 
immunisation, 1 mg of the peptide-MBS-KLH conjugate was mixed with 
Freund’s complete adjuvant (for the primary immunisation) or Freund’s 
incomplete adjuvant (for subsequent booster immunisations) and injected 
subcutaneously into sheep. Injections were given every 28 days and test 
bleeds obtained 7 days after the booster injections. Three test bleeds were 
taken with further bleeds taken if needed. The sheep were not exsanguinated 
at the end of the procedure.
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2.2.9.5 ELISA plate assay
A 50% (v/v) glycerol stock was made in ELISA plate coating buffer. 2 ml of this 
solution was added to 2 mg peptide. 100 pi of this was further diluted in 10 ml 
coating buffer resulting in a concentration of 10 pg/ml. The remaining peptide 
glycerol stocks were stored at -20 °C. C8 Maxisorp plates [Nj were coated with 
100 pi of the 10 pg/ml peptide solution per well, covered and incubated 
overnight at 4 °C. The plates were washed three times with PBS-T with 
rigorous expulsion of liquid out of the wells. The wells were filled with 200 pi 
ELISA plate blocking buffer and incubated, shaking, for 1 h at room 
temperature. The plate was washed twice with PBS-T. A 1:100 dilution of 
antibody was made in PBS-T. 200 pi of this was placed in the first well. 100 pi 
was withdrawn and placed into the second well containing 100 pi PBS-T. This 
serial dilution was performed 12 times across the plate. The plate was then 
covered and incubated with gentle shaking for 2 h at room temperature. The 
wells were washed three times with PBS-T. 100 pi anti-rabbit IgG HRP or anti­
sheep IgG HRP (1:4000 dilution in PBS-T) was added to each well and 
incubated, shaking, for 2 h at room temperature. The plates were then washed 
three times with PBS-T and twice with PBS. ELISA sodium acetate/citrate 
buffer was diluted 1:20 in ddH20  and the pH checked (pH 6.0). 49.5 ml of the 
solution was added to 0.5 ml Tetramethyl Benzidine (TMB) (10 mg/ml in 
DMSO) and 10 pi 30% (v/v) H2O2 . 100 pi of this was added to each of the wells 
and incubated at room temperature until a blue colour has developed over the 
range of dilutions. The reaction was stopped by the addition of 50 pi 1.84 M 
H2SO4 per well. The plates were then read in a Spectra Rainbow Thermo 
microplate spectrophotometer [TE] with filter 1 measuring O.D. at 450 nm and 
filter 2 measuring O.D. at 700 nm (to eliminate background readings).
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2.2.10 Antibody Affinity Purification
The antibody was purified against peptide coupled to SulfoLink® Coupling gel 
[P]. The gel binds peptides containing free sulfhydryl groups through iodoacetyl 
moieties attached to a 12 atom spacer arm, which reduces the steric hindrance 
and allows a more efficient binding. All buffers were degassed before use.
2.2.10.1 Generation of a Peptide Coupled Column
The SulfoLink® gel was brought to room temperature. 2 ml of gel was packed 
into a Talon 2 ml empty disposable column [BD]. The column was equilibrated 
with six column volumes coupling buffer. The bottom of the column was 
capped and 2 ml of 1 mg/ml peptide in coupling buffer was added. An aliquot of 
peptide was retained for protein analysis. The top of the column was capped 
and the column was incubated at room temperature for 15 min with rotation 
followed by 30 min without rotation. The column was drained and washed with 
3 column volumes of coupling buffer. Both the flow through from the column 
and the wash were kept. A BCA protein assay was carried out to determine 
coupling efficiency. The bottom of the column was capped and 2 ml of 50 mM 
L-cysteine in coupling buffer was added to the column to block non-specific 
binding sites on the gel. The top cap was replaced and the column incubated 
at room temperature for 15 min with rotation followed by 30 min without 
rotation. The column was drained and washed with 16 column volumes 1 M 
NaCI and 16 column volumes 0.05% (w/v) sodium azide. The bottom cap was 
replaced and 2 ml 0.05% (w/v) sodium azide was added. The top cap was 
replaced and the column was stored in an upright position at 4 °C.
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2.2.10.2 Affinity Purification of Serum
The column prepared in section 2.2.10.1 was brought to room temperature and 
drained. The column was equilibrated with 4 column volumes PBS. 3 ml serum 
was added to the column followed by 2 ml PBS. The caps were replaced and 
the column incubated at room temperature for 90 min with rotation. The column 
was drained and the flow through retained. The column was then washed with 
2 column volumes 1 M NaCI to remove weakly associated proteins, followed by 
6 column volumes PBS. The antibody was eluted from the column with 8 ml 
100 mM Glycine (pH 2.75) with 1 ml fractions collected and neutralised by the 
addition of 50 pi 1 M Tris (pH 9.5). The column was washed with 8 column 
volumes PBS, followed by 16 column volumes 0.05% (w/v) sodium azide. The 
bottom cap was replaced and 2 ml 0.05% (w/v) sodium azide was added. The 
top cap was replaced and the column was stored in an upright position at 4 °C. 
The eluted fractions were analysed for protein content and the fractions 
containing high levels of protein were pooled together and dialysed overnight 
at 4 °C against 5 L PBS. The dialysed solution was concentrated using either 
PEG 20000 [BDH] which acts to remove water out of the solution or in a 
Centricon-plus 20 spin column [ML]. The protein content was measured using 
a modified BCA protein assay. An IgG protein standard curve was used, 
instead of BSA, to give the concentration of protein in mg/ml IgG. The affinity 
purified antibody solution was made up to a 40% glycerol stock and the protein 





D N A  p rim e rs  w e re  m ade to  o rde r by M W G  [M W G ]. P rim er sequences  fo r s ite - 
d irec ted  m u ta g e n e s is  and sequenc ing  are g iven in T ab les  2 .10  and 2 .11, 
respec tive ly .
Primer Sequence
A la 1 0  fo rw ard C CAA CAG A T A  GGC GCC GAA GAT GGG GAA CC
A la  10 reve rse GG TTC CCC ATC TTC GGC GCC TAT CTG TTG G
A sp  10 fo rw ard C CAA CAG A T A  GGC GAT GAA GAT GGG GAA CC
A sp  10 reverse GG TTC CCC ATC TTC ATC GCC TAT CTG TTG G
A la488  fo rw a rd CAC CGG ACA CCC GCA CTT T T A  GAG CAG G
A la488  reve rse C CTG CTC TAA  AAG TGC GGG TGT CCG GTG
A sp 4 8 8  fo rw ard CAC CGG ACA CCC GAT CTT T T A  GAG CAG G
A sp 4 8 8  reverse C CTG CTC TAA  AAG ATC GGG TGT CCG GTG
Table 2.10 Sequence of primers used for site directed mutagenesis. The bases in 
bold represent the amino acid being mutated.
Primer Sequence
N -te rm ina l c a g c c a c g t c t c a t t g t a g c  
C -te rm ina l g g t t g t t g c g g a g g c t a t g g g g c t c c a g  j
Table 2.11 Sequence of primers used for DNA sequencing.
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2.2.11.2 Site-Directed Mutagenesis
S ite -d ire c te d  m u tagene s is  w as carried  ou t by po lym erase  cha in  reaction  (P C R ) 
using m u ta g e n ic  p rim ers  to the  am ino  acid  be ing m uta ted . C om p lem en ta ry  
p rim e rs  w e re  used w ith  a long annea ling  tim e  so tha t the  w ho le  p lasm id  w ou ld  
be am p lified . D N A w as  m uta ted  by PCR w ith  e ith e r 2 .5  U P fuTurbo  D N A 
p o lym e ra se  [ST] or 2 .5  U P la tinum  P fx D N A po lym erase  [I] in 50 pi reactions 
us ing  a M in iC yc le r [M J], A  typ ica l p rog ram  is illus tra ted  be low  (Tab le  2.12).
Segment Cycles Temperature Time
1 1 95 °C 1 m in
2 18 95 °C 50 sec
64 °C 50 sec
68 °C 18.75 m in *
3 1 68 °C 17.5 m in
Table 2.12 An example of the cycling parameters used for the site-directed
mutagenesis PCR. * 2.5 min / kb of plasmid length.
2.2.11.3 Don I Digestion
10 U Dpn I w as added to the  PCR p roduct and incuba ted  at 37 °C fo r 1 h. The 
e n zym e  w as  then  heat inac tiva ted  at 80 °C fo r 20 m in.
2.2.11.4 DNA Analysis
P C R  p roduc ts  w e re  run on 1% (w /v) aga rose  T ris -a ce ta te  E D TA  (TAE) ge ls at 
160 V  fo r 20 -  40  m in. The  bands w as  v isua lised  by e th id ium  brom ide  s ta in ing  
unde r U V  tra n s illu m in a tio n .
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DNA sequencing was carried out using a PE Biosystems ABI 377 DNA 
Sequencer [AB] at the University of Bath sequencing facility.
2.2.11.5 Transformation
The Dpn 1 digested PCR product was transformed into XL1 Blue (recA1 endA1 
gyrA96 thi-1 hsdR17 supE44 re!A1 lac [F’ proAB lac1qZAM15 Tn10 (Tef)]) 
competent E.coli cells [ST]. 2 pi PCR product was added to 50 pi chemically 
competent cells on ice and incubated for 30 min. The cells were heat shocked 
for 45 sec at 42 °C and then the cells were placed on ice for 2 min. 250 pi Luria 
Broth was added to the cells and incubated at 37 °C for 45 min. All of the cells 
were then plated on agar plates containing 50 pg/ml Ampicillin and incubated 
at 37 °C overnight.
2.2.11.6 Plasmid manipulations
Plasmid DNA was purified from cultures of the transformed XL1 Blue E.coli 
cells in 5 ml LB media using the Wizard Plus SV miniprep DNA purification 
system [P], according to the protocol provided by the manufacturer.
2.2.12 Electroporation of Rat Adipocytes
Rat adipocytes were prepared as in section 2.2.2.1.1 except that all buffers 
were sterile filtered through a 0.2 pm filter [ML] before use and all instruments 
were sterile. The cells were washed twice with 1% (w/v) BSA / aKRH and a 
further two times with DMEM (1). The cell suspension was adjusted to a 49% 
cytocrit. Four cuvettes were used per condition and 200 pi DMEM (1) containing 
0.1 pg HA-GLUT4 DNA and 100 pg sheared herring sperm DNA was added to 
each cuvette. 200 pi of the 49% cell suspension was then added to the cuvette
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and gently shaken to mix. Electroporation was carried out using the Biorad 
gene pulser [BR], with a capacitance extender attached. Each cuvette was 
electroporated once at 400 V, 500 pF. This gave a time constant in the region 
of 13 ms. The cells were washed with DMEM (2) and allowed to float at 37 °C. 
The infranatant was removed and the cells were resuspended with 4 ml DMEM 
(3). The cells were mixed by gentle inversion to disperse any clumps and 
transferred to 35 mm dishes and incubated for 5 h at 37 °C in 5% (v/v) CO2.
2.2.13 Antibody Binding Assay
The electroporated cells were transferred into 4 ml tubes (50 mm x 13 mm 
polypropylene tube [N]) at 37 °C. The cells were washed 2 times with aKRH, 
filling to at least 2 ml and allowing the cells to float up each time. The tubes 
were filled to 1 ml and 20 pi of the cell suspension was removed for SDS- 
PAGE analysis to determine transfection levels. The cells were washed twice 
with 1% (w/v) BSA / aKRH, filling the tubes to 2 ml. 60 nM insulin was added to 
the cells and incubated at 37 °C for 20 min. Trafficking was stopped by the 
addition of 53 pi 80 mM KCN for 3 min at 37 °C. Unless otherwise stated, the 
buffers in the remainder of the assay contained 2 mM KCN. The cells were 
washed twice with 5% (w/v) BSA / aKRH. The primary antibody (Table 2.4) 
was added to the cells and incubated for 1 h, mixing every 15 min. The cells 
were again washed twice with 5% (w/v) BSA / aKRH followed the addition of 
the secondary antibody (Table 2.4) for 60 min, mixing every 15 min. The cells 
were washed once with 5% (w/v) BSA / aKRH and three times with aKRH 
containing no KCN. The cells were resuspended to 1 ml and aliquots were 
removed for protein assay. To assay the bound antibody, 90 pi KRH was 
added into wells of a black 96 well plate [G] and 10 pi of cell suspension was 
also added to each well. 100 pi 0.2 mM fluorescein digalactosidase (FDG) [MP] 
was quickly added to the wells and the plate was read in the FarCyte plate 
reader [A]. The plate reader was set to measure a Z position of 7808, a gain of
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30, no lag time, 40 ps integration time and 30 readings / well. The plate was 
read for 100 cycles to determine where the rate of reaction was linear.
2.2.14 Confocal Microscopy
2.2.14.1 Cardiomvocvtes
Basal and insulin-stimulated cardiomyocytes, prepared as in section 2.2.2.2.1, 
were washed three times in cKRH to remove any BSA. The cells were 
centrifuged at 1,000 x g to pellet the cells between washes. All of the 
incubations were carried out, with shaking, at room temperature. The cells 
were fixed in 4% (w/v) paraformaldehyde in PBS for 20 min. The cells were 
washed three times with PBS and permeabilised for 45 min with confocal 
permeabilisation buffer. The primary antibody (Table 2.5) was added to the 
cells and incubated for 1 h. The cells were then washed three times with 
confocal wash buffer and the secondary antibody (Table 2.5) was added for 1 
h. Following three washes with the confocal wash buffer and three washes with 
PBS, an aliquot of the cells was mounted onto glass slides using Vectashield® 
[VL]. Images were obtained using a LSM 510 Zeiss confocal laser scanning 
microscope [CZ] with a 63x oil-immersion objective. The fluorophores were 
excited at 488 nm with an argon laser and at 568 nm or 633 nm with a helium- 
neon laser.
2.2.14.2 3T3-L1 Adipocytes
3T3-L1 adipocytes, plated on coverslips, were washed with 1 ml of PBS and 
incubated in serum free media (DMEM) for 2 h at different days after 
differentiation. The cells were quickly washed with ice cold PBS and fixed in 
cold methanol for 5 min at -20 °C. Following three washes with PBS, the cells
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were blocked in confocal permeabilisation buffer for 45 min, with gentle 
shaking, at room temperature. The cells were washed four times in confocal 
wash buffer. The primary antibody (Table 2.5) was added to the cells. The 
mouse monoclonal anti-C-terminal GLUT4 antibody was incubated overnight at 
4 °C and the anti-pSer10 antibody was incubated for 1 h at room temperature. 
The cells were washed four times with confocal wash buffer and the secondary 
antibody (Table 2.5) was incubated, shaking, for 1 h. After washing the cells 
four times with PBS, the coverslips were mounted onto glass slides using 
Vectashield® [VL]. Images were obtained using a LSM 510 Zeiss confocal laser 
scanning microscope [CZ] with a 63x oil-immersion objective. The fluorophores 
were excited at 488 nm with an argon laser and at 568 nm with a helium-neon 
laser.
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3 Generation, Purification and Characterisation of 
Phospho-Specific Anti-GLUT4 Antibodies
3.1 Introduction and Experimental Aims
Antibodies have become an essential part of GLUT4 research and have helped 
enable the progress which has been seen in all aspects of GLUT4 research 
over the last 18 years. In 1980, subfractionation and cytochalasin B binding 
identified a subset of glucose transporters in rat adipocyte cells that were 
sensitive to insulin. Under basal conditions these transporters were 
sequestered in intracellular membranes. Following stimulation with insulin, the 
glucose transporters translocated to the plasma membrane where they could 
transport glucose into the cell (Cushman and Wardzala, 1980). In fact, it was 
from the use of a mouse monoclonal antibody (clone 1F8), in western blotting 
analysis, that James and colleagues confirmed that the insulin-responsive 
glucose transporter was solely expressed in insulin-responsive tissues (James 
et al., 1988). This antibody is still frequently used today by many laboratories. 
Since the production of this monoclonal antibody, many other anti-GLUT4 
antibodies have been raised and are frequently used to analyse many different 
areas of GLUT4 biology. For example, they are used to examine the cellular 
distribution and trafficking of GLUT4 as well as helping to identify other 
proteins that are present on GLUT4 containing vesicles (Holman et al., 1990, 
Cain et al., 1992).
Previous studies to identify potential phosphorylation sites within GLUT4 have 
used in vitro phosphorylation experiments, in which rat adipose tissue was 
incubated with [32PJ and, after proteolytic digestion of GLUT4, autoradiography 
was used to detect the sites of phosphorylation (Lawrence, Jr. et al., 1990a). In 
the last decade, with the evolution of the immunology tools, it has become 
possible to raise antibodies which will specifically detect phosphorylated
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residues within a protein. The use of phosphorylation-specific antibodies could 
play an important part in the study of the phosphorylation of GLUT4 by 
corroborating the results seen from the in vitro phosphorylation studies, as well 
as giving a safer alternative to the use of radioactivity.
A previous member of the laboratory, Darren Harper, had raised an antibody in 
rabbit, to a synthetic peptide corresponding to an area at the N-terminus of 
GLUT4 containing phosphorylated serine 10 (pSer10) (Harper, 2002). However, 
raising a highly phospho-specific antibody is very difficult and purification of the 
antibody from the serum is essential. When an antigen is injected into the host, 
the host’s immune response generates antibodies against this foreign body. 
When the antigen contains a phosphorylated residue, three different classes of 
antibody will be produced by the host: phospho-specific, non-phospho-specific 
and PAN-specific antibodies. The phospho-specific antibodies, in which the 
epitope encompasses the phosphorylated residue, are the desired population. 
However, antibodies will also be raised to exactly the same epitope as the 
phospho-specific antibodies, but they will not contain a phosphorylated residue 
because phosphatases in the host may dephosphorylate the antigen. This 
gives the second class of antibodies - non-phospho-specific antibodies. The 
final class of antibodies to be raised will have epitopes which do not contain 
the phosphorylated residue; these are referred to as PAN-specific antibodies 
(Figure 3.1).
The aim of the work described in this chapter was to try to purify and 
characterise a highly phospho-specific population of antibodies recognising the 
phosphorylated serine 10 residue in GLUT4. This chapter will describe the 
purification and characterisation of antibodies from the rabbit serum, which has 
previously been raised against pSer10 in the N-terminus of GLUT4 by Darren 
Harper. The production, purification and characterisation of antibodies in sheep 
will also be discussed. Both antibodies were raised against pSer10 but a 
different antigen sequence was used to raise the antibody in sheep compared 
to that used in rabbit. An antibody to the C-terminus of GLUT4 has previously
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been ra ised  in ra b b it (H o lm an et al., 1990) and the  sam e an tigen  w as used to 
ra ise  an a n tib o d y  in sheep. It w as  tho u g h t tha t a rabb it an ti-C -te rm ina l G LU T4 
an tibod y  cou ld  be used in con junction  w ith  an a n ti-p S e r10 an tibod y  ra ised in 
sheep. A lte rn a tive ly , the  a n ti-p S e r10 an tibod y  ra ised  in rabb it cou ld  be used 
w ith  the  a n ti-C -te rm in a l an tibod y  ra ised in sheep. T h is  w ou ld  be poss ib le  
b ecause  th e re  is no cross reac tiv ity  be tw een  the  a n ti-sheep  and the  an ti-rabb it 
se co n d a ry  a n tibod ies . Th is  w ou ld  p rov ide  an ex te n s ive  range o f an tibod ies  
ava ilab le  fo r use in investiga ting  the phosph o ry la tion  s ta tus  o f G LU T4 and 
hope fu lly  it w ou ld  be poss ib le  to use the  p h o sp h o -sp e c ific  p S e r10 an tibod ies  to 
s tudy  the  in vivo phosph o ry la tion  o f G LU T4. P oss ib ly  the  use o f the  an tibody 
w ou ld  e n a b le  the  iden tifica tion  o f any d iffe rences  in loca lisa tion  o f the 
p h o sp h o ry la te d  and non -pho spho ry la ted  fo rm s o f se rine  10 in G LU T4. The 
an tibod y  m ig h t a lso  aid the cha rac te risa tio n  o f the  func tion  o f th is  
p h o sp h o ry la tio n  s ite .
P h o s p h o - P A N -
S p e c ific  S p e c ific
. A
l-G -S -E -D -G -E-P-P-Q -Q
Y
N o n -P h o s p h o -
S p e c ific
Figure 3.1 Three classes of antibody are produced when an animal is injected 
with a phosphorylated antigen -  phospho-specific, non-phospho-specific and 
PAN-specific antibodies. The peptide illustrated is the antigen used to generate anti- 
pSer10 antibodies in rabbit.
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3.2 Results
3 .2 .1  P u r if ic a t io n  o f  a P h o s p h o -S p e c if ic  P o p u la t io n  o f  a n t i-  
G L U T 4  A n t ib o d ie s  R a is e d  to  S e r in e  10 fro m  R a b b it  
S e ru m
P rev ious ly , D arren H arper had found  tha t the  second  b leed se rum  gave the 
best a n tib o d y  titre  fo r the  p h o sp h o -sp e c ific  an tibody. He purified  an tibody from  
the  second  bleed se rum  using an im m u n o a ffin ity  pu rifica tion  co lum n in w h ich  
Su lfoL ink®  resin  w as  coup led  to  the  phosph o ry la ted  pep tide  (phospho  peptide ) 
used as th e  an tigen  (F igure  3.2) (S ection  2 .2 .10). He show ed  that, by ELISA , 
the re  w a s  a d iffe rence  in sp e c ific ity  fo r the  phosph o ry la ted  and non- 
p h o sp h o ry la te d  fo rm s o f the  pep tide  used as the  an tigen  (H arper, 2002). 
H ow ever, the  purified  popu la tion  o f a n tibod ies  still recogn ised  the  non-phospho  
peptide , so  fu rthe r pu rifica tion  w as  needed to rem ove  the  con tam ina tin g  
popu la tion  o f non -p h o sp h o -sp e c ific  an tibod ies .
Phospho pep tide **-1-6-8 (P) -E-D-G-E-P-P-Q-Q-C-cooh
Non-phospho peptide **-1-6-8 -E-D-G-E-P-P-Q-Q-C-cooh
PAN-specific pep tide SH2-c -g -e -p -p -q -q -C0OH
FQQI phospho-peptide ra2-C-F-Q-Q-I-G-S (P) -E-D-coo„
Figure 3.2 Sequences of the peptides used in the purification of anti-pSer10 
antibodies from rabbit serum.
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3.2.1.1 Analysis of the Different Rabbit Serum Bleeds
Darren Harper had purified an antibody population from the second bleed 
serum. However, the second bleed was a test bleed and so there was only a 
limited amount of serum. It was therefore necessary to investigate whether a 
different bleed of serum could be used for the antibody purification. For this, 
ELISA and Western blotting techniques were used (Section 2.2.9.5 and
2.2.8.3). The second and final bleed sera were screened against the phospho 
and non-phospho peptides by ELISA. There was not a large difference 
between the antibody titres of the second bleed and final bleed sera (Figure
3.3). Even though the second bleed serum did have a slightly higher antibody 
titre, the difference in specificity each serum had for the phospho and non- 
phospho peptides (the difference between the lines) was the same. This 
demonstrated that the two antibody populations were similar. Both sera 
recognised a protein of about 45 kDa (Figure 3.4). This was the same 
molecular weight as the protein recognised by the anti-C-terminal GLUT4 
antibody and indicated that the sera recognised GLUT4. However, contrary to 
the ELISA data, the final bleed serum recognised the band at 45 kDa more 
strongly than the second bleed serum. This suggested that, by Western blot 
analysis, the final bleed serum was better than the second bleed serum. 
Purification was therefore carried out using the final bleed serum, as the two 
bleeds were comparable and there was also only a limited amount of second 
bleed serum remaining. Darren Harper had only analysed the serum by ELISA, 
which could be why he chose the second bleed serum for purification and not 
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Second bleed 
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Figure 3.3 ELISA analysis comparing the second bleed serum with the final 
bleed serum. The second bleed serum (black line) and the final bleed serum (red 
line) were subjected to ELISA analysis against plates coated with the phospho (solid 
line) and non-phospho peptides (hashed lines). T itre values can be estimated by 
analysis o f optical density readings at 450 nm over the logarithm ic dilution range of the 
sera.
45
Figure 3.4 W estern blot analysis comparing the second bleed serum with the 
final bleed serum. SDS-PAGE gels were loaded with 10 pg basal LDM (1) and 
insulin plasma membrane (2) adipocyte fractions and then transferred for Western blot 
analysis. The second bleed serum (a) and the final bleed serum (b) were both used at 
a 1:1000 dilution for detection.
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3.2.1.2 Purification of Antibody from the Final Bleed Rabbit Serum
Antibodies from the final bleed serum were affinity purified against the phospho 
peptide used as the antigen. The resulting antibodies were analysed by ELISA, 
along with those purified from the second bleed by Darren Harper. ELISA 
analysis, testing the affinity of each antibody for the phospho and non-phospho 
peptide, confirmed that the antibody purified from the final bleed serum was 
similar to the antibody purified from the second bleed serum (Figure 3.5). 
However, the antibody purified from the final bleed serum had a higher 
antibody titre than the antibody purified from the second bleed serum, the 
inverse from that seen with the serum (Figure 3.3).
The fact that the purified antibody from the final bleed serum had a greater 
specificity for the phospho peptide than the non-phospho peptide was very 
encouraging. However, further purification of the serum was needed because 
the purified antibody recognised the non-phospho peptide. This indicated that a 
non-phospho-specific population of antibodies had been purified along with a 
phospho-specific population of antibodies.
3.2.1.3 Further Purification Strategies to Produce a Phospho-Specific 
Population of anti-pSer10 Antibodies
To make the antibody population more phospho-specific, cross purification was 
carried out. In this procedure the serum was first purified on a non-phospho 
peptide column to bind and remove all of the non-phospho-specific antibodies 
and the PAN-specific antibodies. The flow through from the non-phospho 
peptide column would contain the phospho-specific antibodies and other serum 
proteins. This flow through was then purified on a phospho peptide column. 
Here the phospho-specific antibodies should bind to the column and a 
phospho-specific population should be purified from the column. The serum 
proteins and other non-GLUT4 antibodies would therefore be removed. The
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antibodies purified using both the non-phospho peptide and the phospho 
peptide columns were analysed by Western blot (Figure 3.6). The antibody 
which had bound to the non-phospho peptide column recognised bands similar 
to those seen previously with the anti-C-terminal GLUT4 antibody (Figure 3.6 
b). Unfortunately, the antibody which was purified from the phospho peptide 
column did not recognise any bands above background level (Figure 3.6 a). As 
the phospho-specific antibodies cross reacted with the non-phosphorylated 
peptide, cross purification was not a method that could be used to purify anti- 
pSer10 antibodies.
As the cross purification method could not be used, a different purification 
strategy was tried using a slightly different phospho peptide (FQQI phospho 
peptide). This peptide had a smaller ‘PAN’ region so fewer non-phospho- 
specific antibodies should bind to the peptide. It was hoped that antibodies 
raised to the pSer10 residue would be purified on the FQQI phospho peptide as 
they had a number of overlapping residues which encompassed the epitope of 
the desired population of anti-pSer10 antibodies (Figure 3.7).
Unfortunately the FQQI phospho peptide did not lead to the purification of any 
antibody from the serum (result not shown). The actual peptide sequence and 
its fold must therefore be essential for the purification of the antibodies from the 
serum.
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-*■ Second bleed purified 
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peptide
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Figure 3.5 ELISA analysis comparing affinity purified antibodies from the second 
bleed serum and the final bleed serum. The affinity purified antibodies from the 
second bleed serum (black line) and the final bleed serum (red line) were subjected to 
ELISA analysis against plates coated with the phospho (solid line) and the non- 
phospho peptides (hashed line). Titre values were estimated by analysis of optical 
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Figure 3.6 Western Blot analysis comparing the antibodies purified after cross 
purification on the non-phospho peptide column followed by the phospho 
peptide column. SDS-PAGE gels were loaded with 10 pg basal LDM (1), insulin LDM 
(2), basal plasma membrane (3) and insulin plasma membrane (4) adipocyte fractions. 
The gel was transferred for Western blot analysis. The final bleed serum was first 
purified on the non-phospho peptide column (b), this should remove the non-phospho 
and PAN-specific antibodies. The remaining serum was then purified on the phospho 
peptide column to obtain a phospho-specific population of anti-pSer10 antibodies (a).
2.5-i
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Ant i gen used in rabbi t
FQQI phospho-pep tide COOH
COOH
Figure 3.7 Comparison of the sequence of peptides used in the antibody 
purification. The FQQI phospho peptide had fewer ‘PAN’ residues so hopefully the 
peptide would purify a specific pSer10 population of antibodies.
T he fina l s tra te g y  tha t w as a ttem p ted  to pu rify  a p h o sp h o -sp e c ific  an tibod y  
p opu la tion  from  the serum  invo lved  the  use o f an o th e r sh o rte r pep tide  (P A N - 
sp e c ific  pep tide ). T h is  rep resen ted  the  area o f the  o rig ina l an tigen  to w h ich  
P A N -sp e c ific  an tibod ies  w ou ld  have  been ra ised  (F igu re  3.8).
Figure 3 8 Comparison of the sequence of peptides used in the antibody 
purification. The PAN-specific peptide was used to remove the PAN-specific 
antibodies that had been purified along with the anti-pSer10 antibodies on the phospho 
peptide column.
A s it w as  no t poss ib le  to  use the  non -pho spho  pep tide  in the cross  pu rifica tion  
techn iqu e , the  P A N -spec ific  pep tide  w as used in the  pu rifica tion  p rocess a fte r 
an in itia l pu rifica tion  on a phospho  pep tide  co lum n. Tw o an tibod y  popu la tions  
w ou ld  have  been co -pu rified  from  the phospho  pep tide  co lum n. A n tibod ie s  
w ou ld  have  con ta ined  ep itopes  ra ised to the  p hosph o ry la ted  S e r10 res idue  and 
to  the  PAN  reg ion o f the  pep tide . T hese  tw o  a n tibod y  popu la tions  w ere
p
A ntigen  used in rabb it nH2-I”G-s -e -d -g -e -p -p -q -q -C“cooh
I I I I I I
PAN-specific pep tide -C-G-E-P-P-Q-Q-NH2 *  *  COOH
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separated by affinity purification on a PAN-specific peptide column. The 
antibodies raised to the PAN region of the peptide bound to the PAN-specific 
peptide column and were eluted. The antibodies with epitopes encompassing 
pSer10 did not bind to the column and were present in the flow through. The 
two antibody populations purified from the two columns were analysed by 
ELISA and Western blot (Figures 3.9 and 3.10, respectively). The newly 
purified phospho-specific antibody population (Figure 3.9, black line) was 
phospho-specific as the antibody had a higher specificity for the phospho 
peptide (Figure 3.9, solid line) than the non-phospho peptide (Figure 3.9, 
hashed line). This antibody population was also more phospho-specific than 
the antibody purified solely on the phospho peptide column because the 
difference between the phospho and non-phospho peptides was greater 
(Figure 3.9 compared to Figure 3.5). In purifying the PAN-specific antibody 
(Figure 3.9, blue line) away from the pSer10 antibody, a large population of 
antibodies that recognised PAN-specific epitopes had been removed. The 
PAN-specific antibody had a high antibody titre for the non-phospho peptide 
(Figure 3.9, blue hashed line). However, the PAN-specific peptide did purify 
some antibodies that contained epitopes raised to the pSer10 residue (Figure 
3.9, blue solid line). The PAN-specific antibody (Figure 3.10 c) recognised a 
protein at the same molecular weight as the anti-C-terminal GLUT4 antibody 
(Figure 3.10 d) with the same expression pattern in basal and insulin- 
stimulated adipocytes. This was as expected, as the PAN-specific antibody 
primarily contained non-phospho-specific antibodies. A comparison of the 
phospho-specific antibody after purification on the PAN-specific peptide 
column (Figure 3.10 b) was carried out with the antibody which Darren Harper 
had purified from the second bleed serum on the phospho peptide column 
(Figure 3.10 a). Both antibodies recognised a weak protein band at 45 kDa 
(arrows on Figure 3.10 a and b). This was the same molecular weight as 
GLUT4 probed with the anti-C-terminal GLUT4 antibody. Both anti-pSer10 
antibodies presented similar bands but the bands identified by the antibody 
purified on the PAN-specific peptide column were less intense. Non-specific
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bands were identified with both anti-pSer10 antibodies, just above 45 kDa, 
which made identification of the GLUT4 band difficult.
The data from the ELISA analysis looked promising in that the purification of a 
phospho-specific anti-pSer10 antibody from rabbit serum was possible. 
However, further work on the characterisation of the antibody and the 
optimisation of Western blots for the use of this antibody was needed before it 
could be used in meaningful experiments that quantified the level of 
phosphorylation at Ser10 in GLUT4.
3.2.1.4 Characterisation of a Phospho-Specific pSer10 Population of 
GLUT4 Antibodies that were Raised in Rabbit
Work was carried out over many months to characterise the anti-pSer10 
antibody population purified from the phospho peptide and PAN-specific 
peptide columns and to characterise the best conditions for the use of the 
antibody.
The optimal conditions for Western blotting were sought in order to enhance 
the affinity of the anti-pSer10 antibody for GLUT4 (Figure 3.11). As non-specific 
bands were being detected around the 45 kDa area of interest, attempts were 
made to increase the resolution of the gel in this area. Both 8% and 10% (w/v) 
acrylamide resolving gels were run. 8% acrylamide gels gave a better 
resolution in the area around 45 kDa and so 8% gels were used for follow up 
studies.
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Figure 3.9 ELISA analysis comparing the two antibody populations purified on a phospho peptide column followed by a 
PAN-specific peptide column. Antibodies purified on a phospho peptide column were further purified on a PAN-specific peptide 
column. The antibodies that did bind to the PAN-specific peptide column (blue line) and the antibodies that did not bind to the PAN- 
specific peptide column (black line) were subjected to ELISA analysis against plates coated with the phospho (solid line) and non- 
phospho peptides (hashed line). Titre values can be estimated by analysis of optical density readings at 450 nm over the logarithm ic 
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Figure 3.10 Western blot analysis of the two antibody populations purified from  
the PAN-specific peptide column along with the anti-C-terminal GLUT4 antibody 
raised in rabbit and the antibody purified from the second bleed serum on the 
phospho peptide column. SDS-PAGE gels were loaded with 10 pg basal LDM (1), 
insulin LDM (2), basal plasma membrane (3) and insulin plasma membrane (4) 
adipocyte fractions and then transferred for W estern blot analysis. The anti-pSer10 
second bleed antibody (a), the antibody purified on the phospho peptide column but 
did not bind to the PAN-specific peptide column (b), the PAN-specific antibody (bound 
to both the phospho peptide and PAN-specific peptide (c) and the anti-C-terminal 
GLUT4 antibody purified from rabbit serum (d) were compared by Western blot 
analysis. The arrows point to the predicted GLUT4 band.
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It was reported by Lawrence et al that incubation with milk (as a blocking 
agent) resulted in an almost complete dephosphorylation of the transporter 
(Lawrence, Jr. et al., 1990b), so various blocking conditions (in TBS-T) were 
tested to try and optimise the blotting conditions (Figure 3.11). 5% (w/v) Marvel 
(Figure 3.11 a), 3% (w/v) TopBlock [S] (Fritsche et al., 1999) (Figure 3.11 b), 
5% (w/v) BSA (Figure 3.11 d) and 1% (w/v) casein (Figure 3.11 e) were tested. 
No major difference could be detected between the different blocking 
conditions in TBS-T. A band about 45 kDa was identified with all four different 
blocking solutions, which was likely to be GLUT4 (Figure 3.11 a -  d arrows) 
based on a comparison with a Western blot using the anti-C-terminal GLUT4 
antibody (Figure 3.11 c). The strong non-specific bands did not disappear after 
blocking with any of the tested conditions. Casein did decrease the number of 
non-specific bands but unfortunately the background from the Western blot 
was very dark and so was not suitable for use (Figure 3.11 e). The other three 
conditions did not decrease the number of non-specific bands.
The length of blocking, either 1 h at room temperature or overnight at 4 °C, was 
also tested to try to improve blocking conditions. One hour blocking gave better 
results than overnight. Therefore Marvel continued to be used for 1 h as the 
blocking agent.
The presence of Tween-20 in the wash buffer was investigated (Figure 3.11 f) 
as it had previously been reported that Tween-20 could be used as a blocking 
agent in the immunological detection of proteins transferred to nitrocellulose 
membranes (Batteiger et al., 1982). However, denaturing agents such as 
detergents could reduce the binding capacity of antibodies to their antigen so, 
as the purified anti-pSer10 antibody had weak affinity for GLUT4, Tween-20 
was omitted from the wash and antibody buffers. The omission of Tween-20 
(Figure 3.11 f, lane 6) produced greater background staining on the Western 
blots and reduced the intensity of specific antibody bands. Therefore Tween-20 
was included in the washing and blocking buffers (Figure 3.11 f, lane 5).
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Different concentrations of secondary antibody were also tested (Figure 3.11 
g). Even though lower concentrations of secondary antibody gave weaker non­
specific bands (Figure 3.11 g, lanes 10, 11 and 12), the GLUT4 band was even 
weaker so the secondary antibody concentration remained at 1:4000. The non­
specific bands on the Western blot were due to the secondary antibody as the 
bands were also present when no primary antibody incubation was carried out 
(Figure 3.11 g, lanes 7, 8 and 9).
Even though the GLUT4 band was still weak and the non-specific bands were 
still detected, the optimal Western blotting conditions to be used with the rabbit 
anti-pSer10 antibody were: 5% Marvel block for 1 h at room temperature, wash 
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Figure 3.11 Optimisation of Western blotting conditions. SDS-PAGE gels were 
loaded with 10 pg basal LDM (1), insulin LDM (2), basal plasma membrane (3) and 
insulin plasma membrane (4) adipocyte fractions and then transferred for Western blot 
analysis, f) and g) are all basal LDM fractions. Different blocking conditions were 
tested, 5% (w/v) Marvel (a), 3% (w/v) TopBlock (b), 5% (w/v) BSA (d) and 1% (w/v) 
casein (e). The arrows indicate the predicted GLUT4 band after comparison with the 
anti-C-term inal GLUT4 antibody raised in rabbit (c). The requirement for the presence 
(lane 5) or absence (lane 6) of Tween-20 in the washing and blocking buffers was also 
tested (f). 1:4000 (lanes 7 and 10), 1:10000 (lanes 8 and 11) and 1:20000 (lanes 9 
and 12) dilutions of secondary antibody in 5% Marvel TBS-T were tested (g). Lanes 7, 
8 and 9 are secondary antibody incubation only and lanes 10, 11 and 12 have both 
primary and secondary antibody incubations.
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As the apparent detection of GLUT4 on the gel was weak, it was imperative to 
further check that the antibody actually recognised GLUT4. 
Immunoprecipitation was used to ensure that the antibody recognised the full 
length GLUT4 protein. Immunoprecipitation (methods 2.2.6.1) was carried out 
using both the anti-pSer10 antibody and the mouse monoclonal anti-C-terminal 
GLUT4 antibody. GLUT4 was then identified, by Western blot analysis, using 
the mouse monoclonal anti-C-terminal GLUT4 antibody or the anti-pSer10 
antibody, respectively. However, no bands were detected at about 45 kDa. 
This could be because the anti-pSer10 antibody and the mouse monoclonal 
anti-C-terminal GLUT4 antibody were both weak antibodies when compared to 
the rabbit anti-C-terminal GLUT4 antibody. The rabbit anti-C-terminal antibody 
could not be used in combination with the anti-pSer10 antibody because the 
IgG eluted following the immunoprecipitation would have been detected by 
Western blot analysis and would have masked the GLUT4 band (result not 
shown). An alternative immunoprecipitation method was carried out using the 
Seize® Primary Immunoprecipitation kit [P] in which the antibody was 
covalently bound onto an agarose gel via primary amino groups present on the 
antibody. The anti-pSer10 antibody was used to immunoprecipitate GLUT4 from 
basal LDM and the eluted protein was detected following Western blot analysis 
with the rabbit anti-C-terminal GLUT4 antibody. The anti-C-terminal GLUT4 
antibody recognised a band at about 45 kDa. This suggested that the anti- 
pSer10 antibody immunoprecipitated GLUT4 from the LDM (Figure 3.12). 
Elution was carried out successively with eight 1 ml aliquots of elution buffer 
(lanes 1-8). The majority of GLUT4 was eluted in the first fraction but the 
protein was still detected in the eighth fraction. It was reported that the beads 
could be re-used but because it was not easy to elute all of the GLUT4 it was 
not viable to reuse the beads. However, this was a good result because it gave 
the first proof that the anti-pSer10 antibody recognised and bound to the native 
GLUT4 protein.
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The remaining concern regarding the anti-pSer10 antibody was the 
identification of which band around 45 kDa on the Western blot was GLUT4, as 
there were also non-specific bands in the 45 kDa region. GLUT4 contains a 
single N-glycosylation site at asparagine 57 (Pessin and Bell, 1992) (Figure 
1.1), therefore, it was considered that it would be possible to identify the 
GLUT4 band by deglycosylating the LDM membranes with Peptide:N- 
glycosidase F (PNGase F) (Section 2.2.2.1.4). This procedure should reduce 
the apparent molecular weight of GLUT4 on a Western blot. Basal LDM 
membranes were treated with PNGase F in the presence or absence of 
phosphatase inhibitors. A no-enzyme control was also carried out. The 
membrane was subjected to SDS-PAGE and following electrophoretic transfer 
to nitrocellulose, Western blot analysis using the anti-pSer10 antibody identified 
the GLUT4 band (Figure 3.13). The GLUT4 band and the non-specific band 
ran very close to one another (51 kDa and 47 kDa) on the nitrocellulose when 
the LDM was not deglycosylated (Figure 3.13 lane 4, arrows a and b). A no­
enzyme control also gave the same result (Figure 3.13 lane 2). However, when 
the LDM had been deglycosylated, the GLUT4 band decreased in molecular 
weight and was clearly identified by the anti-pSer10 antibody as a band at 40 
kDa (Figure 3.13 lane 1, arrow c). The GLUT4 band in lane 4 was therefore 
identified as the lower, 47 kDa, band (arrow b) because the non-specific upper 
band (51 kDa) (arrow a) did not move after deglycosylation. The 
deglycosylation conditions induced dephosphorylation as when the 
deglycosylation was carried out in the presence of phosphatase inhibitors, 
(sodium fluoride, sodium molybdate and sodium orthovanadate) the GLUT4 
band detected was stronger (Figure 3.13 lane 3). This also gave strong 
evidence that the anti-pSer10 antibody was phospho-specific.
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Figure 3.12 GLUT4 was immunoprecipitated from LDM with the anti-pSer10 
antibody and detected by Western blot analysis with the rabbit anti-C-terminal 
GLUT4 antibody. Using the Seize Immunoprecipitation kit, in which IgG was retained 
in the immobilised gel matrix, the anti-pSer10 antibody was used to immunoprecipitate 
GLUT4 from  100 pg basal LDM. The precipitated GLUT4 was then detected on a 
Western blot by use of the rabbit anti-C-terminal GLUT4 antibody. The blot showed 
successive elutions from the beads using 1 ml elution buffer.
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Figure 3.13 Western blot analysis of deglycosylated LDM to identify the GLUT4 
band detected by the anti-pSer10 antibody. 20 pg basal LDM was deglycosylated 
with PNGase F. Western blot analysis with the anti-pSer10 antibody identified the 
GLUT4 band, following SDS-PAGE and electrophoretic transfer to nitrocellulose. 
Basal LDM was deglycosylated in the absence (lane 1) or presence (lane 3) of 
phosphatase inhibitors. A no enzyme control (lane 2) and untreated basal LDM (lane 
4) were also run on the gel. Arrow a indicated the non-specific band, arrow b indicated 
glycosylated GLUT4 and arrow c indicated deglycosylated GLUT4.
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3.2.1.5 Immunocvtochemistrv using Affinity Purified Anti-pSer10 GLUT4
Antibodies
The confocal microscopy studies which involved use of the rabbit anti-pSer10 
antibodies were all carried out by Dr. Frangoise Koumanov. The first study 
involved staining isolated basal and insulin-stimulated cardiomyocyte cells with 
anti-pSer10 antibodies. The staining observed with the anti-pSer10 antibody 
purified from the final bleed serum (on the phospho peptide and PAN-specific 
peptide columns) was compared to the staining observed with the anti-pSer10 
antibody purified from the second bleed serum by Darren Harper (on the 
phospho peptide column) (Figure 3.14). In each case, cardiomyocyte cells 
were dual labelled with the anti-pSer10 antibody (Figure 3.14, green staining) 
and a mouse monoclonal anti-C-terminal GLUT4 antibody (Figure 3.14, red 
staining). This gave a comparison of the distribution of the GLUT4 that was 
phosphorylated at Ser10 compared to the distribution of the total GLUT4 protein 
and identified any co-localisation between the two (Figure 3.14, yellow 
staining). In the basal state, GLUT4 (regardless of phosphorylation state) was 
distributed beneath the plasma membrane, with the majority of GLUT4 
sequestered in the peri-nuclear region of the cell. In the insulin-stimulated 
cardiomyocytes, there was a visible redistribution of GLUT4 to the plasma 
membrane. The anti-pSer10 antibody purified from the second bleed serum 
also stained an intracellular protein in basal cardiomyocytes which was 
concentrated in the peri-nuclear region of the cell. The staining partially co­
localised with the anti-C-terminal GLUT4 antibody staining. This suggested that 
the anti-pSer10 antibody purified from the second bleed serum was recognising 
a subset of GLUT4 transporters. However, the protein recognised by the anti- 
pSer10 antibody purified from the second bleed serum did not translocate to the 
plasma membrane following insulin stimulation. The protein remained in a peri­
nuclear localisation.The apparent distribution pattern of pSer10 GLUT4 
observed when using the anti-pSer10 antibody purified from the final bleed 
serum was similar to that seen with the anti-pSer10 antibody purified from the
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second bleed serum. The anti-pSer10 antibody from the final bleed serum also 
recognised a protein in the peri-nuclear region of the basal cardiomyocyte cell. 
Again, following insulin stimulation, the staining observed from use of the anti- 
pSer10 antibody purified from the final bleed serum remained concentrated in 
the peri-nuclear region of the cell. No staining occurred at the plasma 
membrane.
The anti-pSer10 antibodies, purified from the second bleed serum and the final 
bleed serum, were either recognising a peri-nuclear protein that was not 
GLUT4, or the antibodies were recognising a subset of GLUT4 in the peri­
nuclear region of the cell. If the anti-pSer10 antibodies were recognising a 
subset of GLUT4, which was not stained by the anti-C-terminal GLUT4 
antibody, then the GLUT4 phosphorylated at serine 10 might have been in a 
different conformation compared to unphosphorylated GLUT4. This could 
explain why, in insulin-stimulated cardiomyocytes, the anti-C-terminal GLUT4 
antibody did not bind to the C-terminus of GLUT4 when it was phosphorylated 
at serine 10. Perhaps GLUT4 was folded in a different orientation during 
biosynthesis. Thus, if the anti-pSer10 antibody was phospho-specific, as 
suggested by ELISA, then GLUT4 could have been phosphorylated at Ser10 
during biosynthesis and may have been dephosphorylated when it was 
correctly folded and able to transport glucose.
In the second confocal microscopy study, 3T3-L1 fibroblasts were 
differentiated into adipose like cells (Section 2.2.1). During differentiation, the 
cells started to synthesise lipogenic enzymes and became sensitive to the 
hormones involved in regulating fat metabolism (Mackall et al., 1976, Reed et 
al., 1977, Kuri-Harcuch and Green, 1977, Rubin et al., 1978). 3T3-L1 
adipocytes were fixed at different days of differentiation -  days 3, 5 and 12. 
The study started at day 3 because both GLUT4 mRNA and protein were first 
detected in the adipocytes on day 3 of differentiation and were not present in 
the fibroblast. The expression of GLUT4 mRNA increased from day 3 to day 6, 
when it then stabilised (Garcia de Herreros and Birnbaum, 1989).
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Figure 3.14 Confocal m icroscopy comparing the purified anti-pSer10 antibodies 
from the second and final bleed serums (green) with an anti-C-terminal GLUT4 
antibody (red). Confocal microscopy was carried out on basal (B) and insulin (I) 
stimulated cardiomyocytes. Any co-localisation was shown in yellow. The images were 
kindly supplied by Dr. Franpoise Koumanov.
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Confocal microscopy was carried out on the 3T3-L1 adipocytes at days 3, 5 
and 12 of differentiation using the monoclonal anti-C-terminal GLUT4 antibody 
(Figure 3.15, red staining) and the anti-pSer10 antibody purified from the final 
bleed serum (Figure 3.15, green staining). The anti-pSer10 antibody purified 
from the final bleed serum will be referred to just as the anti-pSer10 antibody in 
the remainder of this section.
On day 3 of differentiation, GLUT4 was identified in a few discreet vesicular 
structures throughout the cytoplasm, from the use of the anti-C-terminal 
GLUT4 antibody. These vesicular structures were not identified by the anti- 
pSer10 antibody but instead, a protein in the peri-nuclear region of the cell, 
located asymmetrically on one side of the nucleus, was stained. By day 5, 
GLUT4, in addition to being in discreet vesicular structures, was also 
concentrated in the peri-nuclear region of the cell. This peri-nuclear staining 
partially co-localised with the staining of the anti-pSer10 antibody. The anti- 
pSer10 antibody staining was only present in the peri-nuclear region of the cell. 
On day 12, when the cells were fully differentiated, GLUT4 was located in the 
peri-nuclear region, as well as throughout the cytoplasm. The anti-pSer10 
antibody, again, only stained a protein in the peri-nuclear region of the cell, but 
it was less intense than either day 3 or day 5. The anti-pSer10 antibody could 
have stained a small pool of GLUT4 transporters. In which case, GLUT4 
phosphorylated at serine 10 co-localised with a subset of GLUT4 transporters, 
which were stained by the anti-C-terminal GLUT4 antibody, in the peri-nuclear 
region of the cell. This subset of GLUT4 could have been GLUT4 in the 
biosynthetic pathway, as mentioned previously. Therefore, if the antibody was 
phospho-specific, GLUT4 could have been phosphorylated at serine 10 during 
biosynthesis.
Brefeldin A (BFA) is a fungal metabolite that is often used to study intracellular 
membrane trafficking. It causes the disassembly of the Golgi apparatus, 
prevents vesicles budding from the Golgi to the trans-Golgi and also causes 
the retrograde transport of Golgi proteins back to the endoplasmic reticulum
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(Fujiwara et al., 1988, Orci et al., 1991). Treating 3T3-L1 adipocytes with BFA 
will help to identify the localisation of GLUT4, whether the stained protein is in 
the Golgi or whether it is post-Golgi. 3T3-L1 adipocytes were treated with BFA 
before the cells were fixed at different days of differentiation -  days 3, 5 and 
12.
The discreet vesicular structures containing GLUT4, at day 3 of differentiation, 
did not disappear after treatment with BFA. The same was true of the vesicular 
GLUT4 structures on day 5 of differentiation. At day 5 and day 12, there was a 
sharp concentration of the peri-nuclear GLUT4 staining after BFA treatment. 
This perhaps resulted from the trans-Golgi collapsing back to the cis-Golgi. 
Thus, the GLUT4 stained by the monoclonal anti-C-terminal GLUT4 antibody 
at day 3 of differentiation was derived from a post-Golgi, BFA insensitive pool 
of GLUT4, and at day 5 the GLUT4 stained were from both BFA sensitive and 
insensitive pools of GLUT4.
At day 3 of differentiation, with no BFA treatment, the anti-pSer10 antibody 
recognised a protein in the peri-nuclear region of the cell. Following treatment 
with BFA, the peri-nuclear staining disappeared. The protein stained with the 
anti-pSer10 antibody was therefore BFA sensitive and was present in the Golgi 
apparatus. This was also true at both day 5 and day 12 of differentiation. Even 
when GLUT4 was fully differentiated, the protein stained by the anti-pSer10 
antibody was BFA sensitive. This was representative of three separate 
experiments.
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Figure 3.15 Confocal m icroscopy comparing the anti-pSer10 antibody (green) 
purified from the final bleed serum with the anti-C-terminal GLUT4 antibody  
(red) at different days of differentiation of 3T3-L1 adipocytes, with and without 
Brefeldin A treatm ent (+ BFA). Any co-localisation was shown in yellow. The images 
were kindly supplied by Dr. Frangoise Koumanov and were representative of three 
separate experiments.
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3.2.2 Generation of Antibodies Against pSer10 and the C- 
terminus of GLUT4 in Sheep
A phospho-specific population of anti-pSer10 antibodies, that recognised the 
native GLUT4 protein, had been purified from rabbit serum. However, there 
was a problem in using the antibody to detect any differences in localisation of 
the phosphorylated and non-phosphorylated forms of serine 10 in GLUT4. The 
problem was the presence of non-specific bands on Western blots that were 
recognised by the secondary antibody. Another antibody was raised to pSer10, 
but this time in sheep, to try to combat the problems encountered with use of 
the antibody raised in rabbit. The antigen design was different to the one used 
in rabbit as the phosphorylated serine 10 was in the middle of the peptide 
rather than at the end. This choice was made so hopefully more of the antibody 
epitopes would encompass the phosphorylated serine, with fewer antibodies 
being raised to the PAN-specific region (Figure 3.16 A). Sheep was the host of 
choice for raising the antibodies because the previous antibodies raised in the 
laboratory (anti-C-terminal, anti-N-terminal and anti-pSer10 antibodies) were 
raised in rabbit. It is useful to have antibodies raised in different species so that 
the antibodies can be used in combination, for example in confocal microscopy 
in which different secondary antibodies have to be used. An antibody was also 
raised in sheep to the C-terminus of GLUT4, using the same antigen as the 
anti-C-terminal GLUT4 antibody raised in rabbit (Figure 3.16 B). It was 
considered that having an antibody raised to the C-terminus of GLUT4 in 
sheep would be a useful tool when working with the anti-N-terminal and anti- 
pSer10 antibodies raised in rabbit. Two sheep were immunised with the 
phospho peptide and one sheep was injected with the C-terminal peptide 
(Section 2.2.9 gives a full explanation of the antibody generation procedure). 
Initially, three bleeds were taken per sheep and ELISA analysis was 
undertaken to ensure that a specific immune reaction had occurred to the 
injected immunogen.
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Figure 3.16 Sequences of the peptides used for the generation and purification  
of (A) anti-pSer10 antibodies and (B) anti-C-terminal GLUT4 antibodies.
3.2.2.1 A n a ly s is  o f A n tib o d ies  G en era ted  A g a in s t the  C -te rm in a l G L U T 4  
P ep tid e  in th e  D iffe ren t B leeds o f S h eep  S erum
ELISA  and W estern  blot analysis was carried out to com pare the difference 
between the different serum bleeds and to ensure that the G LU T4 serum  
recognised the native protein. ELISA analysis was carried out to test the affinity 
of the three test bleeds and the pre-im m une bleed for the C-term inal peptide 
(Figure 3 .17). An immune response had been elicited to the C-term inal peptide 
because antibodies which were not present in the pre-immune bleed were  
produced after immunisation. There was not a big difference in affinity for any 
of the serum bleeds with the C-term inal peptide.
To confirm that the anti-C-terminal G LU T4 antibody raised in sheep was 
recognising the G LU T4 protein, W estern blot analysis of rat adipocyte sub- 
cellular fractions w as carried out (Figure 3.18). This study compared the serum  
(Figure 3 .18 a) to that of the purified anti-C-term inal G LU T4 antibody raised in 
rabbit (Figure 3 .18  c). The sheep serum reacted with a protein about 45  kDa, 
which was the sam e molecular weight as the G LU T4 protein identified with the 
anti-C-term inal G L U T 4 antibody raised in rabbit. The expression of G LU T4 in
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each fraction of basal and insulin-stimulated adipocytes was recognised to the 
same extent by the serum and the anti-C-terminal GLUT4 antibody raised in 
rabbit. The level of GLUT4 in the LDM decreased after the cell was stimulated 
with insulin and a corresponding increase in the level of cell surface GLUT4 
was detected.
3.2.2.2 Immunoaffinitv Purification and Characterisation of an anti-C- 
terminal GLUT4 antibody Raised in Sheep
The ELISA analysis of the different serum bleeds (Figure 3.17) showed that 
there was not a great difference between any of the bleeds. Therefore the first 
bleed serum was affinity purified on a C-terminal peptide linked column. The 
affinity purified antibody was then tested by Western blot analysis on different 
fractions of rat adipocytes and compared to the anti-C-terminal GLUT4 
antibody raised in rabbit. The affinity purified anti-C-terminal GLUT4 antibody 
raised in sheep (Figure 3.18 b) gave a very clean blot. Only one protein was 
identified at 45 kDa. This was the same molecular weight as the protein 
identified by the anti-C-terminal GLUT4 antibody raised in rabbit (Figure 3.18 
c). The characteristic GLUT4 pattern was identified by Western blot analysis of 
basal and insulin-stimulated adipocyte cell fractions. In the basal state, GLUT4 
was sequestered in an intracellular compartment as more GLUT4 was present 
in the LDM than in the PM. Insulin stimulation resulted in a translocation of 
GLUT4 from the intracellular compartment to the plasma membrane which is 
reflected by an increase in the plasma membrane levels of GLUT4. However, 
the affinity purified anti-C-terminal GLUT4 antibody raised in sheep gave a 
weaker signal than the affinity purified anti-C-terminal GLUT4 antibody raised 
in rabbit. The sheep antibody was used at a concentration of 1.4 pg/ml 
whereas the rabbit antibody was only used at a concentration of 0.06 pg/ml.
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Figure 3.17 ELISA analysis comparing the different serum bleeds after injection 
with the C-terminal peptide. All of the serum bleeds from the sheep injected with the 
C-terminal peptide were subjected to ELISA analysis against plates coated with the C- 
terminal peptide. The pre-immune serum was used as a negative control to show that 
the sheep possessed no intrinsic immune response to the peptide antigen before 
immunisation. Titre values can be estimated by analysis of optical density readings at 
450 nm over the logarithmic dilution range of the sera.
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Immunoprecipitation was also carried out to ensure that the antibody did 
recognise the GLUT4 protein, even though the anti-C-terminal GLUT4 antibody 
raised in sheep appeared to recognise GLUT4 after Western blot analysis. 
GLUT4 was immunoprecipitated from LDM with the anti-C-terminal GLUT4 
antibody raised in rabbit and was detected by subsequent Western blot 
analysis using the anti-C-terminal GLUT4 antibody raised in sheep. The anti-C- 
terminal GLUT4 antibody raised in sheep did recognise the native GLUT4 
protein at 45 kDa, which corresponds to the molecular weight of GLUT4 
(Figure 3.18 d).
The affinity purified anti-C-terminal GLUT4 antibody raised in sheep was also 
tested by confocal microscopy on cardiomyocyte cells, but unfortunately no 
staining was detected (results not shown). Secondary antibodies labelled with 
different fluorophores (Alexa Fluor 633 and Alexa Fluor 488) were used in 
combination with the anti-C-terminal GLUT4 antibody raised in sheep to ensure 
that the secondary antibody was working. However, no staining was seen with 
either secondary antibody. This suggested that the anti-C-terminal GLUT4 
antibody affinity purified from the first bleed serum was not suitable for confocal 
microscopy. Analysis of the other two bleeds of the sheep C-terminal serum 
needs to be carried out to determine whether the antibodies purified from these 
bleeds are suitable for confocal microscopy.
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Figure 3.18 Western blot analysis testing the serum and the affinity purified anti- 
C-terminal GLUT4 antibody raised in sheep. SDS-PAGE gels were loaded with 10 
pg basal HDM (1), basal HDM (2), basal LDM (3), insulin LDM (4), basal plasma 
membrane (5), insulin plasma membrane (6), basal cytosol (7) and insulin cytosol (8) 
adipocyte fractions and then transferred to nitrocellulose for Western blot analysis. 
The first bleed C-terminal serum (a) and the affinity purified anti-C-terminal GLUT4 
antibody raised in sheep (b) were compared to the affinity purified anti-C-terminal 
GLUT4 antibody raised in rabbit (c). GLUT4 was immunoprecipitated with the anti-C- 
terminal GLUT4 antibody raised in rabbit, run on an SDS-PAGE gel, transferred to 
nitrocellulose and probed with the anti-C-terminal GLUT4 antibody raised in sheep (d).
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3.2.2.3 Analysis of Antibodies Generated Against the pSer10 GLUT4
Peptide in the Different Bleeds of Sheep Serum
The different serum bleeds from sheep injected with the phospho peptide 
(Sheep A and Sheep B) were analysed by ELISA and Western blot to check if 
an immune response had been elicited and if the serum contained phospho- 
specific antibodies. ELISA analysis compared the affinity of the three serum 
bleeds from both Sheep A and Sheep B, along with the pre-immune bleeds, to 
the phospho peptide. Antibodies had been raised to the phospho peptide in 
both Sheep A and Sheep B. The antibody population was not present in the 
pre-immune serum (Figure 3.19). Sheep B was used for the subsequent 
antibody purifications because Sheep B had a slightly higher antibody titre 
even though there was not a big difference between Sheep A (Figure 3.19 
hashed line) and Sheep B (Figure 3.19 solid line). The affinity of the serum 
bleeds for the phospho and non-phospho peptides was also tested by ELISA 
analysis (Figure 3.20). However, no difference was detected in the specificity 
of the antibody for the phospho (Figure 3.20 solid line) or non-phospho 
peptides (Figure 3.20 hashed line).
Two further boost bleeds were taken from Sheep B after injections were given 
with a slightly different peptide (Figure 3.21). The decision to carry out the 
boost bleeds came as a result of the fact that there was no difference in the 
specificity of the serum for the phospho and non-phospho peptides. It was 
hoped that the additional bleeds would boost the antibody population that had 
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Figure 3.19 ELISA analysis comparing the different serum bleeds from Sheep A 
and Sheep B. All of the serum bleeds along with the pre-immune bleeds from Sheep 
A  (hashed line) and Sheep B (solid line) were subjected to ELISA analysis against 
plates coated with the phospho peptide. Titre values can be estimated by analysis of 
optical density readings at 450 nm over the logarithm ic dilution range of the sera. The 
optical density readings were normalised to the 1:200 dilution of the 3rd bleed serum, 
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Figure 3.20 ELISA analysis comparing the different serum bleeds after injection 
with the phospho peptide - antigen 1. The serum from Sheep B was subjected to 
ELISA against plates coated with the phospho peptide (solid line) and non-phospho 
peptide (hashed line). Titre values can be estimated by analysis of optical density 
readings at 450 nm over the logarithmic dilution range of the sera.
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Figure 3.21 C om parison  o f the  sequences o f the  tw o  an tigens  used to  p roduce  
a n ti-p S e r10 a n tib o d ie s  in sheep.
The  fou rth  and fifth  b leed se rum s w e re  aga in  tes ted  by E L IS A  ana lys is  (F igu re  
3 .22). T he  se rum  w as tes ted  aga ins t an tigen  1 and an tigen  2 as w e ll as the 
u n p h o sp h o ry la te d  fo rm  o f an tigen  1. T he  a n tibod y  recogn ised  an tigen  1 m ore 
s tro n g ly  than  the  pep tide  used in the  boost in jec tion  -  an tigen  2. T h is  w ou ld  be 
b e cause  the  im m une  response  w as m ade  by the  in itia l im m un isa tion  (an tigen  
1), and  an tigen  2 w ou ld  ju s t boost a popu la tion  o f the  a lready  ex is ting  
an tibod ies . The  fac t tha t the  serum  recogn ised  both phospho  pep tides  m ore 
s tro n g ly  than  the  non -pho spho  pep tide  w as a ve ry  e ncou rag ing  s ta rt tha t led to 
fu rth e r pu rifica tion .
3.2.2.4 Immunoaffinity Purification of an Anti-pSer10 GLUT4 Antibody 
from Sheep Serum
D iffe re n t s tra te g ie s  w e re  tried  in the  purifica tion  o f a p h o sp h o -sp e c ific  
popu la tio n  o f an tibod ies  and these  w ill be de ta iled  be low . The  pu rifica tion  o f 
the  a n tib o d y  d id  not invo lve  use o f the  sam e s tra tegy  as tha t used fo r the  an ti- 
p S e r10 a n tib o d y  ra ised in rabbit.
Im m u n o a ffin ity  pu rifica tion  o f a n tibod y  from  the  fifth  b leed serum  w as  carried  
ou t us ing  an tigen  1 bound to the  Su lfoL ink®  co lum n. The  purified  an tibod y  w as 
aga in  tes te d  by E LIS A  and W este rn  b lo tting  techn iqu es . The  E L IS A  ana lys is  
gave  a s im ila r resu lt to tha t ob ta ined  w ith  the  fifth  b leed se rum  (resu lt not
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shown). The antibody had a greater specificity for antigen 1 than antigen 2, 
with the unphosphorylated form of antigen 1 recognised the least. Non- 
phospho-specific antibodies were still present as an antibody population still 
bound to the non-phospho peptide in an antibody concentration dependent 
manner. Western blot analysis of the antibody affinity purified from the fifth 
bleed serum (Figure 3.23) gave a similar result to the anti-C-terminal GLUT4 
antibody. The level of GLUT4 in the LDM decreased after insulin stimulation 
and increased in the plasma membrane. Further purification of the antibody 
was needed due to the presence of a non-phospho-specific antibody 
population.
Cross purification was carried out on the third bleed serum from Sheep B to 
determine whether the non-phospho-specific antibodies could be removed. 
The cross purification method was previously described in section 3.2.1.2. 
Cross purification was carried out using the phospho peptide (antigen 1) and 
non-phospho peptide linked columns. Cross purification did not purify a good 
population of phospho-specific antibodies (result not shown).
Cross purification, in which a fixed amount of non-phospho peptide was bound 
to a solid support, appeared to have poor utility for purification of a phospho- 
specific population of antibodies. Therefore a different method of purifying the 
antibody was needed. The cross purification procedure required the use of a 
large molar excess of non-phospho peptide over specific antibody. Therefore, it 
was tested whether a lower concentration of free non-phospho peptide could 
be used to block the non-phospho-specific antibody in the serum, without 
affecting the subsequent purification of the phospho-specific antibody 
population (Berwick et al., 2004).
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Figure 3.22 ELISA analysis comparing the specificity of the fifth bleed serum for 
antigen 1 (black solid line), antigen 2 (red solid line) and the non- 
phosphorylated form of antigen 1 (black hashed line). Titre values can be 
estimated by analysis of optical density readings at 450 nm over the logarithmic 
dilution range of the sera.
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Figure 3.23 W estern blot analysis of the antibody affinity purified on antigen 1 
from the fifth bleed serum. SDS-PAGE gels were loaded with 10 pg basal LDM (1), 
insulin LDM (2), basal plasma membrane (3) and insulin plasma membrane (4) 
adipocyte fractions and then transferred to nitrocellulose for W estern blot analysis with 
the fifth bleed serum.
147
The serum was incubated overnight, rotating at 4 °C, with a one, two, or tenfold 
molar excess of non-phospho peptide over specific antibody (it was estimated 
that there was 4 mg of specific IgG per ml of sheep serum [MPB]). As a 
control, an incubation was set up without peptide. The specificity of the pre­
blocked serum for the phospho and non-phospho peptides was tested by 
ELISA analysis (Figure 3.24). In all of the conditions tested (Figure 3.24 A, B, 
C and D), the serum had greater specificity for the phospho peptide than the 
non-phospho peptide. The serum that had been pre-incubated with a one, two 
or tenfold molar excess of non-phospho peptide (Figure 3.24 A, B and C 
respectively), had an increased specificity for the phospho peptide than the 
serum alone (Figure 3.24 D) (the difference between the phospho and non- 
phospho peptide lines was greater for the pre-blocked serum than the serum 
alone). However, no differentiation could be made between the different 
concentrations of non-phospho peptide used in the pre-incubation of the serum 
(Figure 3.24 A, B and C). A population of non-phospho-specific antibodies was 
still present in the serum, even after the serum had been pre-blocked with the 
non-phospho peptide, because a signal was detected after ELISA analysis on 
the non-phospho peptide. The serum needs to be pre-blocked with more than 
a tenfold molar excess of non-phospho peptide to remove the entire non- 
phospho-specific population of antibodies.
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Figure 3.24 ELISA analysis comparing the serum that had been pre-blocked with a one, two or tenfold molar excess of non- 
phospho peptide with the serum that had not been pre-blocked. The serum from the fifth bleed of Sheep B was pre-blocked with 
a one (A), two (B) and tenfold (C) molar excess of non-phospho peptide before the serum was subjected to ELISA analysis on a 
phospho peptide (black line) and non-phospho peptide (red line) coated plate. As a control, an incubation was also set up with no 
non-phospho peptide (D). Titre values can be estimated by analysis of optical density readings at 450 nm over the logarithmic 
dilution range of the sera.
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It was necessary to find the optimal ELISA conditions to ensure that the 
maximum signal had been achieved between the antibody and the phospho 
and non-phospho peptides.
The ELISA conditions tested involved changes in the peptide coating buffer 
and the blocking conditions. The peptides were bound to the plate in either the 
carbonate / bicarbonate buffer (as described in methods Section 2.2.9.5) or in 
TBS (Coghlan et al., 1994). When TBS was used to coat the plate, no 
difference in signal was detected between the phospho or non-phospho 
peptide. This experiment showed that TBS was not a suitable medium for 
binding these peptides and that the original coating buffer, the carbonate / 
bicarbonate buffer, was better. The different blocking buffers tested were 1% 
(w/v) casein (as described in methods Section 2.2.9.5) and 1% (w/v) BSA. No 
difference between the two blocking conditions was detected (results not 
shown). So for further ELISA plate assays the coating buffer used was the 
carbonate / bicarbonate buffer and the blocking buffer used was 1% (w/v) BSA.
A competition ELISA was carried out to test whether the antibody could 
discriminate between the phospho and non-phospho peptides (Coghlan et al., 
1994, Coba et al., 2003). The fifth bleed serum from Sheep B was pre-bound, 
overnight, with different concentrations of different peptides; phospho peptide 
(antigen 1), non-phospho peptide and a non-specific peptide (the C-terminal 
peptide). An ELISA was carried out on a 96 well plate coated with the phospho 
peptide. The results were plotted as the percentage of antibody bound to the 
plate, with 100% being the level of no peptide pre-incubation (Figure 3.25).
The serum contained a population of phospho-specific antibodies. Two pieces 
of evidence led to this conclusion; (1) the amount of antibody that bound to the 
plate, after the serum was pre-bound to the phospho peptide, decreased in a 
peptide concentration dependent manner (Figure 3.25 blue line). (2) When the 
serum was incubated with the same concentration of the non-phospho peptide 
compared to the phospho peptide, more antibody bound to the phospho 
peptide coated plate when the serum was pre-blocked with the non-phospho
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peptide (this population of phospho-specific antibodies did not bind to the non- 
phospho peptide) (Figure 3.25 red line). The decrease in signal, with 
increasing concentrations of blocking peptide, was due to the specificity of the 
antibody towards the specific sequence of the peptides. There was no loss in 
the amount of antibody binding to the plate when the serum was incubated with 
a non-specific peptide (Figure 3.25 black line).
From the ELISA analysis, it was possible to find the optimal concentration of 
peptide necessary to block the non-phospho-specific antibody population that 
was present in the serum. Previously, a tenfold molar excess of peptide over 
antibody was used and this corresponded to a peptide concentration of 2 x 10'6 
M (Figure 3.25). For maximal removal of the non-phospho-specific antibody, 
without removing any phospho-specific antibody, a blocking peptide 
concentration of about 1 x 10'5 M was needed (this was the maximum 
difference between the phospho and non-phospho peptide lines). This was 
calculated as a fiftyfold molar excess of peptide.
The serum was incubated with a fiftyfold molar excess of non-phospho peptide. 
ELISA analysis assessed the affinity of the pre-blocked serum for the phospho 
and non-phospho peptides coated on a 96 well plate. A comparison was made 
with the affinity of the unblocked serum for each peptide (Figure 3.26). The 
affinity of the pre-blocked serum (Figure 3.26 black line) for the non-phospho 
peptide (Figure 3.26 hashed line) had decreased in comparison with the 
unblocked serum (Figure 3.26 red hashed line). A population of non-phospho- 
specific antibodies had therefore been removed from the serum following pre­
incubation with the non-phospho peptide. A small population of antibodies that 
had bound to the phospho peptide was also removed in the pre-incubation 
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The pre-blocked antibody population was analysed by using a competition 
ELISA on a phospho peptide coated 96 well plate (Figure 3.27). Before the 
ELISA, the pre-blocked serum was incubated with the three peptides (the 
phospho, the non-phospho and the non-specific peptides) at the 
concentrations previously used. The competition ELISA provided further 
evidence that the pre-blocked serum contained a population of phospho- 
specific antibodies. The affinity of the phospho-specific antibody population to 
the plate was not affected by incubation with low concentrations of the non- 
phospho peptide (Figure 3.27 red line). The level of antibody that bound to the 
plate was similar to that observed with the non-specific peptide. Thus, the non- 
phospho peptide was acting like a non-specific peptide at low concentrations 
and did not affect the amount of phospho-specific antibody that bound to the 
plate. It was only higher concentrations of non-phospho peptide that prevented 
the antibody binding to the plate. The pre-blocked serum incubated with the 
phospho peptide, bound to the plate in a concentration dependent manner i.e. 
the level of phospho-specific antibody binding to the plate decreased as the 
concentration of blocking peptide increased (Figure 3.27 blue line). Pre­
incubation of the serum with the phospho peptide at concentrations of 5 x 10'6 
M or greater caused the peptide to bind to the entire population of phospho- 
specific antibody. This was evident because the level of antibody binding to the 
plate started to plateau at a peptide concentration of 5 x 10"6 M. Any antibody 
binding at higher concentrations of peptide was a background level of binding. 
The effect of incubating the phospho and non-phospho peptides with the pre­
blocked serum was specific because the level of antibody binding to the plate 
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Figure 3.26 ELISA analysis comparing pre-blocking the serum with a fiftyfold 
m olar excess of non-phospho peptide (black line) with no pre-blocking (red 
line). The ELISA was carried out on a phospho peptide (solid line) and a non-phospho 
peptide coated plate (hashed line). Titre values can be estimated by analysis of optical 
density readings at 450 nm over the logarithm ic dilution range of the sera.
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Figure 3.27 Analysis of a competition ELISA in which serum pre-blocked with a 
fiftyfold molar excess of non-phospho peptide, was incubated with different 
am ounts of phospho (blue line), non-phospho (red line) and non-specific 
peptides (black line) before an ELISA was carried out on a phospho peptide 
coated plate. The results were displayed as optical density readings at 450 nm 
versus the log10 the concentration of blocking peptide used for the ELISA analysis.
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Pre-blocking the serum with a fiftyfold molar excess of non-phospho peptide 
produced a population of phospho-specific antibodies. Affinity purification of 
the pre-blocked serum was carried out on a phospho peptide column to 
remove any contaminating serum proteins. This affinity-purified antibody was 
analysed by ELISA (Figure 3.38) and Western blot (Figure 3.29). ELISA 
analysis compared the antibody that did bind to the phospho peptide column to 
the antibody that did not bind to the column. A highly phospho-specific 
antibody population had been purified from the pre-blocked serum (Figure 3.29 
A). The antibody had a strong affinity for the phospho peptide (Figure 3.29 A, 
black line) and had very little affinity for the non-phospho peptide (Figure 3.29 
A, red line). A population of phospho-specific antibodies was detected in the 
flow through from the phospho peptide column (Figure 3.29 B). This population 
was not purified from the serum (Figure 3.29 B black line). Non-phospho- 
specific antibodies had been separated from the purified phospho-specific 
antibody population (Figure 3.29 B red line). Even though there was a 
phospho-specific antibody population present in the flow through, the purified 
antibody contained a highly specific population of phospho antibodies raised to 
serine 10.
The ability of the purified antibody to detect the phosphorylated GLUT4 protein 
was tested using Western blot analysis (Figure 3.29 c). A comparison was 
made with the affinity-purified antibody from the fifth bleed serum, which had 
not been pre-blocked with the non-phospho peptide (Figure 3.29 b). 
Quantification of the intensity of the bands identified by both antibodies was 
carried out (Figure 3.29 d). Western blot analysis was also carried out using 
the anti-C-terminal GLUT4 antibody, raised in rabbit, to quantify the total 
GLUT4 independent of the phosphorylation state (Figure 3.29 a). Both of the 
phospho-specific antibodies were used at the same concentration (2 pg/ml). All 
three antibodies recognised a protein at 45 kDa (Figure 3.29 arrows). 
Stimulating adipocytes with insulin led to a decrease in the level of intracellular 
GLUT4 and a corresponding increase in the level of cell surface GLUT4.
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Figure 3.28 ELISA analysis of the antibodies purified from the phospho peptide  
column after the serum had been pre-blocked with a fiftyfold molar excess of 
non-phospho peptide. The phospho-specific antibody population purified from  the 
phospho peptide column (A) and the population that did not bind to the phospho 
peptide column (B) were subjected to ELISA analysis against plates coated with the 
phospho (black line) and non-phospho peptides (red line). Titre values can be 
estimated by analysis of optical density readings at 450 nm over the logarithm ic 
dilution range of the antibody.
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However, the quantification of the level of GLUT4 in each cellular fraction did 
differ. Insulin caused a decrease in the level of phosphorylation at Ser10 in 
GLUT4 in the LDM fraction (Figure 3.29 b and c). This decrease was larger 
than that observed for the total GLUT4 protein (a), i.e. the decrease could have 
been due to dephosphorylation and not just due to the translocation of the 
transporter out of the LDM compartment. Only a fraction of total GLUT4 was 
phosphorylated at Ser10 at the plasma membrane in the basal state (the 
intensity of the signal at the plasma membrane was less than the signal from 
the C-terminal antibody). A very weak signal was detected by the Western blot 
with the pre-blocked serum even though the same concentrations of anti- 
pSer10 antibodies were used. This could have been because the population of 
GLUT4 phosphorylated at Ser10 was very small in adipocytes and so the signal 
intensity detected on the Western blot from the affinity purified pre-blocked 
serum was weak. Even though the anti-pSer10 antibody purified from 
unblocked serum was used at the same concentration as the pre-blocked 
serum, the antibody population still contained epitopes to unphosphorylated 
GLUT4. The presence of the unphosphorylated epitopes would result in an 
increased signal from binding to unphosphorylated GLUT4. The quantification 
of the Western blot with the pre-blocked serum may not be accurate due to the 
weakness of signal. The antibody needs to be tested further using a higher 
concentration of adipocyte sub-fractions run on an SDS-PAGE gel and a 
higher primary antibody concentration used in the Western blot. If the 
phosphorylation of GLUT4 was limited to a small subset of transporters, then 
running more protein on the gel would result in a stronger signal.
The antibody was also tested by confocal microscopy on basal and insulin- 
stimulated cardiomyocytes. Unfortunately, neither of the affinity purified anti- 
pSer10 antibodies raised in sheep (either pre-blocked or not pre-blocked) 
stained the cardiomyocytes. This may be due to problems with the secondary 
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A 100.0 69.2 42 .8 79.3
B 100.00 24 .56 7.22 22 .79
C 100.00 40.21 22 .94 56 .33
Figure 3.29 Western blot analysis comparing total GLUT4 (a), the anti-pSer10 
antibody purified on the phospho peptide column (b) and the anti-pSer10 
antibody pre-blocked with a fiftyfold molar excess of non-phospho peptide 
before purification on the phospho peptide column (c). SDS-PAGE gels were 
loaded with 10 pg basal HDM (1), insulin HDM (2), basal LDM (3), insulin LDM (4), 
basal plasma membrane (5), insulin plasma membrane (6), basal cytosol (7) and 
insulin cytosol (8) adipocyte fractions and then transferred to nitrocellulose for 
Western blot analysis. The arrows indicated the GLUT4 band. Quantification of the 
Western blot showed the amount of GLUT4 in the relevant fractions compared to 
basal LDM set to 100% (d) (PM = plasma membrane, B = basal, I = insulin).
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3.3 Discussion
A polyclonal anti-pSer10 antibody has been raised in two different species of 
animal (rabbit and sheep). The antibody in rabbit had been raised by a 
previous member of the laboratory. The two antibodies have been purified and 
characterisation has been carried out in order to investigate whether the 
antibodies are specific for the phosphorylated serine 10 residue.
Due to the design of the original antigen used in rabbit (IGSPEDGEPPQQ), 
there is a large proportion of peptide sequence to which ‘PAN-specific’ 
antibodies will be raised. In addition, the acidic region downstream of serine 10 
and the two proline residues in the peptide (which will cause a kink in this area 
of the peptide), may cause this ‘PAN’ region of the peptide to become highly 
immunogenic. This fact led to the purification strategy in which a PAN-specific 
peptide (GEPPQQ) was used to remove the PAN-specific antibodies from the 
serum. A population of phospho-specific antibodies has been purified from the 
final bleed serum (Figure 3.9). This phospho-specific antibody did bind to the 
native GLUT4 protein because it was able to immunoprecipitate GLUT4 from 
LDM (Figure 3.12). However, the antibody is, at present, unsuitable for use on 
Western blot. The GLUT4 band is difficult to identify due to the presence of 
non-specific bands in the 45 kDa area on the nitrocellulose (Figure 3.10). The 
pSer10 GLUT4 band is weak and not detected at 45 kDa when ECL [A] was 
used to develop the Western blot. ECL Advance [A] (a highly sensitive 
chemiluminescent detection agent) is required for a signal to be detected on 
the Western blot. However, the ECL advance will not only increase the 
intensity of the GLUT4 band, it will also increase the intensity of the stronger, 
non-GLUT4 bands that are detected on the nitrocellulose. There are two 
possible explanations for the weak GLUT4 signal. The phosphorylation of 
GLUT4 at serine 10 may only occur in a small subset of transporters, or the 
antibody is a poor antibody and so it does not recognise the phosphorylated 
GLUT4 population with a high intensity. The non-specific bands that are
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detected on the Western blot are due to the secondary antibody (Figure 3.11 
g). Before the anti-pSer10 antibody can be used for Western blot analysis, 
different rabbit IgG secondary antibodies need to be tested. The secondary 
antibody used had only been adsorbed against human protein. A secondary 
antibody adsorbed against rat proteins would hopefully detect fewer non­
specific bands on the Western blot.
In confocal microscopy studies, the anti-pSer10 antibody purified from rabbit 
serum recognises a protein in cardiomyocytes and 3T3-L1 adipocytes. The 
anti-pSer10 antibody recognises a peri-nuclear protein in both basal and insulin- 
stimulated cardiomyocytes. The staining does not co-localise with the anti-C- 
terminal GLUT4 antibody staining in insulin-stimulated cardiomyocytes and 
only partially co-localises in basal cardiomyocytes. The anti-pSer10 antibody 
may be either binding to a peri-nuclear protein that is not GLUT4 or the 
antibody is recognising a subset of GLUT4 that is concentrated in the peri­
nuclear region of the cell. If the anti-pSer10 antibody is recognising 
phosphorylated GLUT4, then the GLUT4 phosphorylated at serine 10 is in a 
different conformation to unphosphorylated GLUT4 and so the anti-C-terminal 
GLUT4 antibody could not bind to the C-terminus. This may occur during 
biosynthesis. The anti-pSer10 antibody also recognises a protein in the peri­
nuclear region of 3T3-L1 adipocytes which is Brefeldin A (BFA) sensitive at day 
3, 5 and 12 of differentiation. The expression of GLUT4 in differentiating 3T3- 
L1 adipocytes has previously been reported (Garcia de Herreros and 
Birnbaum, 1989). On day 3 after differentiation, GLUT4 was mainly peri­
nuclear and was located asymmetrically on one side of the nucleus. The 
GLUT4 protein was also observed in vesicles throughout the cytoplasm. The 
same distribution of GLUT4 was also seen on day 5. In the present study, the 
anti-C-terminal GLUT4 antibody did not stain a peri-nuclear protein at day 3 of 
differentiation. This difference could occur because the GLUT4 antibodies used 
in the present study and by Garcia de Herreos and Birnbaum may be raised to 
a different peptide sequence. Perhaps the C-terminus of GLUT4 is in an
160
orientation that is not accessible to the anti-C-terminal GLUT4 antibody at day 
3 of differentiation and so the anti-C-terminal GLUT4 antibody cannot bind to 
the C-terminus of GLUT4. However, if the anti-pSer10 antibody is binding 
GLUT4, the N-terminus is in an accessible orientation for the anti-pSer10 
antibody. This difference in protein fold may occur during biosynthesis and the 
anti-C-terminal GLUT4 antibody may only recognise the GLUT4 protein at a 
later stage of synthesis than the anti-pSer10 antibody. The anti-C-terminal 
GLUT4 antibody could recognise a small proportion of GLUT4 vesicles that 
had left the biosynthetic pathway at day 3. By day 5, more of the native protein 
has gone through the synthetic pathway and would now be in an orientation so 
that the anti-C-terminal GLUT4 antibody could detect the GLUT4 protein. 
Phosphorylation of GLUT4 at serine 10 may therefore occur during 
biosynthesis so that no staining is seen at serine 10 once the protein has left 
the biosynthetic pathway. This is further corroborated because by day 12, the 
intensity and number of pSer10 positive cells is less than at day 3 or 5. At day 
12, the cells are fully differentiated so there is less GLUT4 in the biosynthetic 
pathway. It has previously been reported that there are both BFA sensitive and 
insensitive pools of GLUT4 and that the insulin sensitive pool of GLUT4 is BFA 
insensitive (Bao et al., 1995). Both BFA sensitive and insensitive pools of 
GLUT4 are stained by the anti-C-terminal GLUT4 antibody. However, only a 
protein in the BFA sensitive pool is stained by the anti-pSer10 antibody. There 
is no definitive proof that the anti-pSer10 antibody is recognising the GLUT4 
protein in the confocal images and it could be recognising a different peri­
nuclear localised protein. If the anti-pSer10 antibody did detect GLUT4 in the 
biosynthetic pathway, then the GLUT4 would be present in the Golgi and it 
would be BFA sensitive. The protein stained with the anti-pSer10 antibody 
needs to be identified before the antibody can be used to investigate the 
localisation of GLUT4 phosphorylated at serine 10. The cells could also be 
treated with kinase inhibitors and the effect of the inhibitors on the level of 
phosphorylation could be investigated. The protein stained with the anti-pSer10 
antibody could perhaps be identified by RNA interference (RNAi). RNAi is a
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mechanism whereby double stranded RNA specifically suppresses the 
expression of the targeted gene. If the peri-nuclear staining in the cell is 
GLUT4, then suppressing the GLUT4 gene would abolish any staining 
observed from the anti-pSer10 antibody.
An anti-C-terminal GLUT4 antibody has successfully been raised in sheep. 
This could be used in experiments involving Western blot and 
immunoprecipitation techniques, with the anti-pSer10 antibody raised in rabbit, 
to aid the study of GLUT4 phosphorylation. However, the antibody would not 
be suitable for use in confocal microscopy studies without future work.
The anti-pSer10 antibody raised in sheep has been successfully purified on a 
phospho peptide column. However, the serum has to be pre-blocked with a 
fiftyfold molar excess of non-phospho peptide over specific antibody before a 
phospho-specific antibody population could be purified. This strategy has been 
successful because the non-phospho-specific antibody bound to the peptide 
and so did not bind to the phospho peptide column in the purification 
technique. However, not all of the phospho-specific antibody has been purified 
from the serum. Nevertheless, a highly phospho-specific population of 
antibodies has been purified from the sheep serum (Figure 3.28). Further 
characterisation of the antibody purified from sheep serum is also needed to 
ensure that the antibody recognises the native GLUT4 protein. This can be 
done by testing the ability of the antibody to immunoprecipitate GLUT4 or to 
recognise GLUT4 that has been immunoprecipitated using the anti-C-terminal 
GLUT4 antibody raised in rabbit.
Both of the anti-pSer10 antibodies raised are phospho-specific as analysed by 
ELISA. The antibodies also bind to a 45 kDa band identified by Western blot 
analysis but the band is weak. This is likely to be because the population of 
GLUT4 phosphorylated at Ser10 is very small. However, due to the weak band, 
at present the antibodies are not suitable for use in Western blot analysis.
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Further characterisation is needed using a large amount of protein in the SDS- 
PAGE and using a higher primary antibody concentration to detect the bands 
on Western blot. Due to the high level of non-specific bands detected on the 
Western blot by the anti-pSer10 antibody raised in rabbit, the anti-pSer10 
antibody purified from the pre-blocked sheep serum is likely to be the most 
useful antibody to use in future. However, if future studies are going to involve 
confocal microscopy, the anti-pSer10 antibody purified from rabbit serum would 
be the antibody of choice, if the antibody does detect the GLUT4 protein. The 
anti-pSer10 antibody raised in sheep is not suitable for confocal microscopy.
As both pSer10 antibodies give a good signal in ELISA analysis, an ELISA plate 
assay could be developed to investigate the phosphorylation state of GLUT4. 
Many photoaffinity labelling reagents have been used for studying glucose 
transporters (Holman et al., 1990, Yang and Holman, 1993, Araki et al., 1996). 
The GLUT4 protein can be photolabelled because the photolabel has a 
glucose moiety, which will covalently bind to the GLUT4 protein after UV 
irradiation. There is a biotin moiety on the other end of the photolabel. The 
GLUT4 can then be separated and bound to a streptavidin coated 96 well 
plate. An assay can then be carried out in which the anti-pSer10 antibody 
detects differences in the phosphorylation state of GLUT4 under different 
conditions.
The antibody could also be used to carry out an in vitro kinase assay on a 
peptide corresponding to the N-terminus of GLUT4. The serine 10 kinase could 
then be identified using fluorescence resonance energy transfer (FRET). FRET 
occurs when the fluorescence spectra of two fluorescent tags overlap. 
Specifically, the emission spectrum of the donor molecule overlaps the 
excitation spectrum of the acceptor. The donor and acceptor molecules must 
be in close proximity, typically 10 - 100 A. Cy3 and Cy5 [A] are two such 
molecules with overlapping spectra. A peptide corresponding to the N-terminus 
of GLUT4 can be labelled with Cy3 [A] and the anti-pSer10 antibody can be
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labelled with Cy5 [A]. If the Cy3 and Cy5 molecules are in close proximity, i.e. 
when the antibody binds to the phosphorylated peptide, an enhanced 
fluorescent signal will be detected. A kinase could therefore be identified if it 
had phosphorylated the N-terminal peptide. A whole cell lysate or different 
cellular fractions could be used to identify in which fractions the kinase is 
located. The use of recombinant protein kinases and known kinase inhibitors in 
this assay system could also be used to identify the GLUT4 N-terminal kinase.
3.4 Conclusion
Two different anti-pSer10 antibodies have been raised and will be useful in 
investigating the phosphorylation state of GLUT4 at serine 10 in combination 
with the anti-C-terminal GLUT4 antibodies that have been raised in rabbit and 
sheep. However, further characterisation of both antibodies is needed before 
they can be used in further experiments. The anti-pSer10 antibody raised in 
sheep was used to identify the GLUT4 N-terminal peptide in the 
phosphorylation experiments discussed in chapter 4.
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4 An Investigation into the Phosphorylation State at 
the N- and C- termini of GLUT4
4.1 Introduction
The many years of investigating insulin signalling have led to the conclusion 
that phosphorylation is a key event in the insulin-signalling cascade which 
ultimately leads to the translocation of GLUT4 to the plasma membrane 
(Section 1.3). The phosphorylation level of many adipose cell proteins 
increases due to the effect of insulin (Belsham et al., 1980, Avruch et al., 
1982). The first studies investigating GLUT1 phosphorylation concluded that 
there was no phosphorylation in response to insulin or isoproterenol in either 
primary adipocytes or 3T3-L1 adipocytes (Gibbs et al., 1986, Joost et al., 
1987). However, GLUT4 contains several potential phosphorylation sites 
(James et al., 1989a). GLUT4 has a 65% identity to GLUT1 and the 
transmembrane regions are the most highly conserved between the two 
proteins. Phosphorylation of GLUT4 is, therefore, likely to occur in the regions 
that are not conserved between the two proteins, these are at the N- and C- 
termini as well as the large intracellular loop between helices 6 and 7 (Figure
4.1).
Previous studies investigating the phosphorylation status of GLUT4 involved ‘in 
vitro’ phosphorylation experiments in which rat adipocyte preparations were 
pre-incubated with a source of [32PJ. The results of these experiments 
concluded that GLUT4 was phosphorylated in rat adipocytes (Joost et al., 
1987, James et al., 1989a, Lawrence, Jr. et al., 1990a, Schurmann et al., 
1992). It was reported that there was a basal labelling of at least 0.2 mole of 
phosphate per mole of GLUT4. The relative level of phosphorylation did not 
change after insulin stimulation at either the LDM or plasma membrane (James 
et al., 1989a). However, the authors did point out that a small subset of 
transporters could be phosphorylated at the plasma membrane in response to
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insulin but could not be detected due to the low number of transporters at the 
plasma membrane in unstimulated cells. In addition, phosphorylation of GLUT4 
was observed in response to isoproterenol after the cells had been stimulated 
by insulin. Isoproterenol stimulated a twofold increase in the level of GLUT4 
phosphorylation compared to the basal level of GLUT4 phosphorylation 
(James etal., 1989a).
In addition to insulin-stimulated glucose transport, glucose transport is also 
stimulated by lipolytic agents, i.e. agents that modulate adenyl cyclase and 
lipolysis (Taylor et al., 1976, Kashiwagi et al., 1983). However, lipolytic agents 
(e.g. isoproterenol) inhibit insulin-stimulated glucose transport in the absence 
of antilipolytic agents (e.g. adenosine) in both muscle and adipose tissue 
(Kashiwagi et al., 1983, Smith et al., 1984, James et al., 1986, Kuroda et al., 
1987). Insulin-stimulated glucose transport was inhibited 40% by the presence 
of isoproterenol (James et al., 1989a). In addition, the inhibition was not 
mediated by a change in the localisation of the transporter but was a result of a 
change in the intrinsic activity of the transporter (Smith et al., 1984, Kuroda et 
al., 1987).
Adenyl cyclase catalyses the conversion of ATP to cAMP, so lipolytic agents 
mediate cAMP synthesis as well as stimulating glucose transport. It was shown 
that the cAMP derivatives 8-bromo-cAMP and dibutyryl-cAMP produced the 
same increased level of phosphorylation of GLUT4 as seen with isoproterenol 
(James et al., 1989a). Protein kinase A (PKA) modulates many of the actions 
of intracellular cAMP and it was therefore considered that GLUT4 could be a 
substrate for PKA. In fact, PKA did phosphorylate GLUT4 vesicles in vitro 
(James et al., 1989a, Lawrence, Jr. et al., 1990a, Nishimura et al., 1991, 
Schurmann et al., 1992).
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GLUT4 RRflSYEhLILH?FLIGHYSGLTSGLVPMYVGEIRPTHLRGRLGTLNQLRIVIGILIfiQVLGLESLLGTflSLMPLLLGLTVLPRLLQLVLLPFCPESPRYLYIIQMLEGPflRKSLKRLTGMROVSGVLREL 
GLUT1 LGKSFEMLILGRFIIGVYCGLTTGFVPtfYVGEVSPTRFRGRLGTLHQLGIWGILIRQVFGLDSIMGNKDLMPLLLSIIFIPflLLQCIVLPFCPESPRFLLINRNEENRflKSVLKKLRGTRDVTHDLQEh
2 G 1  2 7 0  2 8 0  2 9 0  3 0 0  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0  3 6 0  3 7 0  3 8 0  3 9 0
GLUT4 KDEKRKLERERPLSLLQLLGSRTHRQPLIinVVLQLSUQLSGIMflVFYYSTSIFETRGVGQPflYflTIGRGWNTVFTLVSVLLVERRGRRTLHLLGLRGMCGCRILMTVRLLLLERVPfltlSYVSIVfllFG 
GLUT1 KEESRQMMREKKVTILELFRSPRYRQPILIRVVLQLSQQLSGINRVFYYSTSIFEKRGVQQPVYfiTIGSGIVNTflFTVVSLFVVERflGRRTLHLIGLRGHflGCRILMTIRLRLLEQLPMMSYLSIVRIFG
3 9 1  4 0 0  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0  4 6 0  4 7 0  4 8 0  4 9 0  5 0 0  5 0 9
GLUT4 FVRFFEIGPGPIPMFIVRELFSqGPRPHRHRVflGFSNMTSNFIIGMGFQYVREflMGPYVFLLFfiVLLLGFFIFTFLRVPETRGRTFDQISflflFHRTPSLLEQEVKPSTELEYLGPDEND 
GLUT1 FVRFFEVGPGPIPMFIVflELFSQGPRPRRIHVRGFSNMTSHFIVGHCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIflSGF-RQGGRSQSDKTPEELFHPLGRDSQV
Figure 4.1 Alignm ent of the GLUT4 and GLUT1 transporter proteins. There is a 65% sequence identity between the two glucose 
transporters -  GLUT1 and GLUT4. The N- and C- termini along with the large intracellular loop between helices 6 and 7 have the 
least homology. The residues in red are identical in GLUT4 and GLUT1, whereas the residues in blue differ between the two 
proteins. -  indicates where there are additional amino acids in the other protein. The alignment was carried out using Multalin 
(Corpet, 1988).
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It has been suggested that the inhibition of insulin-stimulated glucose transport, 
by isoproterenol, was mediated by the phosphorylation of GLUT4 (James et 
al., 1989a). However, alternative studies have given a different interpretation. It 
was reported that there was not a link between the isoproterenol stimulation of 
PKA and inhibition of insulin-stimulated glucose transport. This suggested that 
changes in GLUT4 phosphorylation, by PKA, were not responsible for the 
inhibition of insulin-stimulated glucose transport (Kuroda et al., 1987). 
Isoproterenol also inhibited the insulin-stimulated transport of glucose through 
the GLUT1 transporter (Joost et al., 1987). However, the fact that GLUT1 was 
not phosphorylated by insulin, adenosine or isoproterenol, suggested that there 
was not a direct link between the inhibition of insulin-stimulated glucose 
transport and the isoproterenol stimulation of PKA.
Nishimura et al attempted to address whether the inhibition of glucose 
transport, by isoproterenol, was mediated by the phosphorylation of GLUT4. 
The study confirmed that GLUT4 was phosphorylated and isoproterenol 
stimulated a 40% increase in the level of phosphorylation in intracellular 
membranes. This increased level of phosphorylation occurred both in the 
absence and presence of adenosine receptor activation. In contrast, the 
inhibition of glucose transport, by isoproterenol, only occurred without 
adenosine receptor activation (Nishimura et al., 1991). This suggested that the 
phosphorylation of GLUT4, in response to isoproterenol, did not mediate the 
inhibition of insulin-stimulated glucose transport. The phosphorylation must 
have an, as yet, unidentified role. This was further corroborated in a study by 
Schurmann et al. They showed that phosphorylation of GLUT4, by PKA, 
produced a much smaller population of phosphorylated GLUT4 at the plasma 
membrane compared to intracellular membranes. The phosphorylation did not 
affect the rate of glucose transport (Schurmann et al., 1992). A final study 
using chimeras of GLUT4 and GLUT1 attempted to identify the region of 
GLUT4 that was involved in the inhibition of insulin-stimulated glucose 
transport as seen by the cAMP derivative dibutyryl cAMP. It found that the
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inhibitory effect was modulated by the binding of the nucleotide to the C- 
terminus of GLUT4 and was distinct from the site of phosphorylation (Piper et 
al., 1993a).
It has also been reported that high cytosolic calcium levels stimulate GLUT4 
phosphorylation and that increased GLUT4 phosphorylation decreases the 
transporters intrinsic activity. This results in a decrease in insulin-stimulated 
glucose transport. The authors conclude that high cytosolic calcium levels 
induce insulin resistance by interfering with the dephosphorylation of GLUT4 
(Reusch et al., 1991, Reusch et al., 1993, Begum et al., 1993). However, 
further study is required to establish if the observed decreases in glucose 
transport activity are the direct result of increased GLUT4 phosphorylation or 
are mediated by another mechanism involving elevated cytosolic calcium 
levels.
When adipocytes are incubated with the phosphatase inhibitor, okadaic acid, 
there is a threefold increase in the level of GLUT4 phosphorylation at the 
plasma membrane (Lawrence, Jr. et al., 1990b). Okadaic acid is a tumour 
promoter that was originally isolated from the sea sponge, Halichondria okadaii 
(Tachibana K et al., 2005), and inhibits Type I and Type lla protein 
phosphatases (Bialojan and Takai, 1988, Cohen et al., 1990). These two 
enzymes are responsible for most of the protein phosphatase activity in the fat 
cells (Haystead et al., 1989). Okadaic acid stimulates 2-deoxyglucose uptake 
in rat adipocytes (Haystead et al., 1989) and results in a fourfold increase in 
the level of GLUT4 at the plasma membrane. Although okadaic acid stimulates 
GLUT4 translocation, it partially inhibits insulin-stimulated GLUT4 transport. 
Okadaic acid alone or in combination with insulin increases the level of 
phosphorylation of GLUT4 threefold at the plasma membrane relative to the 
intracellular pool of transporters (Lawrence, Jr. et al., 1990b). It is unlikely that 
the phosphorylation alone would induce translocation as insulin does not 
increase the phosphorylation of the protein. The inhibitory effect of okadaic
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acid on insulin-stimulated translocation is consistent with the hypothesis that 
the phosphorylation of GLUT4 promotes internalisation.
A single phosphorylation site has been identified in GLUT4 (Lawrence, Jr. et 
al., 1990a). Cyanogen bromide (CNBr) was used to cleave GLUT4 at 
methionine residues from [32Pj] labelled adipocytes. Autoradiography of the 
peptides, separated by SDS-PAGE, identified a single phosphorylated band 
from either the N- or the C-terminus of GLUT4. The band was identified as 
being from the C-terminus after use of an antibody raised to the C-terminus of 
GLUT4 to detect the band. An antibody to the N-terminus of GLUT4 was not 
available at the time of the study. Tryptic digestion identified the 
phosphorylated residue as serine 488. It is interesting to note that this site is 
not present in GLUT1 (Lawrence, Jr. et al., 1990a). Phosphorylation at the 
amino-terminus was not reported and has not been investigated since.
The lack of investigation into the potential phosphorylation of the amino- 
terminus of GLUT4 is surprising as the N-terminal region of GLUT4, 
downstream of the FQQI motif, bears a close sequence identity to a known 
multiple phosphorylation site within the GAD65a subunit (Section 1.6.3). This 
site contains an acidic cluster region that is similar to regions found in CD-MPR 
and furin. Casein Kinase II (CKII) is known to phosphorylate these proteins. It 
is predicted that GLUT4 is phosphorylated by a kinase that is closely related to 
the one that phosphorylates GAD65a. The phosphorylation of this region may 
be involved in modulating GLUT4 cellular routing, sorting from the cell surface, 
or possibly removal of GLUT4 from the recycling endosomal pool into the TGN 
and/or the specialised intracellular insulin-responsive compartment.
Experiments involving GLUT4 phosphorylation have mainly been carried out in 
adipocytes, with one brief report of phosphorylation occurring in GLUT4 
isolated from skeletal muscle (James et al., 1989a). There have been no 
reports investigating phosphorylation in cardiomyocytes. However,
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cardiomyocytes and skeletal muscle are interesting targets as they have an 
additional mechanism that regulates GLUT4 translocation. In addition to 
insulin-stimulated GLUT4 translocation that occurs in adipocytes, GLUT4 
translocation occurs in muscle cells during ischemia and hypoxia by a pathway 
that is not inhibited by wortmannin (Sun et al., 1994, Egert et al., 1997). This 
mechanism is believed to involve AMP-activated protein kinase (AMPK) 
(Russell, III et al., 1999) (Section 1.4).
The aim of the work described in this chapter was to investigate the 
phosphorylation state of GLUT4 in adipocytes and cardiomyocytes, to identify 
any previously unidentified phosphorylation sites especially at serine 10 and to 
confirm that serine 488 was phosphorylated. It was planned that the change in 
phosphorylation in response to different agents would also be investigated as 
well as the relative level of phosphorylation at each terminus. The 
stoichiometry of phosphorylation would then be calculated in both adipocytes 
and cardiomyocytes. In addition, the identity of the kinase(s) responsible for 
phosphorylation would be investigated from kinase inhibitor studies.
4.2 Results
4.2.1 Prediction of the Phosphorylation Sites in GLUT4
Phosphorylation prediction programs have become available since the advent 
of bioinformatics. The NetPhos 2.0 server predicts serine, threonine and 
tyrosine phosphorylation sites in eukaryotic proteins (Blom et al., 1999). 
NetPhos 2.0 was used to predict the phosphorylation sites in GLUT4 (Table
4.1). Numerous phosphorylation sites were predicted in GLUT4. The potential 
phosphorylation sites would most likely be localised in the cytoplasmic regions
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of the transporter (highlighted in blue) since they would be accessible to 
cytoplasmic protein kinases. However, it could not be ruled out that 
phosphorylation could occur in extracellular regions of GLUT4 as these regions 
are intra-luminal in the recycling vesicles. Kinases inside these vesicles could 
then phosphorylate GLUT4 (highlighted in red). The potential phosphorylation 
sites included the two residues of interest, serine 488, which was the residue 
identified by Lawrence et al (Lawrence, Jr. et al., 1990a), and serine 10, which 
was the predicted second phosphorylation site.
4.2.2 Prediction of Possible GLUT4 Kinase(s)
In addition to predicting phosphorylation sites, it is also possible to predict the 
kinase responsible for phosphorylation. The NetPhosK 1.0 Server was used to 
predict the kinase (Table 4.2) (Blom et al., 2004). Currently, NetPhosK covers 
the following kinases: PKA, PKC, PKG, CKII, Cdc2, CaM-ll, ATM, DNA PK, 
Cdk5, p38 MAPK, GSK3, CKI, PKB, RSK, INSR, EGFR and Src. The kinases 
identified were those above the threshold value of 0.5 (values were in the 
range of 0.1 -  1.0). The predicted kinase(s) responsible for phosphorylation at 
serine 10 and serine 488 were CKII and PKA, respectively. GLUT4 had 
previously been shown to be a substrate for PKA (Lawrence, Jr. et al., 1990a) 
and CKII was predicted as a candidate for the serine 10 kinase due to the 
acidic cluster at the N-terminus of GLUT4.
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S e r in e  P h o s p h o ry la t io n  P r e d ic t io n s
Site Sequence Score Region
3 — MPSGFQQ 0.003 C
10 QQIGSEDGE 0.263 C
CO o LAVFSAVLG 0.005 TM
35 AVLGSLQFG 0.011 TM
55 VIEQSYNAT 0.042 E
71 GGPDSXPQG 0.253 E
84 LWALSVAIF 0.016 TM
89 VAIFSVGGM 0.092 TM
95 GGMISSFLI 0.002 TM
96 GMISSFLIG 0.002 TM
103 IGIISQWLG 0.003 C
134 NAAASYEIL 0.874 E
149 IGAYSGLTS 0.008 TM
153 SGLTSGLVP 0.020 TM
194 LGLE SMLGT 0.041 E
226 FCPESPRYL 0.724 C
243 PARKSLKRL 0. 997 C
254 WADVSDALA 0.015 C
274 ERPLSLLQL 0. 948 c
281 QLLGSRTHR 0.006 c
297 VLQLSQQLS 0.009 TM
301 SQQLSGINA 0.600 TM
310 VFYYSTSIF 0.054 E
312 YYSTSIFEL 0.285 E
340 FTLVSVLLV 0.003 TM
379 ERVPSMSYV 0.342 E
381 VPSMSYVSI 0.932 E
384 MSYVSIVAI 0.488 E
412 AELFSQGPR 0.026 C
426 VAGFSNWTC 0.002 TM
480 FDQISATFR 0.204 C
488 RRTPSLLEQ 0. 993 C
497 EVKPSTELE 0.775 c
Threonine Phosphorylation Predictions
Size Sequence Score Region
21 QQRVTGTLV 0 . 0 7 5 C
23 RVTGTLVLA 0 . 5 1 5 C
59 SYNATWLGR 0 . 0 1 4 E
7 6 IPQGTLTTL 0 . 1 3 4 E
78 QGTLTTLWA 0 . 1 9 0 E
79 GTLTTLWAL 0 . 1 3 4 E
152 YSGLTSGLV 0.450 TM
166 EIAPTHLRG 0 . 0 3 3 C
174 GALGTLNQL 0.073 TM
198 SMLGTATLW 0 . 0 2 1 E
200 LGTATLWPL 0 . 2 1 1 E
209 LLAITVLPA 0.029 TM
248 LKRLTGWAD 0 . 3 0 0 C
283 LGSRTHRQP 0 . 4 3 3 C
311 FYYSTSIFE 0 . 0 3 0 E
326 PAYATIGAG 0.181 TM
334 GVVNTVFTL 0.093 TM
337 NTVFTLVSV 0. 471 TM
351 AGRRTLHLL 0 . 3 7 0 C
368 AILMTVALL 0.013 TM
429 FSNWTCNFI 0.003 TM
464 FFIFTFLRV 0.036 TM
471 RVPETRGRT 0 . 4 8 9 C
475 TRGRTFDQI 0 . 0 8 9 C
482 QISATFRRT 0 . 36 7 c
486 TFRRTPSLL 0 . 7 6 0 c
498 VKPSTELEY 0 . 2 4 1 c
Tyrosine Phosphorylation Predictions
Size Sequence Score Region
40 LQFGYNIGV 0.015 TM
56 IEQSYNATW 0.221 E
135 AAASYEILI 0.156 E
148 LIGAYSGLT 0.010 TM
159 LVPMYVGEI 0.016 TM
229 ESPRYLYII 0.709 C
231 PRYLYIIRN 0.109 C
308 NAVFYYSTS 0.072 TM
309 AVFYYSTSI 0.022 E
324 EQPAYATIG 0.974 TM
382 PSMSYVSIV 0.579 E
440 MGFQYVADA 0.309 E
448 AMGPYVFLL 0.778 TM
502 TELEYLGPD 0 .814 C
Table 4.1 Potential GLUT4 phosphorylation sites predicted using a 
phosphorylation prediction program. Phosphorylation sites have been predicted 
using the NetPhos 2.0 Server (Blom et al., 1999). Phosphorylation sites at serine (A), 
threonine (B) and tyrosine (C) residues are given. The predicted phosphorylation sites 
are shown, along with the sequence surrounding the residue. The output scores 
(value in the range [0.000-1.000]) are tabulated. The higher the number, the more 
confidence there is that phosphorylation occurs at the said site. The position of the 













S-96 cdc2 (0 . 54)




S-226 p38MAPK (0 . 52) , GSK3 (0.52"), Cdk5 ("6". 64 )
Y-229 EGFR (0.51)
S-243 PKC (0.85), PKA (0.81)
S-254 CKII (0.62)
S-274 RSK (0.54), PKB (0.50), PKA (0.84)
S-281 PKC (0.51), cdc2 (0.56)
T-283 | PKC











S-488 RSK (0.53) , PKA (0.81) ~
S-497 CKII (0.52), PKA TO.63)
T-498 CKII (0.55)
Table 4.2 Potential kinases involved in phosphorylating GLUT4 at the predicted 
phosphorylation sites. Kinases have been predicted using the NetPhosK Server 1.0 
(Blom et al., 2004). The predicted kinases are given alongside the site of 
phosphorylation and the score (above the threshold score of 0.5). The higher the 
score the more confidence there is in the kinase phosphorylating the said site.
176
4.2.3 Phosphorylation of Full Length GLUT4 in Adipocytes and 
Cardiomyocytes
Adipocyte and cardiomyocyte cells were labelled with radioactive inorganic 
phosphate [32Pj]. Following the labelling, GLUT4 was immunoprecipitated from 
the cell lysate. The GLUT4 was run on a SDS-PAGE gel and transferred to 
nitrocellulose. The 32P signal on the nitrocellulose was detected on a 
Phospholmager [FU], after exposure on an imaging plate [FU], In adipocytes, 
the 32P was recovered as a single species of 45 kDa (Figure 4.2 a). Western 
blot analysis identified the GLUT4 band by use of the anti-C-terminal GLUT4 
antibody raised in sheep (described in chapter 3). The band corresponding to 
GLUT4 was also detected at 45 kDa in adipocytes (Figure 4.2 b). Thus, GLUT4 
was phosphorylated in adipocytes. The same was true with the 
cardiomyocytes. The 32P was recovered as a single species of 43 kDa (Figure 
4.2 c). The band corresponding to GLUT4 was also detected at 43 kDa in 
cardiomyocytes (figs 4.2 d). This was the first evidence that GLUT4 was 
phosphorylated in cardiomyocytes.
4.2.4 Identification of Phosphorylation Sites in GLUT4 
4.2.4.1 Cleavage using Cyanogen Bromide
Cyanogen bromide (CNBr) cleaves proteins on the C-terminal side of 
methionine residues and it is often used to map proteins immobilised onto 
membranes (Luo et a/., 1991). In the GLUT4 protein there are 12 methionine 
residues, including the initiation methionine. On cleavage with CNBr, 13 
peptides would be generated (Table 4.3). The predicted size of the N- and C- 
terminal peptides, which include serine 10 and serine 488, would be 9.5 kDa 
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Figure 4.2 Full length GLUT4 was phosphorylated in both adipocyte and 
cardiomyocyte cells. Adipocyte (a and b) and cardiomyocyte (c and d) cells were 
labelled with [32P|]. GLUT4 was immunoprecipitated from the cell lysate. A fter SDS- 
PAGE, autoradiography detected any 32P incorporated into GLUT4 (a and c). The anti- 
C-terminal GLUT4 antibody, raised in sheep, was used to detect the GLUT4 protein 



















361 -  367 662 cgcailm
368 -  380 1394 tvallllervpsm
381 -  420 4280 avagfsnwtcnfivgm
421 -436 1669 gfqyvadam
437 -  445 953 syvsivaifgfvaffeigpgpipwfivaelfsqgprpaam
446 -  509 7396 gpyvfllfavlllgffiftflrvpetrgrtfdqisatfrrtpslleqevkpstel
eylgpdend
Table 4.3 The predicted sequence and size of the peptides generated after 
GLUT4 had been cleaved with Cyanogen Bromide. Cleavage was predicted using 
the PeptideCutter tool on the ExPASy server (Gasteiger et al., 2003). The residues in 
red are found in the intracellular regions of GLUT4. The residues in blue are 
transmembrane residues and the green residues are found in the extracellular regions 
of GLUT4.
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4.2.4.1.1 CNBr Cleavage of GLUT4 in Primary Adipocytes
Dr Frangoise Koumanov carried out the preliminary experiments in which 
adipocytes were labelled with [32P] and the GLUT4 phosphorylation sites were 
mapped by cleaving GLUT4 with CNBr. The experiment used the method 
essentially carried out by Lawrence and colleagues (Lawrence, Jr. et al., 
1990a). The cells were labelled with [32Pj]. GLUT4 was immunoprecipitated 
from the cell lysate and subjected to tris-glycine SDS-PAGE. The GLUT4 was 
excised from the gel and was cleaved with CNBr. The cleaved fragments were 
resolved on a tris-tricine SDS-PAGE gel and transferred to nitrocellulose. 
Autoradiography detected the bands that contained radioactivity. The peptides 
that contained serine 10 and serine 488 were detected by Western blot 
analysis. The rabbit anti-pSer10 antibody purified from the second bleed serum 
(chapter 3) was used to detect the N-terminal peptide. The Western blot was 
then stripped and reprobed. The C-terminal peptide was detected by use of the 
monoclonal anti-C-terminal GLUT4 antibody.
The majority of radiolabelled GLUT4 derived peptides were resolved in one 
major radioactive fragment at 10 kDa (Figure 4.3 b). However, there were also 
five weaker bands that contained 32P (arrows on Figure 4.3 b). When 
comparing the molecular weight of the 32P bands on the 32P scan with the 
predicted weights of the cleaved peptides (Table 4.3), the peptide closest in 
weight to 10 kDa is the 9.5 kDa N-terminal peptide (residues 2 -  93). In 
comparison, the C-terminal peptide (residues 446 -  509) is predicted to be 7.4 
kDa. Both of these peptides contain a predicted phosphorylation site, serine 10 
or serine 488. Contrary to the molecular weight of the peptide, Western blot 
analysis with the anti-C-terminal antibody identified the strongly 
phosphorylated band at 10 kDa to be the peptide at the C-terminus of GLUT4 
(Figure 4.3 a). Thus, the peptide that included the serine 488 residue was 
phosphorylated. Western blot analysis with the anti-pSer10 antibody identified 
many bands, although, none of the bands were of high intensity in the region of 
interest (Figure 4.3 c). Strong bands were identified at the top of the
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nitrocellulose at 30 and 34 kDa. The bands at 30 and 34 kDa could contain the 
N-terminus of GLUT4 or the bands could contain IgG which was identified by 
the secondary antibody. The presence of IgG could not be ruled out because a 
secondary antibody control was not carried out. This would have identified any 
non-specific IgG bands. However, using Table 4.3 to take into account missed 
cleavage sites, no peptides would have been produced at either 30 or 34 kDa 
that would have included the N-terminal peptide. A peptide with six missed 
cleavage sites would have a molecular weight of 20 kDa and a peptide with 
seven missed cleavage sites would have a molecular weight of 38 kDa. Thus 
the bands at 30 kDa or 34 kDa could not have been due to any missed 
cleavage sites in GLUT4. It seems likely that the strong band was due to IgG 
as the antibodies used in the immunoprecipitation and in the N-terminal 
peptide Western blot analysis were raised in the same species (rabbit). The 
sheep antibodies were not available for use at this point. Therefore any IgG 
that had been eluted after the immunoprecipitation and had been carried 
though the procedure would have been detected strongly by the anti-rabbit 
secondary antibody in the Western blot analysis. This gave a good example of 
the need to raise an antibody to the N-terminus of GLUT4 in sheep. The bands 
were not identified in the C-terminal peptide blot because an anti-mouse 
secondary antibody was used, which did not detect the rabbit IgG. The anti- 
pSer10 antibody recognised weak bands at 5, 7, 10, 17 and 25 kDa in the area 
of interest. Bands at 10, 17 and 25 kDa were also detected on the 32P scan. 
However, the bands on the Western blot were weak. This was because the 
anti-pSer10 antibody was very weak (chapter 3), and so it was difficult to 
identify which band corresponded to the N-terminal peptide of GLUT4. The 
band at 10 kDa, which was the predicted weight of the N-terminal peptide, was 
resolved at the same molecular weight as the C-terminal peptide. This would 
suggest that the N-terminal and the C-terminal peptides may be running at the 
same molecular weight, in which case the N-terminal peptide could also be 
phosphorylated. However, the anti-pSer10 antibody could be cross reacting with 
the C-terminal peptide which would provide an explanation as to why the
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peptides were running at the same molecular weight. Further investigation was 
therefore needed to investigate whether the bands identified by the anti-pSer10 
antibody were real and were those of the N-terminal peptide.
4.2.4.1.2 CNBr Cleavage of GLUT4 in 3T3-L1 Adipocytes on Day 5 of 
Differentiation
Dr Frangoise Koumanov carried out [32PJ labelling and CNBr cleavage of 
GLUT4 in 3T3-L1 adipocytes on day 5 of differentiation. Day 5 of differentiation 
was chosen because a confocal microscopy study with the anti-pSer10 antibody 
had identified an intracellular protein at day 5 and this suggested that the 
phosphorylation of GLUT4 could be involved in the GLUT4 synthetic pathway 
(Section 3.2.1.5). The cells were labelled with [32Pj]. GLUT4 was then 
immunoprecipitated from the cell lysate. The GLUT4 was transferred to PVDF 
membrane after the GLUT4 had been subjected to SDS-PAGE. The PVDF 
membrane was cut to excise the region around GLUT4. CNBr was used to 
cleave the GLUT4 on the PVDF membrane. The cleaved GLUT4 was 
subjected to tris-tricine SDS-PAGE and transferred to nitrocellulose. 
Autoradiography of the nitrocellulose detected the radioactive bands. Western 
blot analysis, carried out with the anti-pSer10 antibody, purified from the final 
bleed serum from rabbit (on the phospho and PAN specific peptides) (chapter 
3), and the mouse monoclonal anti-C-terminal GLUT4 antibody, identified the 
N- and C-terminal peptides, respectively. The blot was stripped between the 








Figure 4.3 Identification of the phosphorylation sites in GLUT4 from rat adipocytes. Primary adipocyte cells were labelled with 
[32Pi]. GLUT4 was immunoprecipitated from the cell lysate and subjected to SDS-PAGE. The GLUT4 was sliced from the gel and 
cleaved with CNBr. The CNBr fragments were subjected to tris-tricine SDS-PAGE and transferred to nitrocellulose. Autoradiography 
was carried out on the nitrocellulose (b). The fragments that contained the C-terminal and N-terminal peptides were detected by 
Western blot analysis, (a) and (c) respectively. Arrows indicate the bands identified in (b) and (c). Images were kindly supplied by Dr 
Frangoise Koumanov.
183
Cleaving the GLUT4 isolated from 3T3-L1 adipocytes at day 5 of 
differentiation, resulted in two bands being identified that contained 32P, one at 
7 kDa and the other at 4 kDa (Figure 4.4 b). Following Western blot analysis, 
the C-terminal peptide was identified at 9 kDa (Figure 4.4 a). The N-terminal 
antibody identified two bands, one band had a molecular weight of 7 kDa and 
the second, stronger, band had a molecular weight of 5 kDa (Figure 4.4 c). The 
7 kDa band was the same molecular weight as the upper band on the 32P scan 
suggesting that the upper band on the 32P scan contained the GLUT4 N- 
terminal peptide. However, neither the stronger N-terminal band nor the C- 
terminal band corresponded to the lower, 32P-containing 4 kDa band. The fact 
that the lower N-terminal peptide fragment did not contain 32P was a concern. 
This could suggest that one of the bands from the Western blot analysis was 
not the N-terminal peptide. The fact that the upper, 7 kDa fragment, is closest 
in molecular weight to the predicted weight of 9 kDa would suggest that the 
upper band is the N-terminal band and that this band is phosphorylated. 
Another concern was that the molecular weight of the GLUT4 C-terminal 
peptide, as identified by Western blot analysis, did not correspond to a 32P- 
containing band, even though phosphorylation had previously been identified in 
the C-terminal peptide (Lawrence, Jr. etal., 1990a).
In an attempt to further resolve the N- and C-terminal phosphorylation sites, 
alternative cleavage strategies were then investigated which were aimed at 













26.6 —  f
17 —  
14.2 —
6.5 —
Figure 4.4 Identification of the phosphorylation sites in GLUT4 from 3T3-L1 adipocytes. 3T3-L1 adipocyte cells at day 5 of
differentiation were labelled with [32Pj]. GLUT4 was immunoprecipitated from the cell lysate and subjected to SDS-PAGE. The gel 
was transferred to PVDF membrane. The membrane was cut around the GLUT4 region and cleaved with CNBr. The CNBr fragments 
were subjected to tris-tricine SDS-PAGE and transferred to nitrocellulose. Autoradiography was carried out on the nitrocellulose (b). 
The fragments that contained the C-terminal and N-terminal peptides were detected by W estern blot analysis, (a) and (c) 
respectively. Images were kindly supplied by Dr Frangoise Koumanov.
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4.2.4.2 Cleavage using Endoproteinase Lvs C
Endoproteinase Lys C (Endo LysC) is an enzyme that cleaves at the C- 
terminal side of lysine residues. GLUT4 has 8 lysine residues so on cleavage 9 
peptides will be generated (Table 4.4). The predicted size of the N- and C- 
terminal peptides, which would include serine 10 and serine 488, would be 5.2 
kDa and 25.1 kDa, respectively. In theory this would give a good alternative to 
the use of CNBr as the predicted bands should be more easily resolved. The 
use of Endo LysC, as an alternative to CNBr, was tested to ensure that the N- 
and C- terminal peptides could be detected. GLUT4 was immunoprecipitated 
from an adipocyte cell lysate using the anti-C-terminal GLUT4 antibody raised 
in rabbit. Following elution with 25 mM Tris-CI, 1 mM EDTA, 0.5% (w/v) SDS, 
pH 8.5, the sample was split into two. One of these samples was digested with 
Endo LysC. The other sample was a control in which no enzyme was used. No 
protease inhibitors were added in the reaction because the Endo LysC enzyme 
would be inhibited. The control was essential as it ensured that the cleavage 
was due to the specific action of the enzyme and not due to proteolysis during 
the reaction incubation. After the incubation, the samples were again split into 
two. The samples were subjected to SDS-PAGE, either on a tris-tricine gel for 
the digested samples or a tris-glycine gel for the undigested samples. The gels 
were transferred to nitrocellulose. Western blot analysis with the mouse 
monoclonal anti-C-terminal GLUT4 antibody and the sheep anti-pSer10 
antibody identified the C- and N- terminal peptides of interest (Figure 4.5). Full 
length GLUT4 was identified by both the anti-pSer10 (Figure 4.5 a) and the anti- 
C-terminal GLUT4 antibodies (Figure 4.5 b) in both of the control, uncleaved, 
samples. After digestion with Endo LysC, the C-terminal peptide was identified 
as being at 23 kDa (Figure 4.5 d) and the N-terminal peptide was identified at 5 
kDa (Figure 4.5 c). This gave a good correlation to the predicted molecular 
weights of 25.1 and 5.2 kDa, respectively. The 17 kDa band was identified as 
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243 - 245 347 slk
246 -  261 1745 rltgwadvsdalaelk
262 -  264 391 dek
265 - 266 303 rk





496 - 509 1579 psteleylgpdend
Table 4.4 Table showing the sequence and predicted size of the peptides 
produced after GLUT4 had been cleaved with Endo-LysC. Cleavage was predicted 
using the PeptideCutter tool on the ExPASy server (Gasteiger et al., 2003). The 
residues in red are found in the intracellular regions of GLUT4. The residues in blue 








6 .5 ----- 6.55 kDa
3.5
Figure 4.5 Endo LysC digestion test. GLUT4 was immunoprecipitated from an 
adipocyte cell lysate. The elution buffer used was 25 mM Tris-CI, 1 mM EDTA, 0.5% 
(w/v) SDS, pH 8.5. GLUT4 was digested with Endo LysC. A  control of no enzyme was 
also carried out. The peptides were resolved by SDS-PAGE. Following electrophoretic 
transfer to nitrocellulose, Western blot analysis identified the N- (a and c) and C- 
term inal fragments (b and d) in both uncleaved (a and b) and cleaved (c and d) 
samples.
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4.2.4.2.1 Identification of the Phosphorylation Sites in Adipocytes and 
Cardiomyocytes
As the N- and C- terminal peptides were well resolved following Endo LysC 
cleavage, the sites of phosphorylation were investigated in GLUT4 isolated 
from adipocyte and cardiomyocyte cells.
Adipocyte and cardiomyocyte cells were labelled with [32Pj] and lysed in their 
respective lysis buffers. GLUT4 was cleaved with Endo LysC, as above, and 
run on tris-tricine SDS-PAGE gels and transferred to nitrocellulose. The 
nitrocellulose was exposed on a phospho screen for 2 -  4 days before 
monitoring the radioactivity on the Phospholmager. Western blot analysis 
involving the use of the sheep anti-pSer10 antibody and the mouse monoclonal 
anti-C-terminal antibody led to the detection of the N- and C-terminal peptides, 
respectively. The blots were not stripped between the probing with the two 
antibodies. This prevented any loss of signal due to the stripping process. 
Stripping was not necessary because the peptides were well resolved on the 
gel. Prior to the Western blot analysis using the primary antibodies, a control 
experiment was carried out in which the secondary antibodies, both anti-sheep 
and anti-mouse, were independently incubated with the nitrocellulose. The 
control experiment would identify any bands that were due to a non-specific 
interaction with non-immune IgG that would also be identified following the 
Western blot analysis with the anti-GLUT4 antibodies.
Autoradiography detected two phosphorylated peptides in GLUT4 isolated from 
adipocytes, at 23.6 kDa and 5.0 kDa (Figure 4.6 b). The peptides could be 
identified by comparison with the predicted molecular weight of the cleaved 
peptides (Table 4.4). The 23.6 kDa peptide would be the C-terminal peptide 
(residues 267 -  495) as it is the peptide with a molecular weight nearest to 25 
kDa. By comparison with Table 4.4, two peptides could account for the lower 
32P-containing band. Peptide 1 -  50 and peptide 51 -  109 would theoretically 
be 5.2 and 6.3 kDa respectively. The molecular weight of lower 32P-containing
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band in adipocytes corresponded exactly to the predicted molecular weight for 
peptide 1 -  50. The identities of the peptides were further confirmed by 
Western blot analysis. The C-terminal peptide was identified as a 23.6 kDa 
band in adipocytes (Figure 4.6 a). The upper 32P-containing band therefore 
corresponded to peptide 267 -  495 from GLUT4. The peptide identified by the 
anti-pSer10 antibody was detected at 5.0 kDa in adipocytes (Figure 4.6 c). The 
molecular weight of the lower 32P-containing band corresponded to the 
molecular weight of the N-terminal peptide 1 -  50. Phosphorylation had been 
identified in two GLUT4 peptides; peptide 1 - 5 0  and peptide 267 -  495. The 
anti-pSer10 and anti-C-terminal antibodies had a specific interaction with the 
32P-containing bands as no interaction was observed between the 23.6 and 5 
kDa bands and non-immune IgG (result not shown).
Two peptides containing 32P were identified, by autoradiography, from GLUT4 
isolated from cardiomyocytes. The two peptides had molecular weights of 28.0 
kDa and 6.2 kDa (Figure 4.7 b). As in adipocytes, comparison with the 
predicted molecular weight of the peptides (Table 4.4) led to the identification 
of the 28 kDa band as being the 267 -  495 C-terminal peptide. Western blot 
analysis with the anti-C-terminal GLUT4 antibody detected the C-terminal 
peptide at 26.6 kDa. Thus providing further evidence that the phosphorylated 
peptide was the 267-495 C-terminal peptide (Figure 4.7 a). After comparison of 
the predicted peptide molecular weights, the 6.2 kDa band on the 32P scan 
seemed to correspond more closely to peptide 51 -  109 (6.3 kDa) than peptide 
1 - 5 0  (5.2 kDa). However, following comparison with the Western blot 
analysis, the N-terminal peptide was identified at 5.8 kDa (Figure 4.7 c). The 
lower band on the 32P scan was therefore identified as peptide 1 -  50. Both of 
the peptides identified from the 32P scan ran at slightly higher molecular 
weights than either the predicted molecular weights of the peptides or the 
weights of the peptides identified on the 32P scan from GLUT4 isolated from 
adipocytes. This could have been due to the experimental differences in the 
running of the markers between experiments. The discrepancy between the
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molecular weight of the peptides could also have occurred because the 
markers had to be manually labelled onto the image from the 32P scan. A small 
error in the labelling of the markers would have resulted in a large difference in 
the calculated molecular weight of the peptides.
4.2A.2.2 Missed Phosphorylation Sites
A comparison was carried out, in cardiomyocytes cells, to investigate whether 
the sum of the phosphorylation that was found in the two GLUT4 peptides 
following Endo LysC cleavage equalled the total phosphorylation that was 
detected in the uncleaved GLUT4 protein.
The intensity of the 32P-containing bands on the 32P scan was calculated in 
photostimulated luminescence (PSL) units. The intensity was calculated using 
the ImageGauge software [FU]. The intensity of the 32P band from the 
uncleaved GLUT4 sample was calculated, along with the sum of the intensities 
of the 32P-containing bands obtained following the Endo LysC cleavage of 
GLUT4. A background value was subtracted from each band. The background 
luminescence was taken as the average background above and below each 
phosphorylated band. The amount of GLUT4 (pmole) in each lane was also 
calculated. For a direct comparison between cleaved and uncleaved GLUT4, 
the intensity (PSL) / pmole of GLUT4 was calculated. Uncleaved GLUT4 had a 
value of 7576 intensity (PSL) / pmole and the sum of the cleaved GLUT4 
bands had a value of 7445 intensity (PSL) / pmole (Table 4.5). Thus the 
intensity of the phosphorylated, uncleaved GLUT4 protein was the same as the 
sum of the intensity of the phosphorylated N- and C-terminal peptides. This 
experiment was only carried out once but it suggested that all of the 
phosphorylation sites in GLUT4 were localised in the N-terminal peptide 

























Figure 4.6 The N- and C-terminal peptides are phosphorylated in primary adipocytes. Primary adipocyte cells were labelled with 
[32Pj], GLUT4 was immunoprecipitated from the cell lysate and cleaved with Endo LysC. The fragments were subjected to tris-tricine 
SDS-PAGE and transferred to nitrocellulose. Autoradiography was carried out on the nitrocellulose (b). The fragments that contained 
the C-terminal and N-terminal peptides were detected by Western blot analysis, (a) and (c) respectively.
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28.0 kDa26.6 kDa 26.626.6 26.6
14.214.2 14.2
5.8 kDa6.2 kDa g 06.56.5
3.53.5 3.5
Figure 4.7 The N- and C-terminal peptides are phosphorylated in cardiomyocytes. Cardiomyocyte cells were labelled with [32Pj]. 
GLUT4 was immunoprecipitated from the cell lysate and cleaved with Endo LysC. The fragments were subjected to tris-tricine SDS- 
PAGE and transferred to nitrocellulose. Autoradiography was carried out on the nitrocellulose (b). The fragments that contained the 
C-terminal and N-terminal peptides were detected by Western blot analysis, (a) and (c) respectively.
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In tens ity  (P S L) / G L U T 4 PS L /
Lane (p m o le ) pm ole  o fG L U T 4
C leaved 36841 .5 4 .9 7444 .5
U n cleaved 30697 .2 4.1 7575 .9
Table 4.5 Identification of any missed phosphorylation sites. The intensity 
(photostimulated luminescence (PSL)) of the phosphorylated band obtained from the 
uncleaved GLUT4 sample was compared to the sum of the intensities of the 
phosphorylated bands obtained from the cleaved GLUT4 sample. A background level 
of luminescence was subtracted from each band. To compare samples, the total 
GLUT4 was calculated per lane and the results were expressed as intensity (PSL) / 
GLUT4 (pmole).
4 .2 .4 .2 .3  The E ffec t o f Insu lin  and O kad a ic  A cid  on the P h o sp h o ry la tio n  
S tate  o f G L U T 4  in A d ip o cytes
The e ffe c t both insu lin  and okada ic  acid  had on the  p hosph o ry la tion  s ta te  o f 
G LU T 4  w a s  investiga ted . The  m ethod  used w as  as described  p rev ious ly , 
e xce p t tha t the  ad ipocy te s  w ere  s tim u la ted  w ith  e ith e r insu lin  o r o ka d a ic  acid  
fo r 20  m in (Tab le  2.7). The  leve ls  o f phosph o ry la tion  unde r these  tw o  
co n d itio n s  w ere  com pared  to the  leve l o f phosph o ry la tion  in the  basa l s ta te  (in 
w h ich  the  ce lls  had had no add itiona l trea tm en t).
Insu lin  increased  the leve l o f phosph o ry la tion  by 1 .5 -fo ld  at the  N -te rm inus  and 
by 1 .2 -fo ld  a t the  C -te rm inus  o f G LU T4. T h is  increase  w as s ig n ifica n t a t both 
the  N -te rm inus  (p = 0 .0109 ) and the  C -te rm inus  (p = 0 .0118 ). Insu lin , the re fo re , 
had a g re a te r e ffec t on the  leve l o f p hosph o ry la tion  at the  N -te rm inus  o f 
G LU T 4  com pared  to  the C -te rm inus (F igu re  4 .8  A ). T h is  w as  ca lcu la ted  from  
an a ve rage  o f 4 ind iv idua l experim en ts .
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Okadaic acid also increased the level of phosphorylation by 1.6-fold at the N- 
terminus and by 2.1-fold at the C-terminus of GLUT4 (Figure 4.8 B). The 
increase was greater than that seen by insulin. In contrast to insulin, okadaic 
acid had a greater effect on the level of phosphorylation at the C-terminus of 
GLUT4. An increase in phosphorylation would be expected as okadaic acid is 
a phosphatase inhibitor that inhibits PPI and PPIIa (Bialojan and Takai, 1988, 
Cohen et al., 1990). The action of PPI and PPIIa accounts for most of the 
phosphatase action in adipocytes and so inhibition of the phosphatase would 
result in an increase in phosphorylation. The result was only representative of 
one experiment, so the investigation of the effect of okadaic acid needs to be 
repeated to confirm the results.
4.2.4.2.4 Relative Levels of Phosphorylation at the N- and C- terminus of 
GLUT4 in Adipocytes
To compare the relative level of phosphorylation at each terminus, the 
percentage phosphorylation was calculated. This was compared to the total 
GLUT4 phosphorylation per condition, which was set to 100%. This form of 
analysis would give some indication as to the relative importance of each 
phosphorylation site in basal, insulin- and okadaic acid-stimulated adipocytes.
In the basal state, 56.0% of GLUT4 phosphorylation occurred at the C- 
terminus, with 44.0% of the phosphorylation at the N-terminus. This ratio 
changed following insulin stimulation to 49% of the total phosphorylation being 
at the C- terminus and 51% at the N-terminus (Figure 4.9 A). There was not a 
significant difference in the relative level of phosphorylation, at either terminus, 
following insulin stimulation, compared to the relative level of phosphorylation 




Figure 4.8 Insulin and okadaic acid increased the level of phosphorylation at the 
N- and C-termini of GLUT4. Adipocytes were labelled with [32P,] and treated for 20 
min with insulin or for 20 min with okadaic acid. GLUT4 was immunoprecipitated and 
cleaved with Endo LysC. The level of phosphorylation was calculated as a percentage 
of basal phosphorylation. The data in A are the combined mean ± S.E M from 4 
independent experiments. *, p<0.05 (paired t-test; compared with the basal state). The 
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Treatment with okadaic acid resulted in 52.7% of the total phosphorylation 
occurring at the C-terminus of GLUT4 and 47.3% occurring at the N-terminus 
(Figure 4.9 B). This was the result from one individual experiment and needs to 
be repeated to obtain an averaged result. Okadaic acid did not significantly 
change the relative level of phosphorylation at either the N- or the C- terminus 
of GLUT4, compared to the relative level of phosphorylation in the basal state.
4.2.4.2.5 The Role of Casein Kinase II Inhibitors on the Phosphorylation 
State of GLUT4 Isolated From Adipocytes
The effect which two different casein kinase II inhibitors had on the level of 
GLUT4 phosphorylation was investigated. It was hoped that this would help to 
identify the kinase that was responsible for phosphorylating GLUT4 at serine 
10 because CKII was predicted to be the kinase responsible for 
phosphorylating serine 10 (Table 4.2). Two different casein kinase II (CKII) 
inhibitors, 5,6-Dichloro-1-p-D-ribofuranosylbenzimidazole (DRB) and 4,5,6,7- 
Tetrabromobenzotriazole (TBB), were investigated. TBB is a specific CKII 
inhibitor while DRB inhibits CKII and to a lesser extent, inhibits CKI. CKII was 
the predicted kinase to phosphorylate serine 10, but Golgi casein kinase (G- 
CK) also has a consensus sequence similar to the serine 10 site (Pinna and 
Ruzzene, 1996) (Section 1.6.3.1). DRB was tested as it is not a specific CKII 
inhibitor and therefore may inhibit G-CK as well as CKII and CKI. Adipocyte 
cells were treated with the CKII inhibitors for 2 h during the [32PJ labelling 
(Table 2.7). Both inhibitors were tested on basal and insulin-stimulated 
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Basal Insulin Okadaic Acid
Figure 4.9 Relative level of phosphorylation at the N- and C-terminus of GLUT4 
in basal (A), insulin (A) and okadaic acid (B) stimulated adipocytes. Total GLUT4 
per lane was set to 100% and the percentage of this that was phosphorylated at each 
term inus was calculated. The data in A are the combined mean ± S.E.M. from 4 
independent experiments, ns, p>0.05 (paired t-test; compared with the basal state). 
The data in B are from one experiment.
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DRB did not have an effect on the level of phosphorylation at the C-terminus of 
GLUT4 in either basal or insulin-stimulated cells (Figure 4.10). This was 
expected because there was not a casein kinase phosphorylation site in the C- 
terminal peptide. There was also no difference in the level of phosphorylation 
at the N-terminus of GLUT4 in basal adipocytes. However, following DRB 
treatment, there was a slight decrease in the level of phosphorylation at the N- 
terminus of GLUT4 in insulin-stimulated adipocytes. The data is only from one 
experiment and so caution must be taken in this analysis. Therefore, if DRB did 
have an effect on the level of GLUT4 phosphorylation, even if it was small, it 
occurred at the N-terminus of GLUT4, which does contain a potential CKII 
phosphorylation site.
The effect TBB had on the level of phosphorylation at the N- and C- termini of 
GLUT4 was tested on basal, insulin and insulin + isoproterenol stimulated 
cells. The data from basal and insulin-stimulated cells were taken from two 
experiments and the data from insulin + isoproterenol stimulated cells was only 
representative of one experiment. The results from the two basal and insulin- 
stimulated adipocyte experiments were variable and so for this reason the 
individual data, as well as the mean value, were represented in Figure 4.11.
As reported in the previous experiments (Figure 4.8 A), insulin increased the 
level of phosphorylation, above the basal level of phosphorylation, at both the 
N- and C-termini of GLUT4. On average, TBB had no effect on the level of 
phosphorylation of GLUT4 at the C-terminus in basal adipocytes. However, 
when basal adipocytes were treated with TBB there was a decrease in the 
level of phosphorylation at the N-terminus of GLUT4. This would be expected 
as the predicted CKII site is at the N-terminus of GLUT4.
The effect TBB had on insulin-stimulated adipocytes was variable. At the C- 
terminus of GLUT4, TBB treatment resulted in an increase in the level of 
phosphorylation in experiment 1, but a decrease in the level of phosphorylation
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in experiment 2, in GLUT4 isolated from insulin-stimulated adipocytes. 
Whereas, at the N-terminus of GLUT4, there was a small increase in the level 
of phosphorylation in experiment 1, but there was a large decrease in the level 
of phosphorylation in experiment 2, in GLUT4 isolated from insulin-stimulated 
adipocytes. It is therefore impossible to conclude whether TBB had an effect 
on the phosphorylation state of GLUT4.
GLUT4 isolated from isoproterenol treated insulin-stimulated adipocytes had a 
lower level of phosphorylation than GLUT4 isolated from insulin-stimulated 
adipocytes. The level of phosphorylation at the C-terminus was the same as 
the level of phosphorylation in basal adipocytes. Whereas, at the N-terminus of 
GLUT4, phosphorylation increased 10% in comparison to basal adipocytes 
(Figure 4.11 I and I + ISO). This did not agree with previous reports in which 
insulin and isoproterenol treatment led to a twofold increase in the level of 
phosphorylation of GLUT4 which was isolated from total membrane (James et 
a/., 1989a). TBB decreased the level of phosphorylation in insulin and 
isoproterenol stimulated adipocytes at the N-terminus of GLUT4. There was no 
effect on the level of phosphorylation at the C-terminus (Figure 4.11). This 
suggests that TBB had an effect at the N- but not the C-terminus of GLUT4. 
However, due to the variability, the experiments need to be repeated before a 
conclusion can be reached as to whether TBB has any effect on the 
phosphorylation state of GLUT4.
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Figure 4.10 The effect of DRB, a casein kinase II inhibitor, on the 
phosphorylation state of the N- and C-termini of GLUT4. Adipocytes were labelled 
with [32P|] and treated for 20 min with insulin and/or for 2 h with DRB. GLUT4 was 
immunoprecipitated and cleaved with Endo LysC. The level of phosphorylation was 
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Figure 4 11 The effect of TBB, a casein kinase II inhibitor, on the phosphorylation state of GLUT4 at the N- and C-termini.
Adipocytes were labelled with [32Pi] and treated for 20 min with insulin, 10 min with isoproterenol and adenosine deaminase or for 2 h 
with TBB. GLUT4 was immunoprecipitated and cleaved with Endo LysC. The level of phosphorylation was calculated as a 
percentage of basal phosphorylation. Basal, Insulin ± TBB conditions were tested twice and insulin + isoproterenol ± TBB was carried 
out once. The mean of the experiments and the data from each of the individual experiments were plotted.
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4.2A2.6 Level of Phosphorylation of GLUT4 in Adipocytes
To understand the relative importance of the phosphorylation at each site, it 
was imperative to calculate the stoichiometry of the GLUT4 phosphorylation. 
This gave a value for the number of moles of phosphate per mole of GLUT4. 
The level of phosphorylation was calculated for the whole (uncleaved) protein 
isolated from basal adipocytes. The level of phosphorylation at each site 
(serine 10 and serine 488) could then be calculated from the ratio of 
phosphorylation at each site (Section 4.2.4.2.4).
Rat adipocytes were labelled with [32PJ and an aliquot of cells was retained. 
GLUT4 was immunoprecipitated from the cell lysate of the remaining cells and 
split into two samples. The samples were run on a tris-glycine SDS-PAGE gel 
and transferred to nitrocellulose. The nitrocellulose containing one of the 
GLUT4 samples was cut into 2 mm pieces and counted in a scintillation 
counter. Western blot analysis was carried out on the second sample, with the 
anti-C-terminal GLUT4 antibody raised in sheep, to determine which of the 2 
mm nitrocellulose pieces contained GLUT4. A small aliquot of the sample 
eluted from the immunoprecipitation was also run on a tris-glycine SDS-PAGE 
gel with known amounts of GLUT4 to act as a standard curve. The gel was 
transferred to nitrocellulose and Western blot analysis was carried out with the 
anti-C-terminal GLUT4 antibody raised in sheep to determine the amount of 
GLUT4 that was counted in the scintillation counter. It was then possible to 
calculate the cpm / pmole GLUT4.
In addition, the specific activity of ATP (cpm / mole y phosphate) was 
calculated. Perchloric acid precipitation was used to precipitate the protein 
from the aliquot of cells retained before cell lysis (Section 2.2.3). The 
concentration of ATP in the resulting supernatant was determined using a 
luciferase bioluminescence assay (Section 2.2.4). A PKA assay was also 
carried out to determine the cpm per y phosphate of ATP. The y phosphate
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was transferred to kemptide (a substrate of PKA) in the presence of PKA. The 
phosphorylated kemptide was separated from the ATP and counted in a 
scintillation counter (Section 2.2.5).
The stoichiometry of GLUT4 phosphorylation (mole phosphate / mole GLUT4) 
was then calculated from the cpm / pmole GLUT4 and the cpm / mole y 
phosphate.
The experiment was carried out twice but unfortunately the results are neither 
reproducible nor sensible. The two individual results obtained were 31.34 and 
22.57 mole phosphate / mole GLUT4 (Table 4.6). These values were too high. 
A figure of 0.1 -  0.2 mole phosphate / mole GLUT4 had been reported 
previously in basal adipocytes (James et al., 1989a, Nishimura et al., 1991). 
The method used in the study described here was similar to that by Nishimura 
and colleagues. They reported that the specific activity of ATP was -500 cpm / 
pmole. The calculated specific activity of 1.91 or 3.06 cpm / pmole y phosphate 
was lower in this study than the previously reported 500 cpm / pmole y 
phosphate (Nishimura et al., 1991). If the reported specific activity of 500 cpm / 
pmole y phosphate was used with the GLUT4 cpm / pmole obtained in the 
present study, then the stoichiometry of GLUT4 phosphorylation works out to 
be -0.1 mole phosphate / mole GLUT4. As this is in agreement with the 
previous reports it would suggest that the error in the present study lies in the 
specific activity determination. This could have occurred in the PCA 
precipitation, ATP determination, the PKA assay or the kemptide purification 
strategy.
To find out if an error had occurred during the ATP determination assay, the 
value obtained from the assay was used calculate the concentration of ATP 
that would be present in the cell. This experimentally calculated value was then 
compared to the published values for the cellular concentration of ATP.
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Experiment 1 2
ATP (cpm) 115.5 284.5
ATP (pmole) (in 10 pi SN) 60.59 93.15
ATP ( cpm  / pm ole  y 
p h o s p h a te )
1.91 3.06
GLUT4 (cpm) 709.15 4037.73
GLUT4 (pmole) 11.85 58.46641
GLUT4 (cpm / pmole) 59.86 69.06
Phosphorylation 
Stoichiometry (mole 
phosphate / mole GLUT4)
31.34 22.57
Table 4.6 Quantification of the level of phosphorylation in basal adipocytes. The
level of phosphorylation was calculated from the GLUT4 cpm / pmole and the ATP 
cpm / pmole y phosphate. The data are from two independent experiments.
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From the ATP determination assay, and using the protein assay calculated 
following cell lysis, the concentration of ATP in the cell was calculated as 3.8 
and 12.5 nmole ATP / mg cell protein for the two experiments, respectively. 
The concentration of ATP in adipocytes had been reported as 8.3 nmole / mg 
cell protein (Pryor et al., 2000). The experimental level of ATP was similar to 
the published level of ATP in the cell. Thus, the ATP determination assay 
appeared to be accurate in determining the level of ATP. The PKA assay was 
therefore likely to be the section of the specific activity measurement in which 
the error had occurred. The fat from the adipocytes may not have been totally 
removed during the PCA precipitation and so traces of fat could have affected 
the PKA assay.
If the value of 0.1 mole phosphate / mole GLUT4 was correct, then this would 
lead to a value of 0.05 mole of phosphate at the N-terminus, and 0.05 mole of 
phosphate at the C-terminus, per mole of GLUT4. However, further work is 
needed to determine where the problem actually lies in the experimental 
procedure and, after this has been rectified, then the stoichiometry of GLUT4 
phosphorylation in adipocytes can be calculated further.
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4.2.4.2.7 Effect of Insulin and Oligomycin on the Phosphorylation State of 
GLUT4 Isolated From Cardiomyocytes
The effect of insulin and / or oligomycin on the phosphorylation state of GLUT4 
was tested in rat cardiomyocytes. In cardiomyocytes, there are two different 
mechanisms for glucose transport. The first is insulin-stimulated glucose 
transport and the second occurs during ischemia and hypoxia, which is 
believed to involve AMP-activated protein kinase (AMPK) (Section 1.4). AMPK 
is activated by an increase in the ratio of intracellular AMP:ATP (Hardie et al., 
1998). An increase in intracellular AMP, at the expense of ATP, can be 
achieved physiologically by an increase in workload, e.g. contraction, and 
pharmacologically by mitochondrial inhibitors. Oligomycin is a potent inhibitor 
of mitochondrial FiFo-ATPase and it elevates the AMP:ATP 2.5-fold in 
cardiomyocytes (Luiken et al., 2003). In this way, oligomycin mimics hypoxic 
conditions. Thus, by testing insulin and oligomycin, the level of GLUT4 
phosphorylation will be investigated in both pathways.
Cardiomyocytes were labelled with [32Pj]. The cells were stimulated with either 
insulin for 30 min and / or oligomycin for 90 min (Section 2.2.2.2.3). GLUT4 
was immunoprecipitated from the cell lysate and cleaved with Endo LysC, as 
previously. The levels of phosphorylation under these two conditions were 
compared to phosphorylation in the basal state, in which the cells had had no 
additional treatment. Both insulin and oligomycin decreased the level of 
phosphorylation at both the N- and the C-termini of GLUT4 (Figure 4.12). 
There was a greater decrease at the N-terminus compared to the C-terminus. 
There was an extremely significant (p = 0.0004) decrease in the level of 
phosphorylation at the N-terminus of GLUT4 isolated from insulin-stimulated 
cells, compared to the level from basal cardiomyocytes. This result was 
consistent throughout six experiments. The effect of insulin on the 
phosphorylation state of GLUT4 was the inverse of that in adipocytes, where 
there was a significant increase in the level of GLUT4 phosphorylation.
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Oligomycin treatment significantly increased (p = 0.042) the level of 
phosphorylation at the N-terminus of GLUT4 isolated from insulin-stimulated 
cardiomyocytes. However, the increase in phosphorylation was not large 
enough to abolish the insulin-stimulated decrease in phosphorylation. At the C- 
terminus, the level of phosphorylation decreased to the same level after insulin 
and / or oligomycin treatment (~80% compared to the basal level of 100%). 
The data are from three to six independent experiments.
4.2.4.2.8 Relative Levels of Phosphorylation at the N- and C-terminus of 
GLUT4 Isolated From Cardiomyocytes
The relative levels of phosphorylation at both the N- and C-terminus of GLUT4 
were calculated. The percentage phosphorylation was calculated from the total 
GLUT4 phosphorylation per condition which was set to 100%. In the basal 
state, 76.6% of GLUT4 phosphorylation occurred at the C-terminus and 23.4% 
was at the N-terminus (Figure 4.13). There was relatively less phosphorylation 
at the N-terminus in cardiomyocytes compared to adipocytes, as in adipocytes 
56.0% of phosphorylation was at the C-terminus and 44.0% was at the N- 
terminus. There was a significant decrease (p = 0.0391) in the relative level of 
phosphorylation at the N-terminus of GLUT4 from insulin-stimulated 
cardiomyocytes, compared to cardiomyocytes in the basal state. Oligomycin 
treatment did not significantly change the relative level of phosphorylation in 
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Figure 4.12 The effect of insulin and / or oligomycin on the phosphorylation state at the N- and C-termini of GLUT4.
Cardiomyocytes were labelled with [32Pj] and treated for 30 min with insulin and / or 90 min with oligomycin. The data are the 
combined mean ± S.E.M. from three to six independent experiments. *, p<0.05. ***, p<0.001 (paired t-test; insulin compared with 
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Figure 4.13 Relative level of phosphorylation at the N- and C-terminus of GLUT4 in cardiomyocytes. Total GLUT4 per lane 
was set to 100% and the percentage of this that was phosphorylation at the N- and C-termini was calculated. The data are the 
combined mean ± S.E.M. from three to six independent experiments. *, p<0.05 (paired t-test; compared with basal).
210
4.2.4.2.9 Level of Phosphorylation of GLUT4 in Cardiomyocytes
The level of phosphorylation (mole phosphate / mole GLUT4) was calculated 
for the uncleaved GLUT4 protein isolated from basal cardiomyocytes. The 
method used was similar to that used in adipocytes (Section 2.2.5) except that 
the composition of the PKA assay was changed.
To determine whether the PKA assay was giving accurate results (Section 
4.2.4.2.6), the PKA assay was tested by the use of [y-32P] ATP [A]. The PKA 
assay was carried out using the [y-32P] ATP, and the phosphorylated kemptide 
was separated from [y-32P] ATP by the use of P81 phosphocellulose paper. 
The phosphorylated kemptide would bind to the P81 phosphocellulose but the 
[y-32P] ATP would not bind. The specific activity of the ATP (cpm / y 
phosphate) was quantified from the scintillation counts of the P81 paper. The 
specific activity of the [y-32P] ATP was also calculated by direct counting of the 
ATP as the concentration of the stock [y-32P] ATP was known. Both methods 
(the PKA assay and the direct counting) gave the same specific activity result 
for the [y-32P] ATP. This indicated that the PKA assay and separation of the 
resulting phosphorylated peptide was accurate. This assay was therefore used 
for the calculation of the stoichiometry of phosphorylation in cardiomyocytes.
The specific activity of ATP was calculated (cpm / pmole y phosphate) as well 
as the level of radioactivity incorporated into GLUT4 (cpm / pmole of GLUT4). 
The results were from three independent experiments and were reproducible. 
On average, there was 2.7 mole phosphate / mole GLUT4 (Table 4.7). This 
result was more sensible than the result obtained in adipocytes. However, the 
result may still be too high. If the value of 2.7 mole phosphate / mole GLUT4 
was correct then there would need to be a third phosphorylation site present in 
GLUT4 in either the N- or the C-terminal peptides.
211
The concentration of ATP in the cardiomyocyte cell was calculated from the 
value of ATP, experimentally determined from the ATP determination assay. 
As with the adipocytes, the experimentally calculated value was compared to 
the published values of the concentration of ATP in cardiomyocytes. From the 
ATP determination assay, and using the protein assay following cell lysis, the 
concentration of ATP in the cel! was calculated as 6.34, 0.34 and 0.44 nmole 
ATP / mg cell protein, for the three experiments respectively. These values 
differed from the published values of ATP in the cardiomyocyte. Values near to 
20 nmole ATP / mg cell protein have been reported in cardiomyocytes 
(Geisbuhler et al., 1984, Smolenski, 2000) (19.5 and 22.1 nmole ATP / mg cell 
protein, respectively). The fact that the experimental and published values 
were not in agreement suggested that the ATP determination assay was not 
accurate in cardiomyocytes and, thus, the stoichiometry of GLUT4 
phosphorylation may not be 2.7 mole phosphate / mole GLUT4.
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Experiment 1 2 3
ATP (cpm) 9416.6 3508.7 10841.3
ATP (pmole) 353.4 35.5 63.7
ATP (cpm / pmole 
y phosphate)
26.6 98.8 170.2
GLUT4 (cpm) 376 1255 1803
GLUT4 (pmole) 4.1 5.9 4.7





(mole phosphate / 
mole GLUT4)
3.48 2.16 2.24
Table 4.7 Quantification of the level of phosphorylation in basal cardiomyocytes.
The level of phosphorylation was calculated from the GLUT4 cpm / pmole and the 
ATP cpm / pmole y phosphate. The data are from three independent experiments.
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4.3 Discussion
Previous studies have reported the phosphorylation of GLUT4 in both 
adipocytes and skeletal muscle, and this site has been localised to the C- 
terminus of the protein (James et al., 1989a). However, no studies have 
investigated whether any of the other predicted phosphorylation sites were 
phosphorylated in vivo and, if they were, whether the phosphorylation had any 
significant effect on GLUT4 function. No studies had been carried out in 
cardiomyocytes.
The results presented in this chapter demonstrate that GLUT4 is 
phosphorylated in cardiomyocytes as well as in adipocytes. GLUT4 is therefore 
phosphorylated in all of the insulin responsive tissue in which it is expressed. In 
cardiomyocytes, glucose transport occurs in response to the stimulation of an 
additional pathway to the insulin signalling pathway that occurs in adipocytes. 
This additional pathway involves the activation of AMPK. The possibility 
therefore exists that the phosphorylation of GLUT4 may be involved in this 
additional pathway, as well as in the insulin signalling pathway.
The experiment carried out to determine the site of phosphorylation in primary 
adipocytes, by Lawrence et al, was repeated by Dr Frangoise Koumanov 
(Lawrence, Jr. et al., 1990a). The same result was found, the major 
phosphorylation site identified was in the C-terminal peptide. A single strong 
band containing 32P was identified at 10 kDa from the 32P scan, compared to a 
band of 8 kDa by Lawrence (Lawrence, Jr. et al., 1990a). The C- and N- 
terminal peptides did not run at their predicted molecular weight (7.4 and 9.4 
kDa, respectively). This could be because both peptides have acidic regions 
which could affect how the peptides ran on an SDS-PAGE gel. The difference 
between the two studies was that Lawrence et al did not have the use of an 
anti-N-terminal GLUT4 antibody. The band detected by Lawrence et al, from
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the use of an anti-C-terminal GLUT4 antibody, may have also contained the N- 
terminal peptide, which was not detected as there was no antibody available.
Cleaving GLUT4, isolated from 3T3-L1 adipocytes at day 5 of differentiation, 
resulted in the N- and C- terminal peptides resolving at a different molecular 
weight to the peptides that were derived from primary adipocyte cells. This 
could be because the GLUT4 was in the synthetic pathway and the 3T3-L1 
adipocytes were not fully differentiated. A different level of glycosylation could 
have affected how the GLUT4 ran on the gel. The C-terminal peptide did not 
correspond to a 32P-containing band but one of the bands identified by the anti- 
pSer10 antibody, raised in rabbit, did correspond to a 32P-containing band. The 
remaining 32P-containing band did not correspond to either the N- or C-terminal 
peptide. The fact that the C-terminal peptide appeared not to be 
phosphorylated could suggest that the N- but not the C-terminal peptide was 
phosphorylated during biosynthesis. This experiment was only carried out once 
and so it needs to be repeated to confirm this conclusion. However, the 
Western blot analysis did lead to the conclusion that the anti-pSer10 and the 
anti-C-terminal GLUT4 antibodies do not cross react with the opposing 
peptides.
Following CNBr cleavage of the GLUT4 isolated from primary adipocytes, both 
the N-and the C-terminal peptides were detected at the same molecular weight 
as the 32P-containing band. Due to the fact that the antibodies do not cross 
react with the peptides, the N- and C- terminal peptides must be running at the 
same molecular weight, even though the predicted size of the two peptides 
differs. This provides an explanation as to why Lawrence et al did not identify 
the second phosphorylation site at the N-terminus of GLUT4.
To check that both the N- and the C-terminal peptides were phosphorylated in 
adipocytes, it would be useful to cleave GLUT4 with a different agent, other 
than CNBr, so that the N- and C-terminal peptides would be resolved at 
different molecular weights. This would also be essential for investigating the
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differences in phosphorylation at each terminus, caused by different agents. As 
multiple bands were identified by the use of the anti-pSer10 antibody raised in 
rabbit, the use of a different anti-N-terminal antibody would help to identify the 
N-terminal peptide. Endo LysC was tested as an alternative to the use of 
CNBr. The monoclonal anti-C-terminal antibody and the anti-pSer10 antibody 
raised in sheep recognised the C- and N- terminal peptides respectively, at the 
predicted molecular weights. Endo LysC can, therefore, be used in the study of 
GLUT4 phosphorylation as the peptides from the N- and C- termini of GLUT4 
resolve at different molecular weights on the gel and so phosphorylation at 
either site can be identified. The anti-pSer10 antibody raised in sheep, gave a 
stronger signal than that previously seen in the experiments with the anti- 
pSer10 antibody raised in rabbit. The sheep anti-pSer10 antibody was, 
therefore, used to identify the N-terminal peptide in future experiments.
Endo LysC proved to be a very a useful alternative to CNBr. The use of Endo 
LysC led to the identification of two distinct phosphorylation sites in GLUT4, 
both in adipocytes and cardiomyocytes. The phosphorylation sites occurred in 
peptide 1 - 5 0  and peptide 267 -  495. The potential phosphorylation sites in 
each of the peptides can be found by comparing the peptide sequence with the 
potential domains in which they are found in GLUT4 (Table 4.4). The red 
residues are found in the cytoplasmic region of the cell, the blue residues 
correspond to the transmembrane region and the green residues correspond to 
the extracellular domain. The potential phosphorylation sites will probably be 
intracellular (red) as they will be accessible to intracellular kinases. However, it 
cannot be ruled out that GLUT4 may be phosphorylated on extracellular 
residues (blue). In the recycling vesicles, the extracellular residues are intra­
luminal and will be available for phosphorylation by kinases inside the vesicle. 
The first 24 amino acids in peptide 1 - 5 0  are predicted to be intracellular. This 
includes 2 serine, 2 threonine and 0 tyrosine residues (Ser3, Ser10, Thr21 and 
Thr2^ . Residues 46 -  50 are extracellular and do not contain any residues that 
could be phosphorylated. In peptide 267 -  495, there are 5 serine residues, 6
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threonine residues and 0 tyrosine residues in the intracellular region of GLUT4 
(Ser274, Ser261, Ser412, Ser480, Ser488, Thr283, Thr351, Thr471, Thr475, Thr482 or 
Thr488). The potential phosphorylation sites in the C-terminus can be narrowed 
down further by comparing the C-terminal peptide obtained from Endo LysC 
cleavage (residues 267 - 495) to the CNBr cleaved fragment (residues 446 -  
509). There are no extracellular residues in the CNBr cleaved fragment and so 
phosphorylation must occur on the intracellular residues. There are 2 potential 
serine phosphorylation sites and 4 threonine sites between residues 446 -  495 
(Ser480, Ser488, Thr471, Thr475, Thr482 or Thr486). HPLC analysis showed that 
serine was the only phosphorylated residue present in GLUT4 (Lawrence, Jr. 
et al., 1990a). Therefore the predicted phosphorylation sites would be serine 3 
or serine 10 at the N-terminus and serine 480 or serine 488 at the C-terminus 
of GLUT4. The kinase must be located in the cytoplasm because the predicted 
phosphorylation sites occur on intracellular residues. When assessing these 
sites as potential phosphorylation sites, the phosphorylation ‘score’ (Table 4.1) 
needs to be taken into account. The score is a number between 0 - 1  and 
represents the likelihood that a site is phosphorylated. The higher the number, 
the more likely it is that the site is a phosphorylation site. In the N-terminal 
peptide, serine 3 and serine 10 have scores of 0.003 and 0.263 respectively. 
Although both numbers are below the usual threshold for phosphorylation of 
0.5, serine 10 is the most likely candidate. A score of 0.003 is very low and so 
serine 3 is extremely unlikely to be phosphorylated. In the C-terminal peptide, 
serine 480 and serine 488 have scores of 0.204 and 0.993. As GLUT4 had 
previously been shown to be phosphorylated at serine 488 and because the 
score is high, it is fair to conclude that the phosphorylation site at the C- 
terminus is serine 488. A novel phosphorylation site at serine 10 has, 
therefore, been identified at the N-terminus of GLUT4, as well as confirming 
the presence of the phosphorylation site previously reported at serine 488 
(Lawrence, Jr. et al., 1990a). There was a possibility that other phosphorylation 
sites could have been missed i.e. if the phosphorylated peptides had been too 
small to be detected on the tris-tricine gel. The region where such peptides
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could occur after Endo LysC cleavage is the large intracellular loop, residues 
223 -  287. Four small peptides could be missed in this region (Table 4.4). 
However, an 18 kDa peptide, residues 196 -  360, would have been present on 
the 32P scan after GLUT4 had been cleaved with CNBr. The 18 kDa peptide 
would have included the regions that could not have been detected after Endo 
LysC digestion. However, an 18 kDa 32P-containing peptide was not present on 
the 32P scan and so phosphorylation at in this region can be excluded. As 
cleavage had been carried out using two different methods, phosphorylation 
could have occurred in any of the intracellular sites and it would have been 
identified. This was also shown quantitatively. The sum of the intensities of the 
32P-containing N- and C- terminal peptides equals the intensity of the 32P- 
containing, uncleaved GLUT4 band. This showed that all of the 
phosphorylation sites had been accounted for and are found in the N- and C- 
terminal peptides. The experimental data is only taken from one experiment so 
this needs to be repeated. However, the experimental data does corroborate 
the theoretical data.
Insulin and okadaic acid increased the level of phosphorylation of GLUT4 at 
both the N- and the C- termini. However, insulin had a greater increase at the 
N-terminus and okadaic acid had a greater increase at the C-terminus. It had 
previously been reported that insulin did not have any effect in the level of 
phosphorylation of GLUT4 (James et al., 1989a). However, in the present 
study, insulin significantly increased the level of phosphorylation at both the N- 
and the C-terminus of GLUT4.
Okadaic acid (a protein phosphatase inhibitor) had been reported to increase 
the phosphorylation state of GLUT4 threefold at the plasma membrane relative 
to the intracellular pool. An increase of twofold was identified in this study. In 
the present study, the phosphorylation state was studied in total cellular 
GLUT4. The level of phosphorylation would therefore be lower than the three 
fold increase seen in plasma membrane. The experiment was only carried out 
once and needs to be repeated to get a more accurate result.
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On average, 56% of the GLUT4 phosphorylation occurred at the C-terminus 
and 44% occurred at the N-terminus. This did not change significantly with 
insulin or okadaic acid treatment. Equal importance must therefore be given to 
each of the sites. The fact that both phosphorylation sites are phosphorylated 
to the same extent could lead to the conclusion that the phosphorylation sites 
are cooperative; one site has to be phosphorylated before the other site is 
phosphorylated.
CKII inhibitors were used to try and identify the kinase responsible for 
phosphorylating GLUT4 at serine 10. If the kinase could be identified, it might 
be useful when the function of the phosphorylation site has been clarified. The 
kinase (or phosphatase) could be a useful target if a defect in the GLUT4 
phosphorylation was involved in the decreased effect of insulin signalling in 
Type 2 diabetes. Neither of the inhibitors tested had a definitive effect on the 
phosphorylation state of GLUT4. It is possible that GLUT4 is phosphorylated 
by an, as yet, unidentified kinase that is not inhibited by either of the inhibitors 
tested in this study. Neither CKII inhibitor affected the phosphorylation site in 
the C-terminus of GLUT4 but both CKII inhibitors did have an effect at the N- 
terminal peptide. DRB treatment only resulted in a small decrease in the level 
of phosphorylation at the N-terminus of GLUT4 from insulin-stimulated 
adipocytes. TBB treatment resulted in a greater decrease in the level of 
phosphorylation of GLUT4 from insulin-stimulated adipocytes rather than from 
basal adipocytes. The greatest decrease in phosphorylation was seen at the N- 
terminus of GLUT4 when insulin and isoproterenol treated adipocytes were 
subsequently treated with TBB. It would be expected that the CKII inhibitors 
would have a greater effect at the N-terminus of GLUT4 because there is not a 
CKII phosphorylation site in the C-terminal peptide. The fact that the results 
were variable between experiments or that only a single test experiment was 
carried out means that the experiments need to be repeated to confirm these 
results. However, both TBB and DRB did have an effect on N-terminal 
phosphorylation, even if it was small. The experiments that tested the kinase
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inhibitors suggested that CKII was perhaps involved in phosphorylation at the 
N-terminus of GLUT4.
The calculation of the stoichiometry of phosphorylation in GLUT4 from basal 
adipocytes was neither sensible nor reproducible between the two 
experiments. The calculation of the specific activity of ATP (Table 4.6) did not 
correspond to the reported 500 cpm / pmole y phosphate figure that had 
previously been reported (Nishimura et al., 1991). If the specific activity of ATP 
was 500 cpm / pmole y phosphate then the calculated stoichiometry was 0.1 
mole phosphate / mole GLUT4 which corroborates the individual studies 
carried out by James and Nishimura (James et al., 1989a, Nishimura et al., 
1991). If the level of phosphorylation was 0.1 mole phosphate / mole GLUT4, 
then 0.05 mol would be at the N-terminus and 0.05 mol would be at the C- 
terminus. Hence, only a small population of GLUT4 would be phosphorylated 
in adipocytes at any one time. The ATP determination assay appears to be 
accurate in determining the level of ATP. The PKA assay is therefore likely to 
be the part of the specific activity measurement in which the error has 
occurred. The specific activity measurements in adipocytes therefore need to 
be repeated but using the PKA assay carried out in cardiomyocytes. A control, 
using [y-32P] ATP as an ATP source, was carried out in cardiomyocytes which 
led to the conclusion that using the different method for the PKA assay was 
accurate (Section 4.2.4.2.9). This will confirm whether the stoichiometry of 0.1 
mole phosphate / mole GLUT4 is correct.
When glucose transport was activated in cardiomyocytes, either by insulin and 
/ or oligomycin, the level of phosphorylation decreased at both the N- and the 
C-termini of GLUT4, compared to the basal level of phosphorylation. Insulin 
significantly decreased the level of phosphorylation at the N-terminus of 
GLUT4 (Figure 4.12). This was the inverse to the effect insulin had on the 
adipocytes (Figure 4.8 A). In adipocytes it was thought that the phosphorylation 
of GLUT4 may promote internalisation (Section 1.6.3). However, this
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hypothesis does not hold in cardiomyocytes. Oligomycin treatment significantly 
increased the level of phosphorylation at the N-terminus of insulin-stimulated 
cardiomyocytes.
Although the effect of insulin and oligomycin is to decrease the phosphorylation 
state of GLUT4, the function of the phosphorylation cannot be elucidated from 
this experimental data. There is a decrease in the level of GLUT4 
phosphorylation in response to both signalling pathways in cardiomyocytes, 
both the insulin-stimulated and the AMPK-activated pathways. Phosphorylation 
of GLUT4 could therefore provide a point of convergence for the two pathways, 
for example, through the activation / deactivation of the kinase(s) and 
phosphatase(s) responsible for the phosphorylation state of GLUT4.
GLUT4 is phosphorylated to a greater extent at the C-terminus in 
cardiomyocytes. In the basal state, 76.6% of GLUT4 phosphorylation occurred 
at the C-terminus and 23.4% at the N-terminus. The stoichiometry of 
phosphorylation resulted in a level of 2.7 mole phosphate / mole GLUT4. This 
value is probably more accurate than that calculated from adipocytes. A test 
using [y-32P] ATP was carried out and the PKA assay and subsequent 
purification of peptide was accurate. No fat was present in the cardiomyocyte 
so no fat contamination could have affected the results. This ruled out the 
concerns from this experiment carried out in adipocytes. If cardiomyocytes had 
a total of 2.7 mole phosphate / mole GLUT4 then 2.07 mole of phosphate 
would be at the C-terminus and 0.63 mole of phosphate would be at the N- 
terminus. There would therefore be two phosphorylation sites at the C-terminus 
of GLUT4. It is likely that this would be at serine 480 as well as the already 
identified serine 488 and serine 10. No missed phosphorylation sites were 
identified in cardiomyocytes (Section 4.2.4.2.4). This confirmed that the 
phosphorylation sites were only present in the N- and C-terminal fragments. 
However, it did not confirm how many phosphorylation sites were on each 
peptide. Further investigation is needed to confirm this additional 
phosphorylation site. This could be done by using a different cleavage agent,
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which would cleave GLUT4 between serine 480 and serine 488. Another 
alternative, discussed in chapter 5, involves the use of a GLUT4 construct with 
a haemagglutinin tag in the first exofacial loop, mutated at both serine 10 and 
serine 488. The serine residues are both mutated to alanine residues and 
cannot be phosphorylated. The mutated construct could be transfected into 
cells and the cells labelled with [32Pj] as before. The mutated GLUT4 protein 
could be immunoprecipitated from the cell lysate by the use of an anti-HA 
antibody. Following Endo LysC cieavage, autoradiography would detect if there 
has been any 32P incorporated into GLUT4 other than at serine 10 and serine 
488.
The experimental and published values for the concentration of ATP in the 
cardiomyocyte were not in agreement. One conclusion would be that the ATP 
determination assay was not accurate in cardiomyocytes. However, it has been 
reported that in anaerobic conditions, the level of ATP in the cell is 0.4 nmole 
ATP / mg cell protein (Geisbuhler et al., 1984). This value of 0.4 nmole ATP / 
mg cell protein is similar to two of the experimentally calculated values (0.34 
and 0.44 nmole ATP / mg). Therefore, the ATP determination assay could be 
correct if the cells were hypoxic by the end of the two hour [32PJ incubation. If 
the cells were hypoxic then there could have been insufficient gassing of the 
buffer throughout the incubation or the amount of buffer in which the cells are 
suspended could have been too small. In which case, the stoichiometry 
calculated (~2 mole phosphate / mole GLUT4) is not representative of basal 
cardiomyocytes but rather that of hypoxic cardiomyocytes.
If the two hour [32PJ incubation does lead to the cells becoming hypoxic, then 
the results of the effect of insulin on the level of phosphorylation need to be 
taken with caution. Insulin caused an increase in the level of phosphorylation in 
adipocytes but a decrease in the level of phosphorylation in cardiomyocytes. It 
could therefore be that insulin, by itself, would also cause an increase in the 
level of phosphorylation in cardiomyocytes above the true basal level. If 
GLUT4 is phosphorylated at 2 mole phosphate / mole GLUT4 in hypoxic
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conditions and insulin acts by decreasing the level of phosphorylation, insulin 
might be over-riding the affect of the hypoxia and decreasing the level of 
phosphorylation to a lower level (e.g. a level of 0.2 mole phosphate / mole 
GLUT4) but this may still be an increase in phosphorylation from true basal 
levels (0.1 mole phosphate / mole GLUT4). The fact that oligomycin did not 
have a significant effect on the level of phosphorylation would be explained by 
the fact that the cells are already hypoxic.
A lot of work needs to be carried out in the investigation of GLUT4 
phosphorylation. One of the most important experiments that need to be 
carried out initially is the investigation into whether the ATP determination 
assay was accurate in cardiomyocytes. The ATP determination assay needs to 
be carried out on freshly isolated cardiomyocytes, cells that have been 
incubated for two hours under the experimental conditions previously used and 
cardiomyocytes incubated in anaerobic conditions (N2 atmosphere and no 
glucose), the level of ATP in the cell can then be determined. The ATP 
determination assay also needs to be carried out to investigate different 
conditions for the two hour incubation, for example, incubating the 
cardiomyocytes in a larger volume of buffer, to help prevent the cells becoming 
hypoxic. This would then be used to determine the optimal conditions for the 
[32Pi] incubation that will not lead to hypoxic cells.
Another important experiment that needs to be carried out is to find out 
whether the cardiomyocytes, after the two hour incubation, were in fact 
hypoxic. The release of lactate dehydrogenase (LDH) into the serum is a 
recognised marker for myocardial hypoxia. The cardiomyocytes can therefore 
be tested whether they are hypoxic by measuring the concentration of LDH in 
the extracellular medium. Commercial kits are available to measure the LDH 
concentration spectrophotometrically. If the cells are becoming hypoxic during 
the two hour incubation, then the effect of insulin and oligomycin on the level of 
GLUT4 phosphorylation of true basal cells needs to be tested again in 
cardiomyocytes.
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The level of ATP / mg cell protein needs to be calculated for all the different 
conditions tested. If different conditions alter the level of ATP in the cell, then 
the stoichiometry of phosphorylation could not be calculated from the relative 
level of phosphorylation at each terminus from each condition (Figure 4.13). 
The specific activity of ATP would need to be calculated, separately, for each 
condition.
Once the labelling conditions have been optimised and the ATP determination 
assay results in a value similar to the published values for basal 
cardiomyocytes, then the ATP concentration, the ATP specific activity and the 
GLUT4 stoichiometry of phosphorylation need to be determined under basal, 
insulin and hypoxic conditions.
A further extension to this study would be to investigate whether GLUT4 is 
phosphorylated at both termini at the same time or if the phosphorylation sites 
have different effects and different locations within the cell. This could be 
investigated using confocal microscopy once highly phospho-specific 
antibodies have been raised to each phosphorylation site.
4.4 Conclusion
The research conducted and which is described in this chapter identified two 
phosphorylation sites in GLUT4. One of these is situated in the N-terminal 
peptide between residues 1 - 5 0  and the other in the C-terminal peptide 
between residues 267 -  495. From the use of a phosphorylation site prediction 
program, the sites of phosphorylation are predicted to be at serine 10 and 
serine 488. The site at the N-terminus of GLUT4 has not been identified prior 
to this study but a site at serine 10 was predicted to be phosphorylated due to 
its homology to the N-terminus of GAD65a and a known phosphorylation site at 
the corresponding serine residue. The phosphorylation site at the C-terminus 
of GLUT4 has previously been identified (Lawrence, Jr. et al., 1990a). GLUT4
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is phosphorylated in all of the insulin-responsive tissues in which the protein is 
expressed. Phosphorylation occurs in cardiomyocytes, which has not 
previously been investigated, in addition to the already identified adipocytes 
and skeletal muscle (James etal., 1989a).
Insulin has opposing effects in the level of phosphorylation in adipocytes 
(increases) and cardiomyocytes (decreases). This difference could occur 
because adipocytes and cardiomyocytes are two distinct cell types. Insulin has 
a greater affect on the level of phosphorylation at the N-terminus compared to 
the C-terminus. Treatment with okadaic acid, the PPI and PPIIa inhibitor, leads 
to increases in glucose transport and the level of phosphorylation in 
adipocytes, in agreement with Lawrence et al (Lawrence, Jr. et al., 1990b). 
This increase occurs at both termini, but okadaic acid treatment leads to a 
larger increase in the level of phosphorylation at the C- than at the N-terminus. 
44% of the GLUT4 phosphorylation occurs at the N- terminus and 56% occurs 
at the C-terminus in basal adipocytes. The fact that each site is phosphorylated 
equally could suggest that phosphorylation at one site is required for 
phosphorylation at the second site. This ratio does not significantly change in 
response to stimulation by insulin or okadaic acid. The quantification of 
phosphorylation does not give a sensible result and error probably occurred 
during the estimation of the specific activity of ATP. However, if the value of the 
specific activity of ATP is taken from published data (Nishimura et al., 1991), 
GLUT4 has 0.1 mole phosphate / mole GLUT4 which agrees with previous 
reports (James et al., 1989a, Nishimura et al., 1991). In which case, 0.05 mol 
phosphate occurs at the N-terminus and 0.05 mol phosphate at the C-terminus 
per pmole of GLUT4.
Due to inconsistencies in the experiments, the kinases responsible for 
phosphorylating GLUT4 in adipocytes were not definitively identified. However, 
the results suggest that CKII phosphorylates GLUT4 at serine 10. This agrees 
with the predicted kinase generated from a kinase prediction program.
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In addition to insulin, oligomycin treatment leads to decreases in the 
phosphorylation state of GLUT4 in cardiomyocytes. There is a greater effect at 
the N-terminus than the C-terminus. GLUT4 phosphorylation decreases in 
response to stimulation of glucose transport. Glucose transport is stimulated by 
two different mechanisms in cardiomyocytes. One involves stimulation by 
insulin and the other by contraction and hypoxia which involves the activation 
of AMPK. Oligomycin activates AMPK and so stimulates the second 
mechanism. GLUT4 is phosphorylated to a higher extent in cardiomyocytes 
compared to adipocytes. In the basal state, there are 2.7 mole of phosphate / 
mole of GLUT4. 76% of this phosphorylation is at the C-terminus and 24% at 
the N-terminus. Thus, 2 moles of phosphate are at the C-terminus and 0.7 
moles of phosphate at the N-terminus per mole of GLUT4. This would imply 2 
phosphorylation sites at the C-terminus, the second site probably being at 
serine 480. The subcellular localisation of each site would be paramount in the 
understanding of the role of each phosphorylation site. Previous reports of 
subcellular localisation are misleading due the existence of additional 
phosphorylation sites. The study has provided an interesting point for future 
investigation; to elucidate the reason why insulin increases phosphorylation in 
adipocytes and decreases the phosphorylation in cardiomyocytes. Whilst this 
study quantified the level of phosphorylation at each terminus, it did not give 
any indication as to the function of each phosphorylation site. The effect each 
phosphorylation site has on the translocation of GLUT4 to the plasma 
membrane will be discussed in chapter 5.
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5 The Effect of Each Phosphorylation Site on the 
Translocation of GLUT4 to the Plasma Membrane
5.1 Introduction
Phosphorylation is a transient phenomenon in living cells. It is, therefore, 
difficult to study the function of the phosphorylation site, especially if the kinase 
and phosphatase involved in the phosphorylation is unknown. Many studies 
designed to investigate the role of phosphorylation in various cellular proteins 
involve the use of site-directed mutagenesis to mutate the residues of interest. 
These mutant proteins were designed to mimic either a phosphorylated residue 
or a non-phosphorylated residue (Fushimi et al., 1997, Namchuk et al., 1997, 
Jarvis et al., 2004).
Transfection studies involving the mutant proteins are often carried out in cell 
lines that express very low levels of the protein of interest, so the effect of the 
mutation can be monitored without any interference from the wild type protein. 
When studying the effect of GLUT4 on insulin-stimulated glucose transport, 
NIH-3T3 fibroblasts and Chinese Hamster Ovary (CHO) cells are often the cell 
types of choice because the cells do not express GLUT4 (Hudson et al., 1992, 
Kanai et al., 1993b). However, caution must be taken in interpreting this data 
because NIH-3T3 fibroblasts and CHO cells cannot mimic the insulin sensitive 
tissues (adipose and muscle cells) in which GLUT4 is found. This is because 
they do not have the same cellular machinery. For example, the cells express 
very low levels of the insulin receptor (Kanai et al., 1993a). This problem could 
partially be overcome by co-expressing the insulin receptor with GLUT4, but 
the cells are less insulin responsive than adipose cells and so are not an ideal 
model to use (Kanai et al., 1993b). A tissue culture model of primary 
adipocytes is available in which 3T3-L1 fibroblasts are differentiated into 
adipose-like cells. Many groups in the GLUT4 field work exclusively with this
227
model and it is a frequently used model in GLUT4 transfection studies. The 
3T3-L1 adipocyte cells have increased sensitivity to insulin (Reed et al., 1977, 
Rubin et al., 1978) and contain the correct insulin signalling machinery. 
However, there are problems in using 3T3-L1 adipocytes in studies involving 
the transfection of mutated GLUT4 proteins because the cells do not 
differentiate completely or uniformly. In addition, the cells have been 
immortalised and so have characteristics that are not found in normal cells, for 
example, aneuploidy (Quon et al., 1993). These problems have been 
overcome by the development of a method for transfecting DNA into primary 
adipocyte cells by the use of electroporation. After one day in culture, there 
was a high level of expression of the transfected protein in the cells and the 
cells remained insulin responsive (Quon et al., 1993). This was an advantage 
as it has been reported that primary adipocytes lose insulin responsiveness 
and GLUT4 expression after several days in culture (Hajduch et al., 1992, 
Gerrits et al., 1993). An epitope tag, haemagglutinin (HA), had been cloned 
between residues 67 and 68 in the first exofacial loop of GLUT4 (GLUT4-HA) 
(Quon et al., 1994) and thus provides a method to discriminate between 
endogenous and transfected GLUT4. Following transfection of the GLUT4-HA 
construct into primary adipocytes, GLUT4 translocation could be studied by 
detection of the HA tag without any interference from wild type GLUT4 present 
in the cell. It has been reported that insulin stimulated a 4.3-fold recruitment of 
transfected GLUT4-HA to the cell surface (Quon et al., 1994). This insulin 
response was not as large as that reported in freshly isolated cells (15- to 20- 
fold) (Holman et al., 1990). This decrease in the fold insulin response, 
compared to freshly isolated cells, occurred because electroporation and 
culturing led to an elevated rate of basal glucose transport, i.e. more GLUT4 
was present at the plasma membrane in basal adipocytes (Quon et al., 1993). 
A double-antibody binding assay was carried out to detect the level of 
transfected GLUT4 at the plasma membrane in either basal or insulin- 
stimulated cells. The cells were incubated with an anti-HA antibody, followed 
by a secondary antibody. The anti-HA antibody would only bind to the GLUT4
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at the plasma membrane in intact cells because the HA epitope was present in 
the first exofacial loop of GLUT4. The transfected GLUT4 was detected at the 
plasma membrane with no interference from the endogenous GLUT4 (Quon et 
al., 1994).
The aim of the work described in this chapter was to mutate the two 
phosphorylated serine residues in GLUT4, serine 10 and serine 488. The effect 
of the mutations, and ultimately the effect of the phosphorylation sites, on the 
translocation of GLUT4 to the plasma membrane was investigated using an 
assay adapted from the translocation assay reported by Quon and colleagues 
(Quon et al., 1994). The effects of single mutations (at one site only) and 
double mutations (at both phosphorylation sites) were both investigated.
5.2 Results
5.2.1 Site-Directed Mutagenesis of the Phosphorylation Sites 
at Serine 10 and Serine 488 in GLUT4
Site-directed mutagenesis is an invaluable technique in which specific 
mutations are carried out at specific sites in DNA. This allows an investigation 
into the contribution specific amino acids have on the function of the protein. 
More importantly, in the study described here, it was used to help to determine 
the effect each phosphorylation site had on GLUT4 translocation to the plasma 
membrane. The phosphorylated residue, serine in the case of GLUT4, was 
mutated to alanine to represent a constitutively unphosphorylated form of the 
residue. The serine was also mutated to aspartic acid to represent a 
constitutively phosphorylated form of the residue, by mimicking the negative 
charge of the phosphorylated serine (Figure 5.1).
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Figure 5.1 The structure of the amino acids involved in the mutagenesis.
The vector containing a haemagglutinin (HA) tagged human GLUT4 construct 
was a kind gift from Dr. S. W. Cushman. The GLUT4 DNA was originally 
cloned from human intestinal and muscle libraries (Fukumoto et a/., 1989). The 
site-directed mutagenesis was carried out on the double stranded GLUT4-HA 
DNA vector so single mutations were achieved, i.e. a mutated residue at one 
phosphorylation site and the wild type residue at the other phosphorylation site. 
Double mutants were also carried out so that each phosphorylated residue was 
mutated to the same residue i.e. alanine 10 and alanine 488 or aspartic acid 10
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and aspartic acid 488. The nomenclature used to depict the mutations involves 
the use of the single letter abbreviation for the amino acids involved. The 
amino acid in wild type GLUT4 is given, followed by the position of the residue 
in the protein and finally the amino acid generated in the mutation. For 
example, mutating the serine residue at residue number 10 to alanine is written 
as S10A.
Oligonucleotide primers were designed to be complementary to the region of 
DNA surrounding the amino acids to be mutated. The serine at position 10 in 
GLUT4 was mutated from TCC to GCC (in the case of alanine) and to GAT (in 
the case of aspartic acid). The serine at position 488 was mutated from TCT to 
GCA (in the case of alanine) and to GAT (in the case of aspartic acid) (Section 
2.2.11.1). An example of the S488A mutagenesis is given below. Essentially 
the same method was carried out for each mutation but the conditions used did 
differ and these will be outlined. A schematic of the method used is illustrated 
in Figure 5.2.
Polymerase chain reaction (PCR) was carried out using the wild type GLUT4- 
HA vector with the alanine 488 mutagenesis primers (Section 2.2.11.2). The 
primers were complementary to opposite strands of the vector and used to 
amplify and extend the vector. Incorporation of the primers would result in a 
mutated vector. Any vector that was produced during the PCR was selected by 
use of the endonuclease Dpn 1. Dpn 1 digests methylated and hemi- 
methylated DNA. Most of the DNA isolated from E. coli strains are methylated 
whereas the vector generated in the PCR is not methylated. Dpn 1 therefore 
digests the parental vector but leaves the PCR product intact. The Dpn 1 
digested PCR product was run on an agarose gel to detect any vector present 
in the sample (Figure 5.3 A).
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GLUT4-HA
GLUT4-HA gene in the pCis2 plasmid. Serine (black) 
is the amino acid to be mutated. Oligonucleotide primers 
were designed to be complimentary to the plasmid except 
for the amino acid to be mutated (red). In this example 
serine is being mutated to alanine.
By the use of polymerase chain reaction, the plasmid is 
denatured and the primers anneal to the plasmid. DNA 
polymerase extends and incorportes the primers into the 
plasmid.
Dpn 1 digestion of the parental vector results in a plasmid 
containing the desired mutation.
Figure 5.2 A schem atic of the method used to mutate the GLUT4-HA vector.
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A band was present in the PCR product at about 8 kb (Figure 5.3 A, lane 2), 
although there was a smear down the entire lane. The exact weight of the band 
was hard to determine as the markers (Figure 5.3 A, lane 1) were not well 
resolved in the 8 kb region. However, the band corresponded approximately to 
the molecular weight of the GLUT4-HA vector. The predicted molecular weight 
of the circularised GLUT4-HA vector was 7.4 kb; the pCis2 vector was 5.4 kb 
and GLUT4-HA was 2.0 kb. The vector was likely to contain GLUT4 that 
contained the S488A mutation because ail of the parental vector should have 
been digested by Dpn 1. Lane 2 did contain a smear throughout the entire 
length of the lane. This was probably because the 7.4 kb vector was relatively 
large and so the DNA polymerase did not always amplify the entire vector in 
one continuous step. The smear was, therefore, probably due to different linear 
truncations of the GLUT4-HA vector generated during the amplification.
The mutations in the GLUT4-HA vector were all carried out using slightly 
different conditions to the one exemplified (Section 2.2.11.2). Initially, the DNA 
polymerase used in the mutagenesis PCR reaction was Platinum® Pfx DNA 
Polymerase [I], The polymerase is in an inactive form, bound to the Platinum® 
antibody and, following the denaturation step in the PCR, the enzyme activity is 
restored. This imitates a ‘hot start’ and so the polymerase provides increased 
specificity, sensitivity and yield and is, therefore, an ideal candidate to be used 
in site-directed mutagenesis. Platinum® Pfx DNA Polymerase was successfully 
used in the generation of the S10A mutant. However, other mutations could not 
be generated in this way, so different DNA polymerases were also tested. 
PfuTurbo DNA polymerase [ST] and BIO-X-ACT Long DNA Polymerase [BL] 
were tested. Both of these polymerases are designed for use in the 
amplification of long, complex genomic targets with high-fidelity. BIO-X-ACT 
Long DNA polymerase was of no use in the mutagenesis because primer 
dimers formed and no other product was visible in the gel. A hot-start was 
carried out with the polymerase but the primer dimers still formed. The primer 
dimers did not form with either of the other two polymerases used. Therefore,
233
the BIO-X-ACT Long DNA polymerase was not used for generating any of the 
mutants. PfuTurbo DNA polymerase was used for the remaining mutagenesis 
reactions. PfuTurbo DNA polymerase produced a smear as identified by 
agarose gel electrophoresis (Figure 5.3). This could be due to mis-annealing of 
the primers so that the full-length product was not produced. However, the full 
length, circularised, mutated product could also be present. Increasing the 
annealing time in the PCR reaction did decrease the intensity of the smears on 
the gel. Different annealing temperatures (55 °C to 64 °C) were required for the 
generation of each mutant due to the different properties of the primers used in 
each case. Increasing the elongation time was the major factor which 
increased the efficiency of the mutagenesis. The elongation time was 
increased from 1 min / kb to 2.5 min / kb. This was because the vector was 
large and so the extra time would enable the additional elongation needed to 
generate the complete circularised vector.
Following the Dpn 1 digestion, the resulting vector was transformed into XL1 
Blue E. coli competent cells. Single colonies were isolated and grown before 
the DNA was isolated and purified. A restriction digest was carried out on the 
resultant DNA using the enzyme Xba 1. This ensured that the vector contained 
GLUT4. There were two Xba 1 sites in the GLUT4-HA vector. One site was 35 
residues before the initiation codon for GLUT4 and the second Xba 1 site was 
1915 residues into the GLUT4 construct. Digestion using Xba 1 would 
generate a band of 1950 bp if the vector contained GLUT4-HA that had no 
insertions or deletions generated in the PCR. The restriction digest was also 
carried out using wild type GLUT4-HA DNA as a positive control. The products 
of the digestion were run on an agarose gel (Figure 5.3 B). The digest of the 
PCR product (Figure 5.3 B, Lane 2) and the positive control (Figure 5.3 B, 
Lane 3) each contained a fragment at the same molecular weight, about 2000 
bp, which corresponded to the molecular weight of the product that would be 
generated if GLUT4-HA construct was present in the vector. As both digestions
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contained a band at the same molecular weight, no insertions or deletions had 
occurred in the GLUT4-HA vector during the PCR.
To ensure that the vector contained the desired mutation in GLUT4, the DNA 
was sequenced (Figure 5.4). The red bases correspond to residues that were 
identical in both the wild type GLUT4-HA vector and the PCR product. The 
blue bases correspond to residues that were different in each sample i.e. a 
mutation had occurred. The desired mutation had occurred because serine 488 
was mutated from TCT to GCA. This corresponded to alanine 488.
The first 35 residues sequenced did not have a strong correlation between the 
sequence of the PCR product and the wild type vector. This was because it 
took about 50 bases before the sequence started to become accurate after the 
sequencing primer bound to the vector. No other mutations had therefore 
occurred at the C-terminus of the vector apart from at alanine 488.
After all of the single mutants had been generated, the double mutation was 
made by mutating the GLUT4-HA vector (that contained a single mutation) at 
the second site. The mutagenesis was carried out successfully for all of the 
desired mutations. The mutations obtained at a single site in the vector were 
S10A, S10D, S488A, and S488D. Double mutations were obtained for S10A 
and S488A, or S10D and S488D.
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Figure 5.3 Site-directed mutagenesis of serine 488 to alanine 488 at the C-terminus of GLUT4. (A) PCR was carried out to 
specifically mutate serine 488 to alanine 488. Lane 1 = 1 kb plus DNA ladder [I], lane 2 = PCR product. (B) Restriction digestion of 
the m ini-preped DNA. Lane 1 = 1 kb plus DNA ladder, lane 2 = DNA from PCR product, lane 3 = GLUT4-HA wild type positive 
control.
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PCR GCCTA-GNCTTNC— CflflGNTNCGGTTC-CCNGNTGGGCTTCTTCRTCTTCfiCCTTCTTflflGRGTRCCTGRRflCTCGRGGCCGGRCGTTTGflCCflGflTCTCRGCTGCCTTCCRCCGGflCRCCCGCfiCTT
GLUT4 GCCCTRCGTCTTCCTTCTRTTTGCGGTCCTCCTGCTGGGCTTCTTCRTCTTCflCCTTCTTRflGflGTRCCTGRRHCTCGRGGCCGGRCGTTTGRCCRGRTCTCflGCTGCCTTCCflCCGGflCRCCCTCTCTT
131 140 150 1G0 170 180 190193
PCR T T RGRGCRGGRGGT GRRRCCCRGCRCRGRRC T T GRG TR T T T RGGGCCRGRTGRGRRCGRC TGR 
GLUT4 TTAGAGCAGGRGGTGRflflCCCAGCRCRGAACTTGAGTATTTRGGGCCAGATGRGARCGACTGR
Figure 5.4 Alignment of the DNA sequence following the site-directed mutagenesis PCR (PCR) with the sequence of wild 
type GLUT4 DNA (GLUT4). The bases in red are identical in both wild type GLUT4 and the PCR sequence, whereas the bases in 
blue differ. -  indicates where there are additional bases in one sequence. The alignment was carried out using Multalin (Corpet, 
1988).
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5.2.2 Transfection of the GLUT4-HA Constructs into Primary 
Adipocyte Cells
The method used to transfect primary adipocytes with the GLUT4-HA DNA 
was adapted by Dr. Scott Lawrence, for use in our laboratory, from the method 
carried out by Quon et al (Quon et al., 1994). Electroporation conditions (the 
voltage, capacitance and the number of shocks) were investigated. It was 
concluded that the optimal electroporation conditions was one shock at 400 V 
and 500 pF. The length of time the cells were incubated in culture following 
transfection, to allow expression of the GLUT4-HA protein, was also 
investigated. Culture times of 5 h and 16 h were investigated. It was found that 
culturing for 16 h resulted in a higher level of overexpressed protein than at 5 h 
but the fold insulin response was lower. The decrease in the fold insulin 
response at 16 h was because the overexpressed GLUT4-HA protein was not 
targeted correctly to the plasma membrane following insulin stimulation, rather 
than the failure to keep the transfected GLUT4-HA protein in an intracellular 
location in basal adipocytes (Al Hasani et al., 1999). This suggested that the 
cell had a limited capacity to recruit GLUT4 to the plasma membrane following 
insulin stimulation. As a result of the decreased response to insulin after 16 h 
in culture, the cells were incubated in culture for 5 h before the antibody- 
binding assay was carried out.
In a single experiment, wild type GLUT4-HA and one mutated construct was 
transfected into primary adipocytes. This was carried out, in triplicate, for each 
mutation.
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5.2.3 Cell-Surface Expression of GLUT4-HA Constructs
The plasma membrane levels of GLUT4-HA, in response to insulin, were 
closely related to the level of GLUT-HA transfected into the cell. Therefore, it 
was essential to determine the expression levels of both the endogenous 
GLUT4 protein and the transfected GLUT4-HA protein, in each sample, before 
the effect of each mutation could be elucidated.
Following transfection of the wild type and mutated GLUT4-HA vectors (as well 
as a control containing no GLUT4-HA vector), the cells were allowed to recover 
for 5 hours. Each of the conditions were split into two and either left in the 
basal state or stimulated with insulin. Trafficking was then stopped by the 
addition of potassium cyanide. A sample of the cells was taken from each 
condition and run on an SDS-PAGE gel. Following transfer to nitrocellulose, 
Western blot analysis was carried out with a mouse monoclonal anti-HA 
antibody which was used to detect the transfected GLUT4-HA protein. An anti- 
C-terminal GLUT4 antibody raised in rabbit was also used to detect the total 
level of GLUT4 in the cell. For comparison between the different conditions, the 
level of transfected GLUT4-HA needed to be normalised to the level of 
heterologously expressed GLUT4. This is illustrated with an example of an 
experiment carried out using the GLUT4-HA S488A vector (Figure 5.5). GLUT4 
was detected in each sample of the Western blot (Figure 5.5 a). There was an 
equal intensity of GLUT4 in each lane because the anti-C-terminal GLUT4 
antibody was essentially only recognising the endogenous GLUT4 protein 
because the level of transfected GLUT4-HA in the cell was very low. The 
transfected GLUT4-HA protein, as identified with the anti-HA antibody, was 
detected in all of the samples that had had the GLUT4-HA vector transfected 
into the cell. No GLUT4-HA was detected in the control sample, lane 1 (Figure 
5.5 b). As the anti-C-terminal GLUT4 antibody was essentially only recognising 
endogenous GLUT4, the intensity of the GLUT4-HA bands in each lane was 
normalised to an equal level of endogenous GLUT4. The percentage of 
GLUT4-HA in each lane was then calculated (Figure 5.5 c).
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Sample Control B WT I W T B Ala4*" I Ala4BB
% GLUT4-HA Com pared 100.0 100.4 129.3 129.4
to Basal WT
Figure 5.5 Relative protein expression levels of the GLUT4-HA wild type and 
GLUT4-HA S488A vectors. Isolated rat adipocytes were transfected with 0.4 pg of 
plasmid DNA and 400 pg carrier DNA (sheared herring sperm DNA) per vector. 
Following recovery, an aliquot of basal and insulin stimulated cells was taken and run 
on an SDS-PAGE gel. Lane 1 = control (transfection only with the carrier DNA), lanes 
2 and 3 = basal (2) and insulin (3) stimulated cells after transfection with the wild type 
GLUT4-HA vector, lanes 4 and 5 = basal (4) and insulin (5) stimulated cells after 
transfection with the GLUT4-HA S488A vector. Following transfer to nitrocellulose, 
Western blot analysis was carried out with the anti-C-term inal GLUT4 antibody (a) and 
the monoclonal anti-HA antibody (b). The antibodies detected heterologously 
expressed GLUT4 in the cell and transfected GLUT4-HA respectively. The amount of 
transfected plasmid in the cell was quantified (c). Results were normalised to an equal 
level of heterologously expressed GLUT4 in each of the samples.
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There was an equal level of transfection in the basal and insulin-stimulated 
samples of the same vector. This was as expected because the cells 
transfected with the same vector were only split after transfection and so 
should have the same level of transfected vector. The mutated GLUT4-HA 
S488A vector had a 1.29-fold higher level of transfection than the wild type 
GLUT4-HA vector. This must be taken into account when comparing the level 
of GLUT4 at the plasma membrane between wild type and S488A transfected 
cells.
5.2.4 The Effect of the Mutations on the Level of GLUT4 at the 
Plasma Membrane
Dr. Scott Lawrence also optimised the antibody-binding assay for use in our 
laboratory. Different ways to detect the HA signal were investigated. Amplex® 
Red [MP] and fluorescein digalactosidase (FDG) [MP] were both tested for use 
as a substrate. Amplex Red, in the presence of peroxidase, reacts with H2O2 to 
produce resorufin, a red-fluorescent oxidation product. In contrast, FDG is a 
fluorogenic substrate for {3-Galactosidase and is nonfluorescent. p- 
Galactosidase hydrolyses FDG, first to fluorescein monogalactosidase and 
finally to the highly fluorescent fluorescein. In each case, the secondary 
antibody was conjugated to horseradish peroxidase or p-Galactosidase, 
respectively. Both methods were successful in monitoring the level of GLUT4- 
HA at the plasma membrane. However, due to the presence of endogenous 
peroxides in the cell, the use of Amplex Red resulted in a higher level of 
background fluorescence. Conversely, FDG resulted in a low level of 
background fluorescence. The assay was originally carried out using a 
secondary antibody conjugated to [125l] and the radioactivity was detected by 
use of a y-counter (Quon et al., 1994, Al Hasani et al., 1999, Al Hasani et al., 
2002). The choice of a fluorescent-based detection assay over a radioactivity-
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based assay was due to the less hazardous working conditions of a 
fluorescent-based assay with no loss in detection sensitivity.
Following transfection of the various GLUT4-HA constructs, the cells were 
allowed to recover and express the transfected protein for 5 hours. An 
antibody-binding assay (Section 2.2.13) was then carried out. The principle of 
the assay was that incubation of the cells with an anti-HA antibody would result 
in the anti-HA antibody only binding to the transfected GLUT4-HA protein in the 
plasma membrane of the cells. A secondary antibody conjugated to p- 
Galactosidase was then incubated to bind to the primary antibody. The 
fluorogenic substrate FDG was added to an aliquot of cells and the 
fluorescence monitored was indicative of the level of GLUT4-HA at the plasma 
membrane. The fluorescence was measured on the FarCyte plate reader [A] 
over 100 cycles, to determine where the rate of reaction became linear. Each 
sample was analysed in quadruplicate. A protein assay was also carried out on 
a separate aliquot of cells. The change in fluorescence per second per mg 
protein was calculated over the range where the rate of reaction was first 
order. The average control sample was subtracted and the results were 
adjusted according to the level of transfection for each construct (Section 
5.2.3). Finally, the results were normalised to that of the insulin wild type 
sample, which was set to 1. The effect of each mutant was tested in three 
independent experiments. The normalised data from each experiment was 
averaged before a comparison between the GLUT4-HA wild type vector and 
the mutant vectors was carried out (Figure 5.6). Any significant difference 
between the level of GLUT4-HA at the plasma membrane between the wild 
type and mutant proteins was analysed by use of an unpaired T-test.
To assess the full effects of the mutants, it was necessary to compare the level 
of GLUT4-HA at the plasma membrane in both basal and insulin-stimulated 
cells, and to calculate the fold change in the level of GLUT4-HA at the plasma 
membrane after the cells were stimulated with insulin. This will be referred to
242
as the fold insulin change in the remainder of the chapter. Use of the fold 
insulin change for comparisons ensures that any effect of the mutation was 
real and not due to an equal proportional increase of the level of GLUT4-HA at 
the plasma membrane in basal and insulin-stimulated cells. The fold insulin 
change was calculated, from Figure 5.6, as a difference in the mean values of 
the level of GLUT4-HA in the plasma membrane for basal and insulin- 
stimulated cells (Figure 5.7).
Insulin stimulated the translocation of all of the mutated GLUT4-HA proteins to 
the plasma membrane (Figure 5.6 (difference between the orange and blue 
bars) and Figure 5.7). There was an increase in the plasma membrane level of 
all of the mutated GLUT4-HA proteins in basal adipocytes, compared to the 
wild type GLUT4-HA protein. However, the differences between the plasma 
membrane levels of the wild type and mutated GLUT4-HA proteins were not 
significant in basal adipocytes (Figure 5.6, orange bars). The plasma 
membrane levels of the different mutated GLUT4-HA proteins varied in insulin- 
stimulated adipocytes. There was an extremely significant increase (p = 
0.0002) in the plasma membrane level of the S488A GLUT4-HA protein 
compared to the wild type GLUT4-HA protein. There was also an extremely 
significant decrease (p < 0.0001) in the plasma membrane levels of the S10D 
GLUT4-HA protein compared to the wild type GLUT4-HA protein (Figure 5.6, 
blue bars). The function of the phosphorylation at each site appeared to be to 
retain GLUT4 in an intracellular compartment.
Insulin stimulation resulted in a fivefold increase in the plasma membrane 
levels of the wild type GLUT4-HA protein (Figure 5.7, red column). However, 
the fold insulin response observed by all the mutated GLUT4-HA proteins was 
less than that observed with the wild type transporter. There was a significant 
increase, as reported above, in the level of the S488A GLUT4-HA protein at 
the plasma membrane after insulin stimulation, in comparison with the wild 
type GLUT4-HA protein. However, the fold insulin response of the S488A
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mutant was the same as the single S10A and the double S10A S488A mutants 
(fourfold insulin response). This was not hugely different to the wild type vector 
(fivefold insulin response). Therefore, there was a proportionally equal increase 
in the plasma membrane levels of S488A GLUT4-HA protein in both basal and 
insulin-stimulated adipocytes. Thus, the lack of a phosphorylation site at serine 
488 does not result in an increased level of GLUT4-HA at the plasma 
membrane.
In comparison to the wild type GLUT4-HA protein, the S10D GLUT4-HA 
protein only had a 2.5-fold increase in the level of GLUT4-HA at the plasma 
membrane following insulin stimulation. The decrease in the plasma 
membrane level of the S10D GLUT4-HA protein, in insulin-stimulated 
adipocytes, was therefore real and not due to a corresponding decrease in the 
plasma membrane level of the S10D GLUT4-HA protein in basal adipocytes.
The only mutation that affected the plasma membrane levels of the GLUT4-HA 
protein was the S10D mutation. The S10D mutation resulted in a decrease in 
the level of GLUT4-HA at the plasma membrane and the fold insulin response 
was halved in comparison to the wild type GLUT4-HA protein. Thus, 












Figure 5.6 Effect of the phosphorylation site at serine 10 and serine 488 on the translocation of GLUT4 to the cell surface in 
basal and insulin-stimulated adipocytes. Isolated adipocyte cells were transfected with 0.4 pg plasmid DNA and cultured for 5 
hours. After harvesting, the cells were incubated without (basal, orange bars) or with insulin (blue bars). The level of GLUT4 at the 
plasma membrane was determ ined using an antibody-binding assay (Section 2.2.13). The data for each mutant is the combined 
mean ± S.E.M. from 3 independent experiments performed in quadruplicate. The data for the wild type data is the combined mean ± 
S.E.M. from 18 independent experiments performed in quadruplicate. ***, p<0.001 (unpaired t-test; compared to wild type values).
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Figure 5.7 Fold increase in the plasma membrane levels of GLUT4-HA after stimulation with insulin, for the wild type and 
mutated proteins. The fold insulin change was calculated, from Figure 5.6, as a difference in the mean values of the level of GLUT4 
in the plasma membrane between basal and insulin-stimulated cells.
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5.3 Discussion
The targeting potential of the phosphorylation motifs was addressed by 
transfecting recombinant GLUT4-HA into a physiologically relevant cell type. 
The recombinant GLUT4-HA had either an aspartic acid or an alanine residue 
substitution at each of the phosphorylation sites, to mimic constitutively 
phosphorylated and non-phosphorylated forms of the protein respectively.
In the present study, there was a fivefold increase in the level of wild type 
GLUT4-HA at the cell surface in response to insulin. This was comparable to a 
previously reported value of 6.7-fold (Al Hasani et al., 2002). The sensitivity of 
the assay was therefore similar to the original assay.
The only mutation to have a real effect on the translocation of GLUT4 was the 
S10D mutation. There was a significant decrease in the level of S10D GLUT4- 
HA at the plasma membrane of insulin-stimulated adipocytes. There was also 
a lower fold increase in the plasma membrane levels of the S10D GLUT4 
protein following insulin stimulation, compared to the wild type GLUT4-HA 
protein.
There was a significantly higher level of the S488A GLUT4-HA protein in the 
plasma membrane of insulin-stimulated adipocytes, but there was also an 
increase in the level of S448A GLUT4-HA in basal adipocytes, although this 
was not significant. Therefore, following insulin stimulation, there was no fold 
change in the level of the S448A GLUT4-HA protein at the plasma membrane. 
This indicated the need for caution when analysing the effect of the mutations.
The result of the S10D mutation strongly argues that, following insulin 
stimulation, the function of the phosphorylation site at serine 10 is to retain 
GLUT4 in an intracellular compartment. This could occur in different ways. The 
phosphorylation could hold the GLUT4 in an intracellular compartment,
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decrease the rate of exocytosis or increase the rate of endocytosis. Either way, 
the level of GLUT4 at the plasma membrane would decrease.
Even though the S10D mutation had an effect on the level of GLUT4 at the 
plasma membrane, the S10A mutation did not have an effect. The S10A 
mutation should not necessarily cause an increase in the level of GLUT4 at the 
plasma membrane (the opposite affect of S10D). The fact that the S10A 
mutant did not have an effect could be because it was the phosphorylation that 
retained GLUT4 in an intracellular localisation, and so no phosphorylation at 
serine 10 would result in the S10A GLUT4-HA protein acting like the wild type 
transporter. The double mutation was carried out to determine if the two 
phosphorylation sites were co-operative in function, i.e. if both sites were 
needed to be phosphorylated before an effect was observed. The double 
mutation, S10D and S488D, did not have any effect on the level of GLUT4 at 
the plasma membrane, even though the S10D mutation did have an effect. 
Therefore, phosphorylation at serine 488 is not required before the effect of the 
phosphorylation at serine 10 is observed. The effect of the mutation at serine 
488 is unknown but appears to override the function of the phosphorylation at 
serine 10. It would be interesting to carry out double mutations, with alanine 
being mutated at one phosphorylation site and aspartic acid at the other site, 
and to determine the effect of this mutation on GLUT4 translocation.
Many other studies have used mutagenesis to investigate the role of particular 
amino acids in the function of GLUT4 (Marsh et al., 1995, Araki et al., 1996, Al 
Hasani et al., 2002). Most of the studies have not included the sites of 
phosphorylation but a few studies have mutated serine 10 and serine 488 
(Garippa et al., 1996, Marsh et al., 1998, Khan et al., 2004).
Garippa et al investigated the effect of both the phosphorylation site at serine 
488 and the dileucine motif in the trafficking of GLUT4 (Garippa et al., 1996). 
Serine 488 was mutated to either alanine or aspartic acid and the dileucine 
motif (LL) was mutated to a dialanine motif (AA). The mutations at the LL and 
serine 488 resulted in a reduction in the rate of internalisation, with more
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GLUT4 being present at the plasma membrane. The AA mutation reduced the 
rate of internalisation by tenfold but the serine 488 mutation only reduced it by 
threefold. As both mutations decreased the rate of internalisation, the study 
concluded that it was the Ser-Leu-Leu motif and not just the Leu-Leu motif that 
was an important signalling motif in GLUT4. The problem with the conclusion 
involving the serine 488 mutation was that both serine 488 mutated to alanine 
and to aspartic acid led to a threefold reduction in internalisation. Therefore, 
the presence of a phosphorylated residue did not change the rate of 
internalisation of the mutated protein. Thus, the experiment did not give a clear 
indication as to the effect of the phosphorylation at serine 488 (Garippa et al., 
1996). Garippa et al were studying the effect of the phosphorylation motif on 
the rate of internalisation in non-insulin-responsive cells. Therefore the results 
by Garippa et al should be compared to the plasma membrane levels of the 
GLUT4-HA protein in basal adipocytes from the present study. The results 
from the study by Garippa et al varied from the present study. In the present 
study, there was not a significant difference between the plasma membrane 
levels of the GLUT4-HA protein mutated at serine 488 and the wild type 
GLUT4-HA protein. The difference in the results between the two studies could 
be because different cell types were used. A physiologically relevant cell type 
(adipocytes) was used in this study and the whole GLUT4 protein was 
expressed. However, Garippa and colleagues only expressed their construct in 
CHO cells which do not contain the same cellular machinery as insulin- 
sensitive cells. The design of the construct used in CHO cells could also 
explain why different results were obtained. In CHO cells, only the C-terminus 
of GLUT4 was expressed as a chimera with the transferrin receptor (Garippa et 
al., 1996). The transfected construct could also have been overexpressed to a 
higher level than in the present study, which could also account for the 
differences observed.
A study by Marsh et al investigated the role of the phosphorylation site at 
serine 488 in an insulin-responsive tissue (3T3-L1 adipocytes). Serine 488 was 
mutated into an alanine residue (S488A) and was transfected into 3T3-L1
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fibroblasts. Phosphorylation of GLUT4 did not affect the subcellular localisation 
of GLUT4 in either basal or insulin-stimulated adipocytes (Marsh et al., 1998). 
The present study is in agreement with the result by Marsh et al because the 
S488A mutation did not affect the level of GLUT4 at the plasma membrane.
The structural motifs involved in the initial sorting of GLUT4 from the 
biosynthetic pathway to the GLUT4 storage vesicle (GSV) have been 
investigated using GLUT4-GLUT1 chimeras (Khan et al., 2004). The amino 
terminus and the large cytoplasmic loop between transmembrane domains 6 
and 7 were found to be necessary for the efficient initial trafficking following 
biosynthesis of the GLUT4 protein. More importantly, residues Phe5 and lie8 
and to a lesser extent Asp12 and Gly13, along with residues 229 -  271 in the 
large intracellular loop, were identified as the essential residues. The amino- 
terminus of GLUT4 is involved in the initial sorting step and in plasma 
membrane endocytosis (Al Hasani et al., 2002, Khan et al., 2004). The 
presence of a phosphorylated serine 10 residue could, therefore, differentiate 
between the two roles elicited by the FQQI motif. A S10A mutation was carried 
out by Khan and colleagues. The S10A mutation did not affect the entry of the 
mutated protein into the GSV (Khan et al., 2004). The result from Khan et al is 
in agreement with the result from the present study in which S10A had no 
affect on the trafficking of GLUT4. However, it may not be the serine residue, 
per se, that is important but it may be the phosphate on the serine residue that 
primarily has an effect on the trafficking of GLUT4. It would have been 
interesting if Khan et al had mutated serine 10 to aspartic acid to identify if the 
phosphorylation at serine 10 had a role in the initial sorting step (from the 
biosynthetic pathway into the GSV) or if the phosphorylation was more likely to 
have a role in the endocytic pathway.
Each phosphorylation site in GLUT4 is in close proximity to a signalling motif 
(FQQI or LL) involved in the subcellular trafficking of GLUT4. The 
phosphorylation sites could modulate the effect of these signalling motifs.
250
Mutations have been carried out on the GLUT4-HA vector at the dileucine motif 
(L489L490) or at F5 in the N-terminal FQQI motif (Al Hasani et al., 2002). The 
specified residues were mutated to alanine residues. The LL motif is adjacent 
to the serine 488 phosphorylation site, and the F5QQI motif is upstream of the 
serine 10 phosphorylation site. The level of the mutated GLUT4 protein at the 
plasma membrane was compared to that of the wild type. The l 498L490 —► AA 
mutation did not have any effect on the cell surface expression of the GLUT4- 
HA protein. However, the F5A mutation resulted in an increase in the cell 
surface level of GLUT4 in both basal and insulin-stimulated adipocytes. The 
result documented in this chapter follows the result of the study investigating 
the effect of the trafficking motifs. Serine 488 or the LL motif did not have an 
effect in either study. It had been reported that the mutated LL motif only has 
an effect at high levels of overexpression (Marsh et al., 1995). The study 
detailed in this chapter did not test high expression levels of the mutated DNA. 
However, high expression levels were tested by Al-Hasani et al, and there was 
no change in the plasma membrane expression levels in any of the constructs 
tested (Al Hasani et al., 2002).
The F5A mutation decreases the rate of internalisation, i.e. there was more 
GLUT4 at the plasma membrane in both basal and insulin-stimulated cells (Al 
Hasani et al., 2002). Perhaps, phenylalanine 5 and phosphorylation at serine 
10 work together in the internalisation mechanism of GLUT4. It has been 
shown that F5QQI is a binding site for the medium chain of the adaptor proteins 
p1, p2, and p3A (Al Hasani et al., 2002). The phosphorylation could be 
involved in modulating the binding site for the adaptor protein. The 
phosphorylation could also have an independent role. It would be interesting to 
investigate the subcellular trafficking kinetics of the S10D mutation and to 
calculate the rate of endocytosis (Araki et al., 1996, Al Hasani et al., 2002). 
This would give some indication of the role of the phosphorylation of serine 10 
and any potential link to the trafficking of the FQQI motif. After transfection, the 
cells would be treated with insulin. Wortmannin treatment would then prevent
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any further translocation. The rate of internalisation could be calculated using 
the antibody-binding assay at different times after the addition of wortmannin.
Due to the lack of time, further studies using the mutant GLUT4-HA vector 
generated in this chapter could not be carried out. Some of the follow up 
experiments are detailed below and would provide an interesting extension to 
the current study.
Phosphorylation at serine 10 decreases the level of GLUT4 at the plasma 
membrane of insulin-stimulated adipocytes but how the phosphorylation elicits 
the effect needs further investigation. Phosphorylation at serine 488 did not 
affect the level of GLUT4 at the plasma membrane in either basal or insulin- 
stimulated adipocytes. The antibody-binding assay cannot identify any 
changes in the intracellular compartment in which the GLUT4 resides. The 
serine 488 phosphorylation could therefore modulate the intracellular 
localisation of the GLUT4 protein. The subcellular localisation of the mutants 
could be investigated using confocal microscopy following the transfection of 
the GLUT4-HA mutants into primary adipocyte cells. Staining the transfected 
adipocytes with the anti-HA antibody would identify the localisation of the 
transfected construct. An anti-GLUT4 antibody could not be used to detect the 
endogenous protein as it would also stain the transfected GLUT4 protein. 
However, the insulin-responsive aminopeptidase (IRAP) protein has been 
identified as a major protein in GLUT4-containing vesicles (Keller et al., 1995). 
There is evidence that GLUT4 and IRAP share the same trafficking routes in 
adipose cells (Ross et al., 1996, Garza and Birnbaum, 2000). Staining 
adipocytes using an anti-IRAP antibody would therefore identify the vesicles 
containing endogenous GLUT4.
The mutant constructs would be useful to corroborate the results from chapter 
4 and to check if there are only two phosphorylated residues in GLUT4 or to 
identify if there is an additional phosphorylation site in the C-terminal peptide. 
Primary adipocyte cells would be transfected with the S10A S488A GLUT4-HA
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vector. The S10A S488A mutant cannot be phosphorylated at either residue 10 
or residue 488. The cells would then be labelled with [32Pj] and the S10A 
S488A GLUT4-HA protein could be isolated from the endogenous protein by 
immunoprecipitation with the anti-HA antibody. Any incorporation of 
radioactivity into the mutant GLUT4 protein could be detected and therefore 
any phosphorylation sites, in addition to serine 10 and serine 488, would be 
identified.
Insulin had opposing effects on the phosphorylation state of GLUT4 in 
adipocytes and cardiomyocytes (chapter 4). To see if the phosphorylation has 
opposing functions between the two cell types, the antibody-binding assay 
needs to be carried out after cardiomyocytes have been transfected with the 
mutated GLUT4-HA constructs. However, cardiomyocytes cannot be 
transfected by electroporation. Transfection in cardiomyocytes is commonly 
carried out by the use of adenovirus. However, before this can be done, each 
of the mutated GLUT4-HA DNA constructs needs to be cloned into separate 
adenoviral plasmids and the transfection technique has to be optimised which 
can be a very lengthy process.
In addition to being involved in the translocation of GLUT4, the phosphorylation 
sites could also affect the transport activity of the transporter. Glucose uptake 
experiments, in which the mutated DNA is transfected into cells lacking 
endogenous GLUT4, would test whether the mutation influenced the transport 
activity of GLUT4.
5.4 Conclusion
The wild type GLUT4-HA vector has been mutated at the GLUT4 
phosphorylation sites. The phosphorylated serines were successfully mutated 
to either aspartic acid, which mimics the negative charge of the phosphorylated
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serine, or to alanine, which mimics the unphosphorylated form of the serine 
residue. These mutations were used to investigate the role of the 
phosphorylation in the translocation of GLUT4 to the plasma membrane in a 
physiologically relevant cell system. The phosphorylation at serine 10 appears 
to cause a decrease in the level of GLUT4 at the plasma membrane of insulin- 
stimulated adipocytes. Phosphorylation of serine 488 has a different role and 




Phosphorylation sites have been identified in two regions in the GLUT4 protein. 
One site which has been identified previously is at the C-terminus of GLUT4 
and is serine 488 (Lawrence, Jr. et al., 1990a). The second site, at the N- 
terminus of GLUT4, is a novel site that was predicted from the homology of the 
N-terminus of GLUT4 with the a-subunit of GAD65. Comparison with a 
phosphorylation prediction program has led to the prediction that the sites of 
phosphorylation are at serine 10 and serine 488 in GLUT4. This study has 
focussed on the identification of the second phosphorylation site in GLUT4 and 
its function.
If the stoichiometry of the phosphorylation in basal adipocytes is 0.1 mole 
phosphate / mole GLUT4 (Section 4.2.4.2.6), then only a small population of 
GLUT4 is phosphorylated at one time (0.05 mole phosphate / mole GLUT4 at 
each terminus). There are two pieces of evidence that suggests that the 
GLUT4 phosphorylated at serine 10 has an intracellular location. Firstly, 
confocal microscopy studies using both of the anti-pSer10 antibodies raised in 
rabbit (purified from the second and final bleed serums) has identified a protein 
in the peri-nuclear region of the cell in both basal and insulin-stimulated 
conditions. No staining was present at the plasma membrane in either 
condition (Section 3.2.1.5). Secondly, mutation of the serine 10 residue to an 
aspartic acid residue (to mimic a constitutively phosphorylated residue), 
resulted in a decrease in the level of GLUT 4 at the plasma membrane, i.e. 
more GLUT4 had an intracellular location (Section 5.2.4). Therefore, the small 
pool of GLUT4 that is phosphorylated at the serine 10 has an intracellular 
localisation.
The small pool of GLUT4 that is phosphorylated at serine 10 could be GLUT4 
that is in the synthetic pathway as previously discussed from the confocal 
microscopy study using brefeldin A in 3T3-L1 adipocytes (Section 3.2.1.5). A
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study investigating the initial sorting of GLUT4, following biosynthesis, 
identified the N-terminus of GLUT4 as being an important region in the process 
(Khan et al., 2004). However, a mutation of serine 10 to an alanine residue had 
no effect. It is possible that phosphorylation at serine 10 during biosynthesis is 
important in the initial intracellular sorting of GLUT4. When GLUT4 has 
reached the correct compartment, it could be dephosphorylated and then the 
GLUT4 would become available for insulin-responsive glucose transport. The 
FQQI motif is an important trafficking motif and is involved in the internalisation 
of GLUT4 from the plasma membrane. Phosphorylation of the serine 10 
residue could work in combination with the FQQI and could therefore provide a 
distinction between the intracellular sorting of GLUT4 to the GSV and 
internalisation from the plasma membrane.
Alternatively, GLUT4 could be phosphorylated to retain the protein in an 
intracellular location. This could happen, for example, if the mechanism of 
GLUT4 cycling put forward by the James lab is correct (Govers et al., 2004, 
Coster et al., 2004). If there is a small latent pool of GLUT4 transporters, which 
do not translocate to the plasma membrane in either basal or insulin-stimulated 
cells, then phosphorylation at serine 10 could keep this pool tethered in an 
intracellular location (Section 1.5.2). Indeed the anti-pSer10 antibody staining 
remained intracellular in both basal and insulin-stimulated cells.
In adipocytes, insulin increases the level of phosphorylation of GLUT4 at serine 
10 and the phosphorylated protein has an intracellular localisation. However, 
insulin also stimulates the translocation of GLUT4 to the plasma membrane. 
Therefore, insulin appears to have opposing functions regarding the subcellular 
localisation of the protein.
In adipocytes, only a small proportion of GLUT4 is phosphorylated at serine 10 
and the translocation experiments identify the effect of the phosphorylation 
when the protein has been overexpressed. If serine 10 is phosphorylated 0.05 
mole phosphate / mole GLUT4 in basal cells, then in insulin stimulated cells 
there would be 0.07 mole phosphate / mole GLUT4. The phosphorylated
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GLUT4 could therefore be internalised after insulin stimulation, but due to the 
fact that there is a large movement of GLUT4 to the plasma membrane, this 
small effect is not identified.
The function of the phosphorylation at serine 488 has not been further 
elucidated in this study, although it is not involved in GLUT4 trafficking to the 
plasma membrane (Section 5.2.4). An antibody to the phosphorylated serine 
488 has not been raised and production of such an antibody would aid the 
study of the function of this phosphorylation site both from use in Western blot 
analysis and confocal microscopy. The antibody would also be invaluable in 




This thesis has included different approaches to investigating GLUT4 
phosphorylation. Antibodies have been raised to the phosphorylated serine 10 
residue in the N-terminus of GLUT4 and these antibodies have been purified 
and partially characterised. However, further characterisation is needed before 
the antibodies can be further used in the investigation of GLUT4 
phosphorylation.
In the first study, the sites of phosphorylation were identified by the use of a 
technique in which adipocytes and cardiomyocytes were labelled with [32Pj]. 
The effect insulin, okadaic acid, CKII inhibitors and oligomycin had on the 
phosphorylation state of GLUT4 was also investigated. Two phosphorylation 
sites have been identified, a novel phosphorylation site was identified at serine 
10 at the N-terminus of GLUT4, and the second site was at serine 488 at the 
C-terminus of GLUT4 which had previously been identified (Lawrence, Jr. et 
al., 1990a).
The second study involved the site-directed mutagenesis of the 
phosphorylated residues. The effect each phosphorylation site had on the level 
of GLUT4 at the plasma membrane was investigated. The only mutation to 
have an effect was the mutation of serine 10 to an aspartic acid residue. 
Introduction of this mutation caused a decrease in the level of GLUT4 at the 
plasma membrane. Thus the role for the phosphorylation of serine 10 in 
defining an intracellular localisation was implicated, e.g. during biosynthesis or 
as an intracellular retention factor.
The ultimate objectives of this investigation would be to identify the function of 
each of the phosphorylation sites, to identify the role the phosphorylation has in 
glucose transport and to investigate how phosphorylation changes, if it does, in 
Type 2 diabetes. The work presented in this thesis, along with the future work
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outlined in the discussion sections, can be combined and together may provide 
a useful insight into the mechanism whereby insulin stimulates the entry of 
glucose into insulin-responsive tissues.
People suffering from Type 2 diabetes have impaired insulin-stimulated 
glucose transport. However, when comparing diabetic patients to non-diabetic 
patients it was found that the levels of GLUT4 and GLUT1 expressed in the 
muscles of these patients are not altered (Kahn, 1992). Understanding the 
mechanism by which insulin stimulates glucose transport in adipocyte and 
muscle cells is therefore essential before this disease can be controlled.
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